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11 
Blood coagulation 
The basis for our modern understanding of the cardiovascular system was set in 
1628 when William Harvey first described the cardiovasculature as a closed 
circulatory system.1 Nowadays, it is known that this system has a total surface of 
about 1000 m2 and consists of approximately 100.000 km of vessels which 
transports blood to provide cells with oxygen and nutrients, and removes metabolic 
waste products.2  
Hemostasis is the process that maintains blood in a clot-free state under 
physiological circumstances and prevents excessive blood loss upon vascular 
injury. When vascular injury occurs, the vessel constricts, platelets aggregate and 
form a platelet plug, and proteins of the procoagulant system will stabilize the clot 
via a dense fibrin network,  while proteins of the anticoagulant and fibrinolytic 
systems prevent uncontrolled clot formation.3 This balance between procoagulant, 
anticoagulant and fibrinolytic factors has to be tightly regulated to ensure rapid and 
localized clot formation, and disturbance of this balance can lead to either a 
hypocoagulable or hypercoagulable state, which can subsequently result in 
bleeding or thrombosis, respectively. Although thrombus formation can occur in 
both the arterial and venous system, the work described in this thesis will focus on 
factors leading to an increased risk for venous thrombosis. 
 
Risk factors for venous thrombosis  
In 1856, Rudolf Virchow postulated 3 causes of thrombosis: changes in blood flow, 
changes in the vessel wall and changes in blood composition.4 Although this 
classification is still valid, epidemiological studies have shown that risk factors for 
venous thrombosis relate to changes in either blood flow or blood composition, 
while changes in the vessel wall seem to be of lesser importance.5 This led to a 
new classification, which separates genetic and acquired risk factors for venous 
thrombosis.   
 
Genetic risk factors 
Genetic risk factors often relate to changes in blood composition, resulting in a 
hypercoagulable state. It is therefore not surprising that the first genetic risk factors 
for venous thrombosis identified were partial deficiencies in the anticoagulant 
factors antithrombin, protein C and protein S. Complete deficiencies of these 
factors result in severe hemostatic dysfunctions that are not compatible with life. 
On the other hand, partial deficiencies due to heterozygosity are rare in the general 
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population with prevalences of less than 0.5% and confer an approximately 10-fold 
increased risk for venous thrombosis.6  
Besides deficiencies in anticoagulant factors, mutations in procoagulant factors 
have also been reported. The factor V Leiden mutation is the most common genetic 
risk factor for venous thrombosis with a prevalence of 5% in the Caucasian 
population.6 This gain-of-function mutation renders a factor V protein that has an 
increased procoagulant and a decreased anticoagulant activity, resulting in a 7-fold 
increased thrombosis risk in heterozygotes, which can increase up to an 80-fold 
higher risk in homozygotes.7 Another common genetic risk factor is the G20210A 
mutation in the prothrombin gene, which is associated with increased prothrombin 
levels in the plasma, thereby leading to a 2- to 5-fold higher risk for venous 
thrombosis.6  
In addition to these mutations within coagulation genes, plasma coagulation factor 
levels can also be indirectly influenced by other genes. For example, ABO blood 
group affects von Willebrand factor levels in the plasma, which subsequently 
influences FVIII levels. This in turn can increase the risk for venous thrombosis 
since high plasma FVIII levels have been identified as an independent risk factor.8 
 
Acquired risk factors  
Over the last years, large epidemiological studies have identified a number of 
acquired risk factors for venous thrombosis that result in stasis and/or a 
hypercoagulable state.5,9 The first category includes factors such as immobilization, 
trauma, plaster casts and major surgery. On the other hand, hypercoagulability 
may be caused by obesity, malignancies, female hormones as in oral contraceptive 
use or pregnancy, and several endocrine disorders like hyperthyroidism, 
acromegaly and the metabolic syndrome are also associated with a 
hypercoagulable state.10-13 However, the underlying mechanisms how these 
acquired factors lead to a hypercoagulable state are largely unknown. 
Besides the association with a hypercoagulable state, another common feature of 
this latter group of acquired risk factors is that they are all, at least to a certain 
extent, able to induce changes in liver homeostasis. For example, estrogens, 
thyroid hormones and obesity can regulate lipid and glucose metabolism in the liver 
via affecting gene transcription of key players involved in these metabolic 
pathways.14-16 Since the liver is also the main site of production of plasma 
coagulation factors we therefore hypothesized that acquired risk factors for venous 
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thrombosis associated with a hypercoagulable state also modulate transcription of 
hepatically expressed genes belonging to the plasma coagulation system 
 
Regulation of hepatic coagulation gene transcription 
There are several ways by which transcription of coagulation genes can be 
modulated, ranging from a direct modulation via nuclear receptors that bind to a 
response element in the coagulation gene, to an indirect modulation where 
transcription is affected as a bystander effect of changes in liver homeostasis.   
A number of acquired risk factors that are associated with a hypercoagulable state 
are hormonal in origin, like the use of oral contraceptives and hyperthyroidism. It is 
known that hormones can affect transcription, as they exert their actions via binding 
to nuclear hormone receptors. When liganded, the hormone receptors can bind to 
the hormone response element in the promoter region of a target gene, thereby 
acting as a transcriptional modulator of transcription.17,18 For example, it has been 
reported that the FVII and FXII genes have functional estrogen response elements, 
which may account for the changes in plasma levels of these factors observed 
during contraceptive use.19,20  
A second mechanism to modulate transcription is by interfering with constitutive 
expression of coagulation genes. To ensure adequate coagulation upon vascular 
damage, coagulation factors have to be continuously produced in order to achieve 
the required steady-state levels in the circulation. This production of coagulation 
factors depends, amongst others, on transcription factors of the hepatic nuclear 
factor (HNF) and the CCAAT/enhancer-binding protein (CEBP) family. HNF4α is of 
particular interest since it is not only the most abundantly expressed transcription 
factor in the liver and is important for the transcription of a number of pro- and 
anticoagulant genes,21,22 but also because hormones like estrogens and thyroid 
hormone can interact with HNF4α. 
Acquired risk factors may also modulate transcription of coagulation genes via 
transcription factors that play a minor role in constitutive expression, but have a 
highly inducible activity. For instance, a hallmark of obesity is an increased insulin 
level and a chronic inflammatory state, which coincides with an increased 
transcriptional activity of nuclear factor (NF)-κB.23 In vitro studies have 
demonstrated that NF-κB can induce the expression of fibrinogen, factor VIII and 
PAI-1,23,24 and this mechanism may also extent to other coagulation genes that 
form part of the hypercoagulable state associated with obesity.  
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Finally, risk factors can induce changes in liver homeostasis, resulting in a long 
chain of events in which transcriptional modulation of coagulation genes can be 
considered as a bystander effect. For example, estrogens, thyroid hormone and 
obesity can affect the lipid metabolism and triglyceride accumulation in the liver, 
which in the case of obesity can lead to steatohepatitis. Due to this effect on liver 
metabolism and physiology, it is not difficult to imagine that transcription of 
numerous genes, including coagulation genes may be affected as well. 
Thus, there are several levels by which transcription of hepatically expressed 
coagulation genes can be modulated. We hypothesize that transcriptional 
modulation of coagulation genes by hormones like estrogens and thyroid hormone 
will be direct, i.e. that liganded hormone receptors directly interact with their 
respective hormone response elements in the promoter region of coagulation 
genes. On the other hand, obesity is more likely to modulate coagulation gene 
transcription through an indirect multistep process, as the result from changes in 
liver physiology. 
 
Strategies to study transcriptional modulation of coagulation genes 
Several strategies to study transcriptional modulation can be used to test our 
hypotheses. With in silico approaches, transcription factor binding sites can be 
predicted by combining sequence databases and algorithms, like consensus 
sequences for hormone response elements. This method has been applied to 
determine estrogen response elements in both the human and mouse genome and 
indentified response elements in a number of coagulation genes.25 However, an 
important limitation of predicting transcription factor binding sites in silico is that 
they are not necessarily functional in vivo. The opposite can also occur: functional 
response elements do not always contain the consensus sequence used by an 
algorithm and may therefore erroneously be overlooked as a response element. 
These limitations are nicely illustrated by comparing an in silico study performed by 
Bourdeau and colleagues which identified estrogen response elements in the 
murine FVII, FX, FXIII and α2-antiplasmin genes, with an in vivo ChIP-on-chip study 
that showed that fibrinogen, FII, FXI, antithrombin, heparin cofactor II, protein S, 
protein Z and plasminogen were directly bound to the estrogen receptor α.15,25 
In contrast to in silico studies, in vitro studies can be used for functional testing of 
e.g. hormone response elements, as has been done for coagulation factors VII, IX 
and XII.19,20,26 However, the disadvantage of in vitro approaches is that they often 
focus on a specific cell type, which makes it difficult to reproduce physiological 
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processes since they often require multiple interactions between cells of different 
origins. In addition, some risk factors like obesity cannot be mimicked in vitro, as 
the key intermediates leading to obesity, and the resulting hypercoagulable state, 
are not known.  
Therefore, it is important to have a complete physiological system that provides all 
the known and unknown but essential factors necessary to modulate transcription. 
Another advantage of in vivo models is that they provide the opportunity to study 
whether the modulating effects on transcription are translated in the plasma protein 
levels and subsequently in a thrombosis phenotype. Hence, the use of an in vivo 
model is warranted.  
 
Animal models  
Mice are by far the most used animals in thrombosis research. They are not only 
appealing because of their small size and short generation time, but also because 
of the relative ease of genetic manipulation. Furthermore, liver-specific gene 
regulation is fairly conserved between humans and mice, suggesting a highly 
comparable regulation of hepatic gene transcription.27 As previously mentioned, it 
is also important to evaluate whether transcriptional effects translate into altered 
plasma protein levels and a thrombotic phenotype. Although there are some 
differences between human and mouse coagulation on the plasma level, e.g. the 
fact that protein S in mice does not bind to C4BP as it does in humans28, in general 
murine coagulation factors and their functions are quite similar to their human 
counterparts.29,30 This has the advantage that a large number of assays used to 
determine the functional levels of human plasma coagulation factors can be 
relatively easy adapted for their application in mouse research.  
To evaluate changes in the coagulation profile and its impact on the thrombotic 
phenotype, the use of mice has its limitations, as they do not develop thrombosis 
spontaneously. To overcome this problem, several experimental models have been 
developed in which thrombus formation is triggered either by stasis or by vessel 
wall damage due to ferric chloride, photochemical injury, mechanical trauma, or by 
applying an electric current.31-33 In addition to these experimental models, 
transgenic mouse models have been generated by disrupting or manipulating 
coagulation factors, like the factor V Leiden and thrombomodulin proline mutant 
mice. As a result of these mutations, mice display tissue fibrin depositions which 
are considered to be a marker for a thrombotic phenotype. Moreover, they also 
have the potential to develop macrovascular thrombosis.34,35  
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As the use of mice can provide information on the mechanisms of transcriptional 
modulation following risk factor exposure, and whether these transcriptional 
changes alter the plasma coagulation profile and subsequently the thrombotic 
tendency, murine in vivo models were used in the experiments described in this 
thesis.  
 
Aim and outline of the thesis 
The aim of this thesis was to obtain a better understanding of the biological 
mechanisms underlying acquired risk factors that lead to an increased risk for 
venous thrombosis. The risk factors studied, i.e. female hormones, thyroid 
hormone and obesity, are all associated with a hypercoagulable state and are all 
capable of interfering with liver metabolism. Therefore, we hypothesized that these 
risk factors modulate transcription of coagulation genes, either directly via nuclear 
hormone receptors and hormone response elements in the target gene (female 
hormones and thyroid hormone), or indirectly by affecting liver homeostasis 
(obesity). This in turn may result in a hypercoagulable state and subsequent 
increased venous thrombotic risk. To test these hypotheses, we used an in vivo 
approach which enabled us to not only study transcriptional modulation but also the 
resulting effects on both the plasma protein levels and the thrombotic phenotype, 
which we assessed by using both experimental and genetic thrombosis models.  
As we considered mice to be a valuable tool to study risk factor-induced effects on 
hepatic transcription, plasma coagulation and thrombosis, chapter 2 reviews the 
literature with respect to the available genetic mouse models of venous thrombosis, 
of which two models are chosen to use in studies described later in this thesis.  
In chapter 3, the effects of oral ethinylestradiol on the mouse plasma coagulation 
profile are presented. In addition, the underlying mechanism of estrogen-induced 
changes in coagulation is elucidated. As the acquired risk factors of oral 
contraceptive use and hormone replacement therapy contain both an estrogen and 
progestin component, the effect of this combined therapy on transcript levels of 
hepatically expressed coagulation genes is described in chapter 4.  
Experiments in chapter 5 were initiated to study the effects of oral ethinylestradiol 
and obesity on experimentally induced thrombosis. In addition, as venous 
thrombosis is considered to be a multicausal disorder, the interaction between 
these two risk factors with respect to the thrombotic tendency was also evaluated. 
The long-term effects of estrogen administration on plasma coagulation parameters 
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and the subsequent effect on a spontaneous thrombotic phenotype, i.e. fibrin 
deposition, of two different transgenic mouse models are presented in chapter 6. 
In addition to chapter 5, chapter 7 focuses specifically on obesity and describes the 
relation between coagulation and the development and regression of nutritionally-
induced obesity. The effects of hyperthyroidism on coagulation and part of the 
underlying mechanism by which thyroid hormone modulates the coagulation profile 
are the topic of chapter 8.  
In chapter 9, data on the generation and evaluation of factor V Leiden hemizygous 
mice are presented, showing the impact of an additional genetic factor instead of 
an acquired risk factor on the thrombotic phenotype of factor V Leiden mice.  
Finally, chapter 10 discusses the overall findings presented in this thesis.  
 
References 
 1  Harvey W. Excercitatio anatomica de motu cordis et sanguinis in animalibus. 1628. 
 2  van de Graaff K, Fox SI. Concepts of human anatomy and physiology. 1989. 
 3  Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb 
Vasc Biol 2006;26:41-8. 
 4  Virchow R. Phlogose und Thrombose im Gefäßsystem; Gesammelte Abhandlungen zur 
Wissenschaftlichen Medizin. 1856. 
 5  Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. 
Hematology Am Soc Hematol Educ Program 2005;1-12. 
 6  Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 
2001;109:369-84. 
 7  Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients 
homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8. 
 8  Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-73. 
 9  Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 
2003;107:I9-16. 
 10  Franchini M, Lippi G, Manzato F, et al. Hemostatic abnormalities in endocrine and metabolic 
disorders. Eur J Endocrinol 2010;162:439-51. 
 11  Pomp ER, le Cessie S, Rosendaal FR, et al. Risk of venous thrombosis: obesity and its joint 
effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007;139:289-
96. 
 12  Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. 
Thromb Res 2010;126:5-11. 
 13  Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of 
venous thrombosis. N Engl J Med 2001;344:1527-35. 
 14  Flores-Morales A, Gullberg H, Fernandez L, et al. Patterns of liver gene expression governed 
by TRbeta. Mol Endocrinol 2002;16:1257-68. 
 15  Gao H, Falt S, Sandelin A, et al. Genome-wide identification of estrogen receptor alpha-
binding sites in mouse liver. Mol Endocrinol 2008;22:10-22. 
Chapter 1 
18 
 16  Radonjic M, de Haan JR, van Erk MJ, et al. Genome-wide mRNA expression analysis of 
hepatic adaptation to high-fat diets reveals switch from an inflammatory to steatotic 
transcriptional program. PLoS One 2009;4:e6646. 
 17  Bagamasbad P, Denver RJ. Mechanisms and significance of nuclear receptor auto- and 
cross-regulation. Gen Comp Endocrinol 2011;170:3-17. 
 18  Glass CK. Going nuclear in metabolic and cardiovascular disease. J Clin Invest 
2006;116:556-60. 
 19  Di Bitondo R, Hall AJ, Peake IR, et al. Oestrogenic repression of human coagulation factor VII 
expression mediated through an oestrogen response element sequence motif in the promoter 
region. Hum Mol Genet 2002;11:723-31. 
 20  Farsetti A, Misiti S, Citarella F, et al. Molecular basis of estrogen regulation of Hageman factor 
XII gene expression. Endocrinology 1995;136:5076-83. 
 21  Inoue Y, Peters LL, Yim SH, et al. Role of hepatocyte nuclear factor 4alpha in control of blood 
coagulation factor gene expression. J Mol Med (Berl) 2006;84:334-44. 
 22  Safdar H, Inoue Y, van Puijvelde GH, et al. The role of hepatocyte nuclear factor 4alpha in 
regulating mouse hepatic anticoagulation and fibrinolysis gene transcript levels. J Thromb 
Haemost;8:2839-41. 
 23  Iwasaki Y, Nishiyama M, Taguchi T, et al. Insulin exhibits short-term anti-inflammatory but 
long-term proinflammatory effects in vitro. Mol Cell Endocrinol 2009;298:25-32. 
 24  Liu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and 
inflammation. Am J Physiol Lung Cell Mol Physiol 2006;290:L622-L645. 
 25  Bourdeau V, Deschenes J, Metivier R, et al. Genome-wide identification of high-affinity 
estrogen response elements in human and mouse. Mol Endocrinol 2004;18:1411-27. 
 26  Crossley M, Ludwig M, Stowell KM, et al. Recovery from hemophilia B Leyden: an androgen-
responsive element in the factor IX promoter. Science 1992;257:377-9. 
 27  Schmidt D, Wilson MD, Ballester B, et al. Five-vertebrate ChIP-seq reveals the evolutionary 
dynamics of transcription factor binding. Science 2010;328:1036-40. 
 28  Tchaikovski SN, Van Vlijmen BJ, Cleuren AC, et al. Pregnancy-associated changes in the 
hemostatic system in wild-type and factor V Leiden mice. J Thromb Haemost 2009;7:312-8. 
 29  Emeis JJ, Jirouskova M, Muchitsch EM, et al. A guide to murine coagulation factor structure, 
function, assays, and genetic alterations. J Thromb Haemost 2007;5:670-9. 
 30  Tsakiris DA, Scudder L, Hodivala-Dilke K, et al. Hemostasis in the mouse (Mus musculus): a 
review. Thromb Haemost 1999;81:177-88. 
 31  Day SM, Reeve JL, Myers DD, et al. Murine thrombosis models. Thromb Haemost 
2004;92:486-94. 
 32  Dorffler-Melly J, Schwarte LA, Ince C, et al. Mouse models of focal arterial and venous 
thrombosis. Basic Res Cardiol 2000;95:503-9. 
 33  Diaz JA, Hawley AE, Alvarado CM, et al. Thrombogenesis with continuous blood flow in the 
inferior vena cava. A novel mouse model. Thromb Haemost 2010;104:366-75. 
 34  Cui J, Eitzman DT, Westrick RJ, et al. Spontaneous thrombosis in mice carrying the factor V 
Leiden mutation. Blood 2000;96:4222-6. 
 35  Weiler-Guettler H, Christie PD, Beeler DL, et al. A targeted point mutation in thrombomodulin 









Transgenic mouse models of venous  























Over the past 15 years, transgenic mice have been generated that carry defective 
and/or mutant alleles of the natural anticoagulant genes, thereby displaying a 
spontaneous thrombotic phenotype. With the generation of these mouse lines, 
better opportunities became available for investigating both existing and novel risk 
factors for venous thrombosis. In addition, these models could serve as a tool for 
evaluating novel antithrombotic strategies. In this review, we will summarize these 




Mice are at present the most frequently used experimental animals. Their 
popularity is mainly due to their short breeding time, and easy low-cost 
maintenance. More importantly, as we have gained extensive knowledge of the 
mouse genome, mice have also proven to be extremely useful for carrying out 
genetic modification like transgenesis and gene targeting. However, because 
regular inbred mice do not develop venous thrombosis spontaneously, their use in 
animal research on venous thrombosis has been quite limited. A thrombotic 
phenotype could only be obtained by crude experimental approaches like ferric 
chloride induced injury, mechanical injury, photochemical injury or ligation induced 
stasis (reviewed in 1,2). Although such models provide some insight into the 
thrombotic tendency under different genetic and environmental circumstances, 
there are important limitations. The major drawback is that these models lead to 
thrombus formation in normal blood vessels by inducing endothelial damage (in a 
largely platelet dependent process), whereas venous thrombi in humans are 
formed under conditions of stasis and/or hypercoagulability. In addition, subtle 
effects on the thrombotic tendency, which are a hall-mark of human studies, cannot 
be detected in these inducible mouse models. Finally, these models do not allow 
evaluation of the effects of prolonged exposure to certain inherited and acquired 
risk factors.  
A potential breakthrough to circumvent these limitations came with the 
development of transgenesis and gene targeting in mice. These techniques allow 
the introduction of genes, the mutation of genes, or the knock-out of complete 
genes in the mouse genome. This technological advance opened an avenue to 
study risk factors for venous thrombosis in a more clinically relevant manner. In the 
past 15 years, most genes known to be involved in primary hemostasis, secondary 
hemostasis and fibrinolysis have indeed been targeted in mice, resulting in 
complete deficiencies, mutated gene products or altered protein levels, and these 
models have been extensively reviewed elsewhere.3-11 
This review will focus on genetic mouse models for venous thrombosis and 
therefore we evaluate the results of deletions and modifications of natural 
anticoagulant factors, as they are key elements in altering the venous thrombotic 
risk. Gene modifications in murine tissue factor pathway inhibitor, antithrombin and 
the proteins involved in the protein C pathway, including protein C, 
thrombomodulin, the endothelial protein C receptor and factor V (factor V Leiden) 
yielded mouse lines with spontaneous thrombotic phenotypes. These phenotypes 
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range from mildly enhanced tissue fibrin deposition, to lethal thrombosis-induced 
consumptive coagulopathy.  
With the generation of these mouse lines, better opportunities became available for 
investigating both existing and novel risk factors for venous thrombosis. In addition, 
these models could serve as a tool for evaluating novel antithrombotic strategies. 
Here we will summarize the mouse models that lack or carry mutant anticoagulant 
factors and display a spontaneous thrombotic phenotype. Furthermore, we 
evaluate whether these mouse models based on genetic modification have fulfilled 
the expectations, i.e. whether these models contributed to our understanding of risk 
factors that modulate the venous thrombotic risk, and if they have provided novel 
strategies for evaluating antithrombotic therapies.  
  
Tissue factor pathway inhibitor 
Tissue factor pathway inhibitor (TFPI) directly inhibits activated factor X (FXa), and 
subsequently inhibits the tissue factor/factor VIIa (TF/FVIIa) complex which is 
responsible for the initiation of coagulation. Mice deficient in TFPI were generated 
by disruption of the Kunitz domain 1 (TFPIK1-/-), which is required for TF/FVIIa 
inhibition.12-14 Homozygosity for this mutation results in embryonic lethality and 
examination of TFPIK1-/- embryos revealed a severe thrombotic phenotype including 
signs of yolk sac hemorrhage, immunoreactive fibrin(ogen) in the liver and 
intravascular thrombi, symptoms that are indicative for a consumptive 
coagulopathy. Mice heterozygous for the TFPI mutation have plasma TFPI activity 
levels about 50% of wild-type mice, are fertile and do not display a thrombotic 
phenotype.12-14 
Chan et al. showed that the survival rate of TFPIK1-/- mice depends on the level of 
FVII.15 When FVII levels are decreased genetically - by crossing with FVII knock-
out mice - homozygous TFPI deficient mice survive the embryonic period. 
However, after birth the combined knock-out still succumbs due to a perinatal 
consumptive coagulopathy. In line with this study, it appeared that a low level of 
tissue factor (TF) (obtained by crossing the TFPI mutant mice with mice expressing 
a low levels of human TF) also rescues the intrauterine lethality of TFPI deficient 
embryos.15,16 Surprisingly, in contrast to the perinatal death observed in TFPI 
deficient mice having a decreased FVII level, TFPI-/-/low TF mice are viable and 
show no signs of thrombosis. Also, TFPI-/-/low TF mice do not show signs of 
hemorrhage in the lung nor cardiac fibrosis, which is seen in pure low TF mice.  
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These studies demonstrated that the severe thrombotic phenotype seen in tissue 
factor pathway inhibitor deficient mice can partly be rescued by restoring the 
hemostatic balance, i.e. by lowering tissue factor or FVII levels.  
 
Antithrombin  
Antithrombin (AT) is a serine protease inhibitor that inactivates several coagulation 
proteases that are generated during blood coagulation, particularly thrombin and 
FXa. AT deficient mice (AT-/-) die in utero and the embryos show extensive 
subcutaneous and intracranial hemorrhages. Fibrin deposition was present in the 
liver and myocardium but no fibrin was present at the site of hemorrhage, which 
might be due to consumptive coagulopathy and/or liver dysfunction, indicating a 
severe thrombotic phenotype.17 
Although AT+/- mice have significantly reduced plasma antithrombin antigen and 
activity levels, their external appearance is normal and they do not show signs of 
spontaneous thrombosis.17 However, an additional thrombogenic stimulus results 
in a mild thrombotic phenotype with increased tissue fibrin deposition as compared 
to challenged wild-type mice.18 
Because heparin is an important enhancer of antithrombin activity, mice have been 
generated that carry a mutation in the heparin binding site of AT, which 
corresponds to the R47 mutation frequently seen in AT deficient patients.19 Mice 
homozygous for this mutation (ATm/m) are born, but exhibit extensive fibrin 
deposition and develop spontaneous life-threatening thrombosis, predominantly in 
the heart and liver.  
To evaluate whether diminished tissue factor activity could rescue the 
hypercoagulability of AT-/- mice, AT deficiency was introduced on a low TF 
background.20 However, the resulting AT-/-/low TF mice die in utero and exhibit 
disseminated thrombosis in the liver and heart.  
The rather mild thrombotic phenotype of AT+/- mice and the more severe phenotype 
of ATm/m mice, make these mice a potentially suitable model for studying risk 
factors of thrombosis and antithrombotic strategies. Until now, only ATm/m mice 
have been used for this purpose. Dewerchin et al. have shown that the human 
monoclonal anti-FVIII antibody LCL-mAb-LE2E9 efficiently prevents thrombosis 
(presented as priapism) in male ATm/m mice, indicating that FVIII is a potential 
target for anticoagulation therapy.21  
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Protein C pathway 
The protein C pathway consists of two circulating proteins, protein C (PC) and 
protein S, and two endothelial transmembrane proteins, thrombomodulin (TM) and 
the endothelial protein C receptor (EPCR). Furthermore, the factor V Leiden (FVL) 
mutation also affects the protein C pathway as FVL leads to an increased APC 
resistance. All of these genes, except protein S, have been inactivated and 
modified in mice, and will be discussed below.  
 
Protein C 
Activated protein C, in association with its cofactor protein S, can cleave FVIIIa and 
FVa, thereby inhibiting coagulation. Homozygous PC deficient embryos show early 
signs of thrombosis, beginning at the embryonic age of 12.5 days (E12.5).22 
Although some PC-/- pups are born, they do not survive beyond 24 hours after 
delivery. Microscopically, scattered microvascular thrombosis in the brain and focal 
liver necrosis was seen, as well as hemorrhages in the brain. This combination of 
thrombosis and bleeding in the brain is indicative of a consumptive coagulopathy.  
Whereas complete PC deficiency leads to embryonic lethality, PC+/- mice appear 
healthy and reproduce normally.22 As is seen in heterozygous AT deficient mice, 
heterozygous PC deficient mice also exhibit more pronounced intravascular fibrin 
deposition, but only after a thrombogenic stimulus.23  
Mice with severe PC deficiency (PC levels less than 4%; these mice were 
generated by introducing a PC gene construct back into the PC deficient mice) 
survive beyond birth and develop spontaneous thrombosis characterized by large 
thrombi and fibrin depositions in the lungs, liver and heart.24 The survival of these 
mice, and the onset and severity of the thrombotic phenotype, strongly depends on 
the actual plasma PC levels.  
To determine whether the coagulopathy in PC-/- embryos can be compensated by 
additional deletion of the FVII gene, double deficient mice were generated.25 PC-/- 
embryos with heterozygous FVII deficiency are born but die of consumptive 
coagulopathy. Double homozygous deficient embryos show from day E12.5 intra- 
and extravascular coagulopathy, resulting in hemorrhages and immediate death 
after birth.  
However, PC deficient mice can be rescued from embryonic lethality by a 
combination with FXI deficiency.26 The resulting double homozygous mice can live 
up to 3 months but eventually die of thrombotic diseases as is demonstrated by 
massive systemic fibrin depositions.  
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Taken together, these data show that interruption of the protein C pathway by 
deleting protein C itself generates several prothrombotic phenotypes. These 
phenotypes range from a slightly increased thrombotic risk as is seen in PC+/- mice, 
to severe spontaneous thrombotic events present in mice with very low PC levels. 
Several gene-gene interactions have been studied, resulting in the rescue of 
completely PC deficient mice when it is combined with FXI deficiency, although 
these mice develop spontaneous thrombosis later in life. This has led to the 
opportunity to study protein C deficiency in adult mice, and suggests a role for the 
intrinsic pathway to manipulate the thrombotic outcome.  
 
Endothelial protein C receptor 
EPCR can bind protein C, thereby facilitating the rate of PC activation by the 
thrombin-thrombomodulin complex. Total EPCR deficiency leads to intrauterine 
death.27 It has been suggested that thrombosis at the maternal-embryonic interface 
might contribute to embryonic death, as the developing placenta is positively 
stained for fibrin.  
EPCR+/- mice develop normally, appear healthy and do not show apparent 
thrombotic complications upon a thrombogenic stimulus.27,28 In contrast to the 
EPCR-/- embryos, mice with very low EPCR levels are viable, and do not show 
increased fibrin deposition after a challenge as compared to wild-type mice.29  
In an attempt to determine the cause of the embryonic lethality, Li et al. used 
conditional knock-out strategies to selectively express EPCR in the embryo or in 
the placenta.30 Embryonic EPCR expression in the absence of placental 
expression could not circumvent the embryonic lethality. In contrast, ablation of 
EPCR in the embryo but not in the placenta resulted in viable EPCR deficient mice 
with an age-dependent spontaneous thrombotic phenotype. In addition, the 
combination of EPCR deficiency with low TF activity (less than 1%) is also able to 
rescue EPCR deficient mice by preventing local thrombin generation at the 
maternal-embryonic interface.30  
Summarizing, EPCR expression in the placenta (in particular trophoblast cells) is 
essential for the maintenance of pregnancy, as only embryonic EPCR can be 
selectively knocked-out without resulting in embryonic lethality. A low level of 
EPCR expression is able to maintain a normal phenotype and only a total 
deficiency of EPCR results in a severe thrombotic phenotype.  
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Table 1: transgenic mouse models of venous thrombosis. 
Gene  Genotype¶ Thrombotic phenotype# Reference  
Tissue factor 
pathway inhibitor 
TFPIK1-/- Embryonic lethality, 
consumptive coagulopathy 
12,13 
 TFPIK1+/- Normal phenotype  12,13 





 TFPIK1-/-/low TF Normal phenotype 16 
Antithrombin AT-/- Embryonic lethality, 
consumptive coagulopathy 
17 
 AT+/- Normal phenotype,  
unless challenge 
18 
 ATm/m Fatal thrombosis at later age 19 
 AT-/-/low TF Embryonic lethality, 
consumptive coagulopathy 
20 
Protein C PC-/- Embryonic lethality, 
consumptive coagulopathy 
22 
 PC+/- Normal phenotype,  
unless challenge 
23 
 Low PC (<4%) Fatal thrombosis at later age 24 
 PC-/-/FVII-/- or 
PC-/-/FVII+/- 
Perinatal death,  
consumptive coagulopathy 
25 
 PC-/-/FXI-/- Fatal thrombosis at later age 26 
Endothelial protein 
C receptor 
EPCR-/- Embryonic lethality, placental 
thrombosis 
27 
 EPCR+/- Normal phenotype 27 
 Low EPCR Normal phenotype 29 
 EPCR-/-/low TF Normal phenotype,  
unless challenge 
30 
Thrombomodulin  TM-/- Embryonic lethality, 
developmental retardation 
31,32 
 TM+/- Normal phenotype 31,32 
 *TMpro/pro  Fibrin deposition 32-34 
 TMLox Partial embryonic lethality, 
Fatal thrombosis at later age 
38 
Factor V Leiden * FVQ/Q Fibrin deposition  42 
 FVQ/Q/FVIII-/- or  
FVQ/Q/FIX-/- 
Restore ability clot formation 43 
 FVQ/Q/GLA-/- Fibrin deposition,  
non-fatal occlusive thrombi 
44 
 FVQ/Q/TFPI+/- Perinatal lethality 45 
 FVQ/Q/PZ-/- Perinatal lethality 46-48 
 ¶ Additional abbreviations: TFPIK1: tissue factor pathway inhibitor with a disrupted Kunitz 1 domain; low TF: reduced tissue factor 
levels; ATm/m: antithrombin with R48C mutation; TMpro/pro: thrombomodulin with E387P mutation; TMLox: endothelium-specific 
thrombomodulin loss; FVQ/Q: factor V with R504Q mutation (factor V Leiden); GLA: α-galactidose A; PZ: protein Z. 





Endothelial membrane bound thrombomodulin (TM) forms a complex with thrombin 
and inhibits the amplification loop of the coagulation cascade by activating protein 
C. Mice with a complete TM deficiency die before embryonic day 9.5 and it is 
suggested that this is due to an inhibition of growth and development, secondary to 
a defect in the parietal yolk sac.31,32 TM+/- mice show a 50% reduction in TM levels 
compared to wild-type mice, but they appear normal and are free of thrombotic 
events.31,32  
The knock-in of a TM mutation at position 387 (glutamic acid to proline), which is 
thought to cause a loss of protein C co-factor activity, bypasses embryonic 
lethality.32 The TMpro/pro mutation leads to a severely reduced capacity to generate 
activated PC and to inhibit thrombin. This in turn results in a mild thrombotic 
phenotype with fibrin depositions in the spleen, heart and lung.32-35 Overt 
thrombosis occurs only in the presence of an additional pathological challenge.34,36 
Interestingly, these results depend on the genetic background of the mouse. 
TMpro/pro mice with a mixed 129Sv/C57BL/6J background show intravascular fibrin 
depositions whereas these depositions are not present in TMpro/pro mice with a 
C57BL/6J background.34  
Using tetraploid aggregation, Isermann et al. showed that restoring TM expression 
in extraembryonic tissue can rescue TM-/- mice from early embryonic lethality. 
However, absence of TM from the endothelium still causes late embryonic lethality 
due to consumptive coagulopathy.37 Furthermore, using a conditional (Cre/LoxP) 
approach the same research group showed that the endothelium-specific loss of 
TM results in partial embryonic lethality.38,39 Mice that survive to birth, and beyond, 
are born healthy and lack a visible thrombotic phenotype until the age of two to 
three weeks. After this period, all mutant mice develop severe thrombosis, 
terminating in a lethal consumptive coagulopathy.  
In conclusion, these studies have been extremely valuable in unraveling the 
functions of thrombomodulin. As the thrombotic phenotype of TMpro/pro mice is 
variable and dependent on interaction with secondary genetic modifiers, this model 
is attractive as a tool for future research on risk factors that modulate the venous 
thrombotic risk and to study novel strategies for antithrombotic therapies.  
 
Factor V Leiden 
Normally, factor V (FV) is degraded by activated protein C (APC), but due to an 
arginine to glutamine substation at position 506 in the human FV gene (also known 
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as the factor V Leiden (FVL) mutation40), FV is more resistant to the actions of 
APC. This mutation of the FV gene is the most common genetic risk factor for 
venous thrombosis in humans.  
In 1998 Yang et al. showed that the murine R504Q mutation in the FV gene, which 
corresponds to the human FVL mutation, results in partial APC resistance.41 Cui et 
al. generated mice carrying this homologous mutation in the FV gene by a gene-
targeting knock-in approach.42 Adult hetero- and homozygous mice (FV+/Q and 
FVQ/Q) are fertile and exhibit normal survival, but FVQ/Q mice reveal evidence for 
chronic low-grade thrombin generation, resulting in fibrin deposition in multiple 
tissues. As with the TMpro/pro mice, the genetic background of the mouse is 
important for the thrombotic phenotype, with the mixed 129Sv/C57BL/6J 
background being more prone to developing fibrin depositions than C57BL/6J 
mice.  
FVQ/Q mice have been crossed with hemophilia A (FVIII-/-) and hemophilia B (FIX-/-) 
mice.43 The hemophilia mice show spontaneous hemorrhages and are not able to 
form thrombi after vascular injuries. However, an additional FVL mutation (FV+/Q or 
FVQ/Q) can restore the ability to form a thrombus after injury.  
Fabry disease, a deficiency in α-galactidose A (GLA), is associated with premature 
vascular events that, in human, may be thrombotic in nature.44 When GLA-/- mice 
are mated with FVQ/Q mice, the offspring shows greatly increased fibrin deposition 
and occlusive thrombus formation as compared with mice with only one defect. 
This indicates a synergistic interaction between GLA deficiency and factor V 
Leiden.  
Eitzman et al. demonstrated that a modest reduction in TFPI levels, which is by 
itself not sufficient to cause a thrombotic phenotype, combined with FVQ/Q is nearly 
completely fatal in the early perinatal period.45 FVQ/Q/ TFPI+/- mice show increased 
fibrin deposition, suggesting disseminated thrombosis. The same holds for protein 
Z (PZ) deficiency: PZ-/- mice appear healthy and have no signs of vascular 
thrombosis or hepatic fibrin depositions, whereas in combination with FVQ/Q 
mutation intrauterine and perinatal thrombosis results, eventually leading to 
mortality.46-48 
Recently, Sood et al. described a mouse model in which TM and EPCR variants 
are experimentally validated as modulators of pregnancy success in FVQ/Q 
mothers.49 It appears that the interaction between these thrombotic risk factors has 
different consequences on disease manifestation, depending on the vascular bed 
in which the interaction occurs.  
Chapter 2 
30 
In the FVL mouse model, the severity and phenotypic expression of spontaneous 
thrombosis is proven to be variable and dependent on interaction with secondary 
genetic or environmental modifiers, including the genetic background of the mouse, 
FVIII, FIX, α-galactidose, TFPI and protein Z. Thus, the FVL model represents 
important aspects of thrombophilia and thrombosis in humans, and has proven to 
be valuable to validate existing, and develop novel, concepts of disease 
mechanisms in human.  
 
Discussion 
Mouse models that lack or carry mutant anticoagulant factors yielded several 
insights regarding the role of these factors and provided several mouse models that 
display a spontaneous thrombotic phenotype. In mice, complete deficiencies of 
natural anticoagulants results in many cases in embryonic lethality, mostly related 
to hemodynamic dysfunction. This demonstrates that anticoagulant factors are 
crucial for embryonic survival, and explains why complete deficiencies are rare in 
humans.3 In contrast to complete deficiencies, heterozygous deficiencies coincide 
with normal survival. For antithrombin and protein C, deletion of one allele results 
in an increased thrombotic tendency, however, only when an additional thrombotic 
stimulus is applied. These latter two models, as well as the TMpro/pro and FVQ/Q 
mice, display a mild thrombotic phenotype characterized by tissue fibrin deposition 
as a sign of chronic low-grade thrombosis.  
To circumvent embryonic lethality, different models have been developed, resulting 
in viable mice with a strong thrombotic tendency or a spontaneous thrombotic 
phenotype. These models include the homozygous mutation in the heparin binding 
site of AT, severe protein C deficiency, combined complete PC/FXI deficiency, 
TMpro/pro and deletion of TM expression on endothelial cells. Interestingly, some of 
the thrombotic phenotypes in these models are dependent on the genetic 
background of the mice.  
The generation of genetic thrombosis models was expected to provide better 
opportunities to study risk factors for venous thrombosis, and novel antithrombotic 
drugs. The question is whether the models discussed in this review indeed have 
fulfilled these expectations. Severe spontaneous thrombosis models can be useful 
for testing new antithrombotic strategies. However, to our knowledge, Dewerchin et 
al. were the only to employ such a model for evaluating the use of a monoclonal 
anti-FVIII antibody in preventing thrombosis.21 
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Of the mouse thrombosis models that followed from deletion and/or mutation of 
anticoagulant factors, the FVQ/Q model appears to be particularly successful in 
studying risk factors for venous thrombosis. The FVQ/Q model demonstrates that 
the intensity of the thrombotic phenotype can be modified by other apparently 
neutral prothrombotic factors. Examples are TFPI and protein Z; since they 
emerged as candidate modifying genes for thrombotic risk in human FV Leiden 
carriers. 
It is possible that the use of mice displaying a spontaneous thrombotic phenotype 
will become more popular in studying gene-gene and gene-environment 
interactions. For example, pro- and anti-inflammatory genes are potential candidate 
genes in modulating thrombotic risk, and prothrombotic mice like AT+/-, PC+/-, 
TMpro/pro and FVQ/Q mice could be of great value in a first validation of these 
candidate genes. In addition, epidemiological findings in large case-control studies 
have yielded several environmental risk factors, like estrogens, progestins, obesity, 
pregnancy and malignancies. Perhaps it is possible to recapitulate the effect of 
these risk factors in prothrombotic mice, which would give a unique opportunity to 
dissect the underlying mechanisms.  
A major breakthrough in the application of mice displaying spontaneous thrombotic 
phenotypes could also come from whole genome mutagenesis screens that are set 
up to identify genes that counteract the thrombotic phenotype. In these studies 
mice with a lethal prothrombotic phenotype are randomly mutagenized, in the 
expectation that some mutations will rescue the mice. To our knowledge such 
screens are currently ongoing but have not been published in full.50 In the future, 
these screening programs can provide additional information on protective gene-
gene and gene-environment interactions. This is of particular interest, as the 
mouse models also have taught us that thrombosis is a multi-causal disease that 
not only depends on prothrombotic risk factors but also on protective factors like 
the deficiency in a procoagulant factor.  
Although the use of genetically altered mice in thrombosis research was thought to 
be a major breakthrough, providing excellent opportunities to study the interaction 
between different risk factors and to study novel antithrombotic strategies, we 
consider their application at present limited. However, we are convinced of the 
potential of these models and think that the limited use of these models is because 
they are time-consuming and labour-intensive, rather than that these are 
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Background: Oral estrogen use is associated with changes in plasma levels of 
many coagulation proteins. 
Objective: To gain more insight in the underlying mechanism of estrogen-induced 
changes in coagulation.  
Methods: Ovariectomized female mice were used to study the impact of oral 17α-
ethinylestradiol (EE) on plasma coagulation, hepatic coagulation gene transcript 
levels, and dependence on estrogen receptor (ER) α and β. 
Results: 10 day oral EE treatment resulted in significant reduced plasma activity 
levels of factor (F) VIII, XII, combined FII/VII/X and antithrombin, while FIX activity 
significantly increased. Regarding hepatic transcript levels, oral EE caused 
significant decreases in fibrinogen-γ, FII, FV, FVII, FX, FXII, antithrombin, protein 
C, protein Z, protein Z inhibitor and heparin cofactor II mRNA levels, whereas FXI 
levels significantly increased and transcript levels of FVIII, FIX, protein S and α2-
antiplasmin remained unaffected. All EE-induced coagulation-related changes were 
neutralized by co-administration of the non-specific estrogen receptor antagonist 
ICI182780. In addition, ERα deficient mice lacked the EE-induced changes in 
plasma coagulation and hepatic transcript profile whereas ERß deficient mice 
responded similarly as non-deficient littermate controls. A crucial role for the 
estrogen receptor was further demonstrated by its rapid effects on transcription, 
within 2.5 to 5 hours after EE administration, suggesting a short chain of events 
leading to its final effects.  
Conclusions: Oral ethinylestradiol administration has a broad impact on the mouse 
coagulation profile at the level of both plasma and hepatic mRNA levels. The 
effects on transcription are rapidly induced, mostly down-regulating and principally 





Estrogens in contraceptives and hormone replacement therapy cause changes in 
the plasma coagulation profile. These changes include increases in the levels of 
the procoagulant factors II, VII, IX, X, XII, XIII and fibrinogen, and reductions in the 
natural anticoagulants protein S and antithrombin, resulting in an increased risk for 
venous thrombosis (reviewed in 1,2). Changes in coagulation were firstly identified 
in women taking oral contraceptives and not in women using transdermal 
patches,3,4 suggesting that the first-pass effect by the liver is important for inducing 
these changes, presumably via affecting the transcription of hepatically expressed 
coagulation genes. However, several studies have demonstrated that 
ethinylestradiol-containing patches may also confer an increased venous 
thrombotic risk,5,6 indicating that also the type of estrogen is of importance with 
respect to modulating coagulation and thereby the risk for venous thrombosis. 
Estrogens largely mediate their effects via binding to the estrogen receptor (ER) α 
or β, which subsequently functions as a transcription factor by binding to estrogen 
response elements (EREs) in the promoter or enhancer regions of estrogen-
responsive genes. Functional EREs have been identified with certainty for a limited 
number of coagulation factors, including factor VII and factor XII.7,8 Recent human 
and mouse genome-wide searches for high-affinity estrogen response elements 
demonstrated that near-consensus EREs occur in many of the genes belonging to 
the pro- and anticoagulant pathways.9 For the human genome, these include the 
liver-specific coagulation factors (F) II, FV, FVII, FIX, FX, FXI, FXII, protein S, 
protein Z and heparin cofactor II, whereas this list is less extensive for the mouse 
genome with FVII, FX, FXIII and α2-antiplasmin. For the mouse, however, 
functional genome-wide screening of hepatic estrogen receptor α binding regions 
identified ERα-binding regions in the fibrinogen, factor II, factor XI, antithrombin, 
protein C, protein S, protein Z, plasminogen and heparin cofactor II genes.10  These 
genome-wide results predict that estrogens potentially modulate transcription of a 
large number of coagulation genes expressed in the liver through the direct action 
of estrogen receptors. In this respect, it is surprising that coagulation-dedicated 
cDNA microarray analyses of livers of mice treated with estrogen revealed that 
none of the liver-specific coagulation genes were regulated by 17β-estradiol.11  
Given the inconsistency between the results of these studies, we set out a series of 
in vivo experiments to directly study effects of oral 17α-ethinylestradiol (EE), the 
estrogenic and most thrombogenic component of oral contraceptives, on the 
plasma coagulation profile on the one hand, and the impact of a single and multiple 
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EE dose on hepatic coagulation gene transcription and its possible dependency on 




Heterozygous mice carrying an estrogen receptor α knockout allele (Esr1+/-) or 
estrogen receptor ß knockout allele (Esr2+/-) on a C57Black/6J background were 
obtained from the Jackson Laboratories (Bar Harbor, USA) and intercrossed to 
generate female mice with a complete receptor deficiency (Esr1-/-  or Esr2-/- mice). 
To avoid possible baseline differences in plasma and mRNA expression levels due 
to the different origins of the mice, experiments with Esr1 and Esr2 mice included 
littermate wild-type controls as a reference (Esr1+/+ or Esr2+/+, respectively). 
Genotypes were confirmed by PCR analysis according to the protocol provided by 
the Jackson Laboratories. For experiments performed with wild-type female mice 
only, C57Bl/6J mice were purchased from Charles River (Maastricht, the 
Netherlands). All mice were housed under a 12-hour light/dark cycle and standard 
chow diet and drinking water were provided at libitum. At eight weeks of age, mice 
were bilaterally ovariectomized under isoflurane anaesthesia and after a two week 
recovery-period, they were randomly assigned to either the experimental or vehicle 
treatment group. For the Esr1+/+ and Esr1-/- mice, ovariectomy was performed 
between an average of ten and twelve weeks of age. 
 
Hormone treatment 
Ethinylestradiol (EE) and ICI182780 (both from Sigma Aldrich) stocks were 
prepared in ethanol and subsequently diluted in arachid oil with a final 
concentration of 1% ethanol. For estrogen treatment designated as ‘multiple 
doses’, mice received a daily gavage of 1 μg ethinylestradiol in 100 µl arachid oil 
for 10 consecutive days. In experiments designated as ‘single dose’, EE was given 
only once. The non-specific estrogen receptor antagonist ICI182780 was injected 
subcutaneously in a daily dose of 100 µg per mouse, starting one day prior to the 
ethinylestradiol administration in the case of the combined treatment. For the 
vehicle treatment, mice received 100 µl arachid oil with an ethanol concentration of 
1% either orally or subcutaneously, as appropriate. In addition, separate 
experiments were performed to determine whether alternative estrogen treatment 
protocols yielded essentially different results and included subcutaneous treatment 
of ovariectomized mice with 1 µg 17ß-estradiol/day for 10 days, or oral treatment 
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with 1 µg EE/mouse/day for 50 days. Furthermore, non-ovariectomized female 
mice were treated with 1 µg EE/mouse/day for 10 days to determine the additional 
effect of exogenous estrogen administration. After the last administration, mice 
were anesthetized by an intraperitoneal injection with a mixture of ketamine (100 
mg/kg), xylazine (12.5 mg/kg) and atropine (125 µg/kg) after which the abdomen 
was opened by a midline incision and a blood sample on sodium citrate (final 
concentration 0.32%) was drawn from the inferior caval vein. Plasma was obtained 
as previously described,12 and stored at -80°C until use. Part of the left liver lobule 
was isolated and snap-frozen for mRNA analyses and the uterus was collected and 
weighed to determine the biological activity of both EE and ICI182780.  
All experimental procedures were approved by the animal welfare committee of the 
Leiden University.  
 
Plasma analyses 
Alkaline phosphatases (ALP), aspartate transaminase (AST) and alanine 
aminotransferase (ALT) levels were determined using routine clinical chemistry 
assays. 
Plasma activity levels of factor VIII, IX, XI and XII were determined in an APTT-
based assay13 by mixing individual mouse plasmas with human plasma deficient for 
the respective factor (STA factor VIII from Diagnostica Stago, factor IX and factor 
XI deficient plasma from Biopool and HemosIL factor XII from Instrumentation 
Laboratories) and automated APTT-reagent (Biomerieux). Combined factor II/VII/X 
activity was assessed by using Thrombotest (Axis-Shield). For all these activity 
assays, clotting times were measured with a semi-automated coagulometer (ACL-
300, Instrumentation Laboratories).  
In addition to the combined activity, FII, FVII and FX were also measured 
separately. Factor II activity was determined after complete activation with ecarin 
(Sigma Aldrich) followed by determination of the FII amidolytic activity using the 
chromogenic substrate S2238 (Chromogenix). For FX activity, plasma was 
activated with Russell’s Viper Venom (Haematologic Technologies Inc.) and activity 
was measured by S2765 substrate (Chromogenix) conversion. Factor VII and 
antithrombin activity were determined using commercially available kits (Biophen 
FVII, Hyphen Biomed and Coamatic Antithrombin kit, Chromogenix, respectively) 
according to the manufacturer’s protocol. Plasma antithrombin antigen and 
fibrinogen antigen levels were assessed by using commercial murine ELISA kits 
from Affinity Biologicals.  
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For all plasma assays performed, mouse calibration curves paralleled human 
calibration curves, indicating specific reactions between mouse and human 
proteins. Pooled normal mouse plasma was used to generate standard curves 
which were used to calculate the activity or antigen levels and subsequently the 
wild-type vehicle-treated group was set as a reference (100%).  
 
RNA isolation and real-time RT-PCR 
Individual liver samples (20-30 mg) of 10 animals per group were homogenized in 
RNAzol (Tel-Test) and RNA isolation and cDNA synthesis was performed as 
previously described,14 with minor adjustments. Gene specific QPCR primers were 
designed with the Primer Express software (Applied Biosystems) and are 
presented in supplemental table 1. Quantitative real-time PCR was performed on 
the ABI Prism 7900 HT Fast Real-Time PCR System from Applied Biosystems and 
data were analysed using the accompanying Sequence Detection System 
software. The comparative threshold cycle method with β-actin as internal control 
was used for quantification and normalization. The vehicle-treated wild-type group 
was set as a reference and the ΔCt values of the individual samples were related to 
the mean ΔCt of the reference group.  
 
Statistical analyses 
Data are expressed as mean ± standard error of the mean (SEM) or as the 
difference between the experimental and the vehicle-treated group with the 
standard error of the difference, as appropriate. Data were analysed with the 
GraphPad Instat software and statistical differences between groups were 
evaluated using a one-way analysis of variance (ANOVA) with a Dunnett post-hoc 
test to evaluate the dose-finding study and a Bonferroni post-hoc test in the case of 
experiments performed with ethinylestradiol and ICI182780. For the estrogen 
receptor deficient mice, a Student’s t-test was used to compare the estrogen-
treated with the vehicle-treated mice of the same genotype. P-values <0.05 were 




A dose-finding study was performed as previously described15 and an in depth 
analyses is presented here, showing a hormone-dependent increase in uterus wet 
weight (fig. 1A), with a dose of 0.1 µg EE/mouse/day restoring the uterus wet 
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weight in ovariectomized mice to that observed in non-ovariectomized female mice, 
thus mimicking the endogenous estrogen levels. Analyses of circulating liver 
enzyme levels revealed a slight, but significant increase in ALP and ALT levels in 
mice treated with 10 µg EE/day, whereas these levels, and the levels of AST were 
normal for all other EE doses tested (data not shown).  
Oral EE dose-dependently increased factor IX activity (fig. 1B) whereas the levels 
of factor VIII, XII, combined factor II/VII/X (fig. 1C) and antithrombin antigen levels 
were decreased. For hepatic mRNA analyses, glutathione peroxidase 3 (Gpx3) and 
the mannose receptor (Mrc1) were used as positive controls, as it has been shown 
that these genes are estrogen-responsive,16,17 and as expected a dose-dependent 
increase in hepatic transcript levels was observed (fig. 1D). The changes in plasma 
coagulation factor levels of combined FII/VII/X and antithrombin coincided with 
dose-dependent changes in hepatic mRNA levels of these factors (fig. 1E), while 
factor IX remained constant in transcript levels. In addition, although FXI activity in 
plasma was not significantly altered by EE treatment, mRNA levels were dose-








Figure 1: Dose-dependent effects of oral ethinylestradiol administration in ovariectomized female mice. 
Effects of 10-day oral ethinylestradiol (EE) treatment on the uterus wet weight (A) and plasma coagulation factor 
activity levels (B-C) and hepatic transcript levels (D-F) in ovariectomized female mice (N=6 per group). Hepatic 
transcript levels are relative to ß-actin as an internal control and data are presented as mean±SEM. Original data 
presented in supplemental tables 2 and 3. *p-value<0.05, †p-value<0.01 and ‡p-value<0.001 versus vehicle-treated 
animals.  
A B C 
D E F 
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A dose of 1 µg EE/mouse/day was selected for further evaluation as this resulted in 
significant changes in the coagulation profile without affecting liver enzymes. This 
evaluation included comparison of the dose ethinylestradiol with a similar dose of 
the natural occurring 17ß-estradiol (subcutaneous injection) in ovariectomized 
mice, which resulted in comparable effects on uterus weight and plasma 
coagulation (data not shown). Furthermore, oral treatment of non-ovariectomized 
female mice with 1 µg EE/mouse/day caused comparable effects on plasma 
coagulation as observed under ovariectomized conditions, although these were 
less pronounced in general, and a 50-day treatment regime (1 µg EE/mouse/day) 
did also not yield essentially different results as compared to the 10-day treatment 
period (data not shown). 
 
Estrogen receptor antagonist 
We subsequently determined whether the effects on the plasma coagulation profile 
and transcript levels observed under multiple doses of oral ethinylestradiol were 
mediated by estrogen receptors α and/or β, by additionally treating mice daily with 
the non-specific estrogen receptor antagonist ICI182780 (n=15 mice per group). 
This compound was also active in the mouse, because the uterus wet weight of 
mice treated with both ICI182780 and EE reverted to that of vehicle-treated animals 
(10.6±0.5 mg vs. 9.5±0.6 mg for the vehicle treatment), whereas EE alone induced 
a significant increase in the uterus wet weight (107.8±3.9 mg; p<0.0001). 
ICI182780 alone had no effect (9.7±0.6 mg).  
Plasma coagulation factor activity levels of FVIII, FIX, FXII and combined FII/VII/X 
and antithrombin, as well as the antithrombin antigen levels were significantly 
altered due to estrogen administration (fig. 2A), which was consistent with the 
results of the dose-finding. Co-administration with ICI182780 counteracted the 
ethinylestradiol-induced changes in plasma, whereas ICI182780 treatment alone 
had no effect on the plasma coagulation profile.  
Figure 2B shows that the strong estrogen-induced up-regulation of Gpx3 and Mrc1 
transcript levels was completely antagonized by ICI182780 co-administration. 
Estrogen alone caused a significant down-regulation in mRNA levels of fibrinogen-
γ, FII, FV, FVII, FX, FXII and antithrombin, whereas factor XI transcript levels were 
significantly increased, which was again comparable to the changes previously 
observed in the dose-finding study. The panel of coagulation factors was extended 
and revealed significant reductions following EE administration in mRNA levels of 
plasminogen, protein C, protein Z, protein Z inhibitor and heparin cofactor II. Again, 
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ICI182780 co-administration counteracted the EE-induced changes in hepatic 
transcript levels, resulting in mRNA levels comparable to vehicle-treated animals 
(fig. 2B) and ICI182780 treatment alone had no effect on hepatic transcript levels. 
Protein C inhibitor and α2-macroglobulin mRNA levels were also measured but 







As the effects on the coagulation profile were sensitive to oral estrogen 
administration and an estrogen receptor antagonist was able to counteract these 
effects, experiments were repeated in ovariectomized mice lacking either estrogen 
receptor α (Esr1-/-) or β (Esr2-/-) to determine the contribution of the individual 
estrogen receptor subtypes in the EE-mediated changes of the coagulation profile. 
As expected, 10-day oral EE administration did not cause a significant increase in 
the uterus wet weight of Esr1-/- mice (uterus: 16.7±1.2 mg for the vehicle treatment 
vs. 16.3±1.4 mg for EE treatment), whereas it did in the Esr1+/+ littermate controls 
(15.9±1.8 mg vs. 116.5±1.5 mg, p<0.0001). Upon EE administration, Esr1-/- mice 
displayed no effects on plasma coagulation factor levels, whereas the littermate 
Esr1+/+ controls responded to EE with significant reduced FXI and increased FIX 
Figure 2: Hormone-induced 
effects on the coagulation profile 
of ovariectomized female mice.   
Differences between mice 
treated with 1µg ethinylestradiol 
(EE) alone as compared to 
vehicle-treated mice (□), or mice 
treated with 1µg EE and 100µg 
ICI182780 as compared to 
vehicle-treated animals (◊), on 
the plasma coagulation profile 
(A; N=15 per group) and hepatic 
transcript levels (B; N=10 per 
group). Original data presented 
in supplemental tables 4 and 5. 
Data are presented as difference 
± standard error of the 
difference; black symbols p<0.05 
as compared to vehicle-treated 
controls (0µg EE / 0µg 
ICI182780). Ag: antigen level; 
act: activity level.  
 
A B 
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activity levels (fig. 3A). Although the plasma coagulation profile of Esr1+/+ mice was 
only modestly affected by ethinylestradiol treatment, evaluation of hepatic mRNA 
levels showed significant up-regulation of the estrogen-responsive GpX3 and Mrc1 
transcripts (fig. 3B). In addition, hepatic mRNA levels of factor XI and protein S 
were also significantly higher in EE-treated Esr1+/+ mice as compared to vehicle-
treated animals of the same genotype. Fibrinogen-γ, factor V, VII and X, 
plasminogen, protein C, protein Z and α2-antiplasmin transcript levels were 
significantly down-regulated following EE treatment, thereby mimicking the 
observations in EE-treated wild-type C57Bl/6J mice. In contrast, for the Esr1-/- 
mice, no significant alterations were observed when comparing vehicle-treated to 
EE-treated mice (fig. 3B).  
In the Esr2-/- mice, EE-induced effects on the uterus wet weight were comparable to 
those observed in the Esr2+/+ mice (20.1±1.1 mg vs. 116.0±5.0 mg for Esr2-/- and 
16.3±1.0 mg vs. 114.2±5.1 mg for Esr2+/+, both p-values <0.0001). Figure 4A 
shows that oral ethinylestradiol administration resulted in comparable effects on the 
plasma coagulation profile for both genotypes and also with respect to hepatic 
transcript levels, Esr2-/- mice responded similarly to ethinylestradiol administration 





Figure 3: Ethinylestradiol-induced 
changes in the coagulation profile 
of ovariectomized female Esr1+/+ 
and Esr1-/- mice.  
Differences between Esr1+/+ mice 
treated with 1µg ethinylestradiol 
(EE) as compared to vehicle-
treated mice (□), or 
ovariectomized Esr1-/- mice 
treated with 1µg EE as compared 
to vehicle-treated animals (◊), on 
the plasma coagulation profile (A; 
N=12-15 per group) and hepatic 
transcript levels (B; N=10 per 
group). Original data presented in 
supplemental tables 6 and 7. Data 
are presented as difference ± 
standard error of the difference; 
black symbols p<0.05 as 
compared to vehicle-treated 
controls of the same genotype. 











Single EE dose  
To extend the understanding of 17α-ethinylestradiol modulation of transcription of 
coagulation genes in the liver, we determined the immediate effects of EE on 
transcription in mice orally treated with a single dose of EE, alone or in combination 
with a subcutaneous ICI182780 injection. Hepatic transcript levels were determined 
2.5 and 5 hours after administration and already 2.5 hours after the estrogen 
administration significant EE-induced changes were observed for fibrinogen-γ, FII, 
FIX, FX, antithrombin, plasminogen, protein C and protein S (fig. 5A). Evaluation of 
the hepatic transcript levels 5 hours after the EE treatment showed more 
pronounced effects of EE and ICI182780 for fibrinogen-γ, factor II, plasminogen 
and protein S when compared to the 2.5 hour time-point, and an additional down-
regulation of FV, FVII, FXII, protein Z, protein Z inhibitor and α2-antiplasmin was 
observed, whereas factor XI mRNA levels were up-regulated (fig. 5B). All EE-
induced effects were counteracted in the EE/ICI182780 treated animals. 
Comparing these results with the results after a 10-day treatment period 
demonstrates that only protein S acts differently, as transcript levels are reduced 
after a single dose, but increase after multiple EE doses.  
Figure 4: Ethinylestradiol-induced 
changes in the coagulation profile 
of ovariectomized female Esr2+/+ 
and Esr2-/- mice.  
Differences between 
ovariectomized Esr2+/+ mice 
treated with 1µg ethinylestradiol 
(EE) as compared to vehicle-
treated mice (□), or 
ovariectomized Esr2-/- mice 
treated with 1µg EE as compared 
to vehicle-treated animals (◊), on 
the plasma coagulation profile (A; 
N=13-15 per group) and hepatic 
transcript levels (B; N=10 per 
group). Original data presented in 
supplemental tables 8 and 9. 
Data are presented as difference 
± standard error of the difference; 
black symbols p<0.05 as 
compared to vehicle-treated 
controls of the same genotype. 











In the present study, we demonstrate that oral administration of the synthetic 
estrogen 17α-ethinylestradiol to ovariectomized mice has a broad impact on the 
hepatic transcript levels of both pro- and anticoagulant genes. The 17α-
ethinylestradiol effect on transcript levels of the coagulation genes was mostly 
down-regulating and, as analyzed for a limited set of factors, largely coincides with 
lowered plasma activity levels. Furthermore, the effects of 17α-ethinylestradiol on 
both the plasma and hepatic transcript levels of coagulation factors were dose-
dependent, counteracted by the estrogen receptor antagonist ICI182780, absent in 
estrogen receptor α deficient mice, and already present shortly after oral 
administration. We conclude that in mice, 17α-ethinylestradiol has widespread and 
rapid effects on coagulation which requires the involvement of estrogen receptor α. 
The results of the present study are in contrast with the study performed by 
Movérare et al. in which microarray analyses of liver samples from mice treated 
with 17β-estradiol did not yield altered hepatic coagulation gene transcript levels as 
compared to vehicle-treated mice.11 We have no explanation for the difference in 
findings other than a difference in treatment protocol, i.e. subcutaneous injection of 
2.3 μg 17β-estradiol benzoate/mouse/day for 5 days per week for 3 weeks versus 
Figure 5: Short term hormone-
induced effects on the 
coagulation profile of 
ovariectomized female mice. 
Differences between 
ovariectomized mice treated with 
1µg ethinylestradiol (EE) alone 
as compared to vehicle-treated 
mice (□), or mice treated with 
1µg EE and 100µg ICI182780 as 
compared to vehicle-treated 
animals (◊), on hepatic transcript 
levels 2.5 hours after 
administration (A; N=6 per 
group) or 5 hours after 
administration (B; N=6 per 
group). Original data presented 
in supplemental table 10. Data 
are presented as difference ± 
standard error of the difference; 
black symbols p<0.05 as 
compared to vehicle-treated 






our daily oral administration of 1 µg 17α-ethinylestradiol for 10 days, or the fact that 
the cut-off value of at least 1.6-fold of the microarray data analyses might be too 
high to detect the subtle changes in coagulation gene transcript levels. In contrast, 
two recent genome-wide screens identified high-affinity estrogen receptor binding 
sites in the mouse liver for many genes belonging to both the pro- and 
anticoagulant pathway, including fibrinogen, factor II, V, VII, X, XI, antithrombin, 
plasminogen, protein C, protein S, protein Z, α2-antiplasmin and heparin cofactor 
II.9,10 Thus, these genome-wide studies predict that estrogens can potentially 
modulate transcription of a large number of coagulation genes expressed in the 
liver through a direct interaction with estrogen receptors. Our study demonstrates 
that the transcription of these genes is indeed estrogen-responsive and controlled 
by ERα. However, our study does not allow the conclusion that the observed 
responses upon EE are the result of a direct interaction between ERα and the gene 
of interest, as predicted by the genome wide studies.  
In humans, oral contraceptive use causes changes in the plasma coagulation 
profile, resulting in a prothrombotic shift of the hemostatic balance and hence an 
increased venous thrombotic risk. In mice however, the effects of oral 
ethinylestradiol on plasma and/or hepatic mRNA levels of procoagulant factors 
were unexpectedly mostly down-regulatory, with the exception of factor IX and XI. 
Therefore, we considered the possibility that our EE dose was outside the 
therapeutically relevant window, and the results being in part an artefact or side 
effect of a relatively high oral estrogen dose. However, several observations argue 
against such an artefact: although the liver weight of mice treated with 1 µg EE was 
increased as compared to the vehicle-treated mice, no effects on liver enzymes 
were observed and histological analyses of haematoxylin/eosin-stained liver 
sections did not yield morphological abnormalities like hepatocyte degeneration or 
infiltration of inflammatory cells which are typical for EE-induced hepatotoxicity.18 
As the decreasing effects are already present with low doses EE administered 
(from 0.1 µg EE/mouse/day onwards), this implies a specific effect of the estrogen 
treatment. The observed effects may be related to the synthetic nature of the 
estrogen, however subcutaneous injections with 17ß-estradiol resulted in 
comparable effects on both plasma and transcript levels, indicating that there is no 
difference in response to either 17α-ethinylestradiol or 17ß-estradiol. Furthermore, 
non-ovariectomized female mice also showed comparable (decreasing) effects on 
coagulation due to EE treatment, indicating that there is no additional effect of 
endogenous estrogen levels. Besides, with respect to plasma analyses, our 
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observations are in line with data from Wong et al. who showed that procoagulant 
factor activity levels are lower in female mice than in male mice. This may, at least 
in part, be due to the higher estrogen levels in females.19 Taken together, we 
conclude that the observed EE-induced effects on both mouse plasma and hepatic 
transcript levels are within a biologically and pharmacologically relevant range. 
The question remains how 17α-ethinylestradiol induces a fast ER-mediated 
decrease in transcript levels for a large number of coagulation genes. Estrogen 
generally regulates gene expression by transcriptional activation. However, an 
increasing number of studies demonstrate that ligand-bound estrogen receptors 
may also mediate transcriptional repression. A recent genome-wide gene 
expression profiling study of 47,000 murine transcripts showed that of the 78 genes 
regulated by EE in the liver for which the change was at least 1.5-fold, 17 genes 
were down-regulated.20 As this cut-off of >1.5-fold change is higher than the fold 
changes observed in coagulation factors, this might not only explain why 
coagulation genes were not found in this genome-wide study, but it might also 
imply that many more genes are affected by EE administration, either in a positive 
or a negative fashion.  
An other possible explanation for the reduced transcript levels is that estrogen 
induces or represses expression of a transcription factor important in the control of 
gene expression. For example, Gao et al. has shown that STAT3 expression levels 
in estrogen-treated obese mice  are up-regulated, resulting in reduced transcript 
levels of genes involved in hepatic lipid biosynthesis.21 With respect to coagulation 
genes, the hepatocyte nuclear factor 4α (HNF4α) could be such a transcription 
factor as it is known that it can regulate transcription of several coagulation factors 
and can interfere with estrogen signaling.22,23 However, in our study, the rapidly EE-
induced effects on coagulation factor mRNA levels where independent of 
significant changes in hepatic HNF4α transcript levels (data not shown). 
Furthermore, it has become clear that activating protein-1 (AP-1) proteins play a 
role in gene repression,24 and in this respect it is striking that AP-1 elements are 
often found together with EREs,10 which also might provide an explanation for the 
reduced transcript levels observed in the present study. Besides altering 
transcriptional activity and thereby lowering mRNA levels, EE could also affect the 
mRNA stability itself. However, for now this is a subject for speculation and further 
research is needed to clarify this overall decreasing mechanism.  
In summary, our data demonstrate that oral ethinylestradiol treatment can have a 
major and rapid impact on mouse coagulation. Future studies should identify the 
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sequence of molecular steps through which the estrogen receptor α evokes the 
overall decreased transcription levels of coagulation factor levels. While this 
question for now remains unanswered, we believe that this work describes novel 
and important insights in the sequence of events contributing to the sex hormone-
induced changes in coagulation. 
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Table 4: plasma coagulation factor activity (act) and antigen (ag) levels of 
ovariectomized mice treated with 1 µg oral ethinylestradiol (EE) and / or 100 µg 
subcutaneous ICI182780 injections for 10 consecutive days.  
 Control EE EE + ICI182780 ICI182780 
Fibrinogen ag (%) 100±8.6 77.3±5.0 89.0±7.3 98.6±5.8 
Factor II act (%) 100±2.0 93.6±2.2 100.9±1.8 95.5±2.1 
Factor VII act (%) 100±5.5 93.2±4.5 111.3±8.5 102.4±6.3 
Factor VIII act (%) 100±3.5 83.7±3.3† 103.8±3.3 104.4±2.3 
Factor IX act (%) 100±2.2 121.3±2.9‡ 108.9±2.9 102.0±3.0 
Factor X act (%) 100±2.6 98.3±2.5 105.3±3.6 101.9±3.2 
Factor XI act (%) 100±5.5 96.0±4.6 103.0±3.8 97.7±3.6 
Factor XII act (%) 100±2.0 91.9±2.0* 104.3±2.2 99.4±1.8 
Factor II/VII/X act (%) 100±2.3 90.4±2.4* 103.8±2.4 99.0±2.4 
Antithrombin act (%) 100±3.7 79.6±3.5‡ 95.3±2.3 97.1±2.1 
Antithrombin ag (%) 100±2.0 90.4±2.6* 101.6±2.0 99.7±2.0 
Data are represented as mean±SEM and the vehicle-treated group is set as a reference. *p<0.05, 
†p<0.01 and ‡p<0.001 versus vehicle treatment. 
 
  
Table 5: hepatic transcript levels of ovariectomized mice treated with 1 µg oral 
ethinylestradiol (EE) and / or 100 µg subcutaneous ICI182780 injections.  
 Control EE EE + ICI182780 ICI182780 
GpX3 1±0.14 1.87±0.38‡ 0.81±0.18 0.78±0.1 
Mannose Receptor 1±0.17 1.50±0.14† 0.94±0.11 1.00±0.23 
Fibrinogen-γ 1±0.21 0.59±0.07‡ 0.86±0.10 0.98±0.19 
Factor II  1±0.10 0.62±0.07‡ 0.89±0.10 0.99±0.07 
Factor V 1±0.10 0.63±0.04‡ 0.84±0.07 0.96±0.11 
Factor VII  1±0.24 0.55±0.03‡ 0.88±0.09 0.97±0.08 
Factor VIII  1±0.15 0.99±0.09 0.88±0.22 0.89±0.22 
Factor IX  1±0.07 0.96±0.10 0.99±0.15 1.15±0.11 
Factor X  1±0.11 0.52±0.05‡ 0.91±0.06 1.00±0.13 
Factor XI  1±0.14 1.65±0.25† 1.26±0.27 1.06±0.27 
Factor XII  1±0.08 0.76±0.07† 0.89±0.12 0.92±0.08 
Antithrombin 1±0.15 0.66±0.06‡ 0.91±0.07 1.04±0.13 
Plasminogen 1±0.06 0.59±0.04‡ 0.92±0.14 1.05±0.13 
Protein C 1±0.08 0.76±0.11* 1.00±0.13 1.04±0.12 
Protein S 1±0.09 1.21±0.12 0.98±0.13 0.98±0.12 
Protein Z 1±0.07 0.81±0.08* 1.00±0.12 1.11±0.11 
Protein Z Inhibitor 1±0.11 0.68±0.09‡ 0.95±0.11 1.06±0.15 
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α2-Antiplasmin 1±0.06 0.87±0.10 1.12±0.14 1.01±0.46 
Heparin Cofactor II 1±0.05 0.84±0.05* 0.97±0.11 1.03±0.11 
Data are represented as mean±SEM and normalized for β-actin with the vehicle-treated group set as 
reference. *p<0.05, †p<0.01 and ‡p<0.001 versus vehicle treatment. 
 
Table 6: plasma coagulation factor activity (act) and antigen (ag) levels of 
ovariectomized Esr1+/+ and Esr1-/- mice orally treated with 1 µg ethinylestradiol 
(EE).  
 Esr1+/+ Esr1-/- 
 Control EE Control EE 
Fibrinogen ag (%) 100±4.6 107.3±8.4 115.4±6.3 136.7±13.0 
Factor II act (%) 100±2.5 103.9±1.9 105.7±2.3 107.7±4.6 
Factor VII act (%) 100±4.4 96.0±6.9 100.1±4.5 118.0±11.6 
Factor VIII act (%) 100±7.2 88.8±9.0 118.5±8.3 104.8±12.4 
Factor IX act (%) 100±3.4 122.1±6.6† 86.1±4.6 96.2±5.4 
Factor X act (%) 100±2.6 105.9±2.6 104.0±2.2 108.4±2.7 
Factor XI act (%) 100±2.9 87.4±4.5* 84.3±2.5 90.2±5.9 
Factor XII act (%) 100±5.2 101.2±5.8 95.1±4.9 97.6±5.5 
Factor II/VII/X act (%) 100±2.8 100.1±2.7 104.5±3.9 106.9±6.0 
Antithrombin act (%) 100±4.9 98.0±3.3 104.1±4.6 109.9±5.4 
Antithrombin ag (%) 100±2.3 98.5±2.7 103.3±2.1 103.8±1.2 
Data are represented as mean±SEM and the wild-type vehicle-treated group is set as a reference. 
*p<0.05 and †p<0.01 versus vehicle treatment of the same genotype. 
 
Table 7: hepatic transcript levels of Esr1+/+ and Esr1-/- mice orally treated with 
ethinylestradiol (EE).  
 Esr1+/+ Esr1-/- 
 Control EE Control EE 
GpX3 1±0.20 1.92±0.36‡ 1.04±0.24 1.26±0.41 
Mannose Receptor 1±0.19 1.76±0.37† 0.79±0.20 0.88±0.26 
Fibrinogen-γ 1±0.09 0.75±0.13* 1.00±0.15 0.95±0.16 
Factor II  1±0.22 0.78±0.11 0.83±0.21 0.78±0.35 
Factor V 1±0.23 0.70±0.07* 0.95±0.13 0.91±0.13 
Factor VII  1±0.17 0.66±0.09† 0.94±0.11 0.81±0.28 
Factor VIII  1±0.19 1.25±0.15 0.86±0.14 0.90±0.35 
Factor IX  1±0.08 0.91±0.14 0.83±.011 0.92±0.18 
Factor X  1±0.27 0.60±0.11† 0.87±0.22 0.68±0.24 
Factor XI  1±0.23 1.44±0.17* 0.81±0.14 0.79±0.32 
Factor XII  1±0.23 0.91±0.05 1.00±0.16 0.92±0.14 
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Antithrombin 1±0.22 0.65±0.21* 1.06±0.15 1.01±0.11 
Plasminogen 1±0.12 0.65±0.13† 0.97±0.15 0.82±0.19 
Protein C 1±0.14 0.75±0.11* 0.85±0.10 0.83±0.16 
Protein S 1±0.16 1.31±0.15* 0.97±0.18 1.10±0.30 
Protein Z 1±0.21 0.63±0.12† 0.71±0.10 0.67±0.19 
Protein Z Inhibitor 1±0.15 0.88±0.13 0.95±0.13 1.33±0.64 
α2-Antiplasmin 1±0.08 0.76±0.11
† 1.00±0.13 0.93±0.23 
Heparin Cofactor II 1±0.14 0.84±0.11 0.91±0.09 0.80±0.17 
Data are represented as mean±SEM and normalized for β-actin with the wild-type vehicle-treated group 
set as reference. *p<0.05, †p<0.01 and ‡p<0.001 versus vehicle treatment of the same genotype. 
 
Table 8: plasma activity (act) and antigen (ag) levels of Esr2+/+ and Esr2-/- mice 
treated with oral ethinylestradiol (EE).  
 Esr2+/+ Esr2-/- 
 Control EE Control EE 
Fibrinogen ag (%) 100±8.0 69.6±4.5† 105.8±7.7 64.6±4.0‡ 
Factor II act (%) 100±3.8 102.9±2.9 104.2±5.9 97.6±3.6 
Factor VII act (%) 100±4.6 66.7±4.2‡ 112.9±4.7 73.1±6.0‡ 
Factor VIII act (%) 100±5.4 89.1±4.9 100.9±5.5 76.8±5.2† 
Factor IX act (%) 100±4.1 127.8±3.2‡ 116.6±4.2 127.3±4.7 
Factor X act (%) 100±3.5 108.6±3.0 107.6±5.6 101.8±3.8 
Factor XI act (%) 100±2.5 88.3±3.2† 106.4±3.3 80.5±3.6‡ 
Factor XII act (%) 100±3.7 90.7±1.9* 109.0±3.5 85.0±2.3‡ 
Factor II/VII/X act (%) 100±3.0 86.8±2.4† 101.3±2.9 86.1±2.5‡ 
Antithrombin act (%) 100±4.1 99.3±5.4 114.9±7.6 107.2±8.6 
Antithrombin ag (%) 100±4.9 91.6±2.6 102.7±3.8 93.4±5.9 
Data are represented as mean±SEM and the wild-type vehicle-treated group is set as a reference. 
*p<0.05, †p<0.01 and ‡p<0.001 versus vehicle treatment of the same genotype. 
 
Table 9: hepatic transcript levels of Esr2+/+ and Esr2-/- mice orally treated with 
ethinylestradiol (EE). 
 Esr2+/+ Esr2-/- 
 Control        EE Control        EE 
GpX3 1±0.18 2.34±0.72‡ 1.04±0.16 2.14±0.33‡ 
Mannose Receptor 1±0.23 1.28±0.27 0.81±0.15 1.66±0.17‡ 
Fibrinogen-γ 1±0.18 0.53±0.23* 0.89±0.12 0.57±0.07‡ 
Factor II  1±0.10 0.47±0.09‡ 0.92±0.13 0.44±0.05‡ 
Factor V 1±0.16 0.52±0.08‡ 0.90±0.24 0.39±0.05‡ 
Factor VII  1±0.10 0.47±0.09‡ 0.99±0.15 0.43±0.06‡ 
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Factor VIII  1±0.15 0.85±0.18 0.86±0.22 0.74±0.13 
Factor IX  1±0.12 0.64±0.18* 0.92±0.10 0.63±0.06‡ 
Factor X  1±0.17 0.39±0.09‡ 1.00±0.19 0.34±0.07‡ 
Factor XI  1±0.29 0.98±0.28 1.07±0.19 1.08±0.17 
Factor XII  1±0.15 0.73±0.12* 0.82±0.29 0.48±0.29 
Antithrombin 1±0.12 0.59±0.09‡ 0.98±0.13 0.51±0.05‡ 
Plasminogen 1±0.12 0.52±0.09‡ 0.92±0.15 0.45±0.06‡ 
Protein C 1±0.13 0.59±0.09‡ 0.92±0.14 0.54±0.06‡ 
Protein S 1±0.09 1.09±0.19 0.95±0.16 1.02±0.14 
Protein Z 1±0.13 0.53±0.21† 0.99±0.14 0.56±0.06‡ 
Protein Z Inhibitor 1±0.17 0.81±0.15 1.00±0.17 0.65±0.06‡ 
α2-Antiplasmin 1±0.15 0.66±0.14
† 0.98±0.14 0.62±0.08‡ 
Heparin Cofactor II 1±0.12 0.62±0.11‡ 0.94±0.11 0.57±0.06‡ 
Data are represented as mean±SEM and normalized for β-actin with the vehicle-treated group per 
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Oral contraceptive (OC) use affects the plasma levels of several pro- and 
anticoagulant as well as fibrinolytic factors, overall leading to an increased risk of 
venous thrombosis. The estrogen in OCs is considered to be the main 
prothrombotic constituent, however, the introduction of the third generation 
contraceptives containing desogestrel instead of levonorgestrel, revealed a 
modulating anti-estrogenic effect of progestins on estrogen-induced alterations in 
the coagulation profile and thrombotic risk.1 Such anti-estrogenic effects of 
progestins are also established for murine uterine gene transcription.2  
Here, we examined the anti-estrogenic effects of the second-generation progestin 
levonorgestrel (LNG) and third-generation desogestrel (DSG) on coagulation gene 
transcription in the liver, i.e. the major source of plasma coagulation factor 
synthesis. As a model we use mice orally treated with the estrogen 17α-
ethinylestradiol (EE) for which we previously demonstrated rapid estrogen receptor 
(ER) α-dependent changes in hepatic transcription of coagulation genes.3 As 
changes could be fully counteracted by the ER antagonist ICI182780, this model is 
suitable for detecting anti-estrogenic effects on coagulation factor levels (table 1, 
reference 3). 
Ovariectomized C57Black/6J mice (Charles River, Maastricht, the Netherlands) 
were treated with either vehicle (100 µl arachid oil/day), 3 or 10 µg LNG/day, or 3 or 
10 µg DSG/day, both in the absence and presence of 1 µg EE/day (Sigma, 
Steinheim, Germany and Duchefa Farma, Haarlem, the Netherlands; n=12 per 
group). This EE dose was based on our previous experiments,3 whilst the progestin 
doses were chosen to reflect the 5-fold (w/w) ratio with EE in OCs. RNA isolation 
and quantitative real-time PCR of individual liver samples, as well as plasma 
analyses were performed as previously described.3 
To establish the biological effect of ethinylestradiol and the progestins, 
haematoxylin/eosin stained vaginal smears were evaluated, showing 
predominantly leukocytes in smears of vehicle-treated mice and mainly cornified 
cells in smears of EE-treated mice. Mice treated with both EE and a progestin 
(either LNG or DSG) showed nucleated epithelial and cornified cells with some 
leukocytes. In addition, gross inspection of the uterus (haematoxylin/eosin stained 
sections) showed that EE-treated mice had increased myometrium, stromal and 
endometrial epithelium thickness, resulting in an increased uterus wet weight as 
compared to vehicle-treated mice (16.3±0.1 mg vs. 123.1±7.6 mg, p<0.0001). In 
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contrast, mice treated with both EE and a progestin showed a significant dose-
dependent reduction of the uterus weight when compared to EE-only treated 
animals, with uterus weights of 53.2±2.9 mg and 46.3±3.8 mg for EE/10 µg LNG 
and EE/10 µg DSG respectively (p<0.01). LNG or DSG alone had no effect on 
vaginal smears or uterus phenotype. Based on these results, we conclude that both 
progestins have similar biological activity in the mouse, and are able to modulate 
the estrogen-induced effects on the uterus. 
Table 1 shows significant increases in hepatic transcript levels of glutathione 
peroxidase 3 (GpX3), coagulation factor (F) XI and protein S levels, and significant 
decreases in FV, FVII, FX, FXII and antithrombin transcript levels upon EE 
treatment as expected,3 while fibrinogen-γ and FII levels were not affected (data 
not shown). Importantly, addition of either LNG or DSG to EE treatment did not 
result in statistically significant modulating effects on transcript levels as compared 




Table 1: Summary significantly affected relative transcript levels of mice treated with 17α-
ethinylestradiol (EE), levonorgestrel (LNG), desogestrel (DSG), or the estrogen receptor 
antagonist ICI182780. 






GpX3 1±0.20 2.57±0.67* 2.40±0.35* 1.92±0.71* 0.81±0.18# 
Factor V 1±0.16 0.65±0.08* 0.67±0.08* 0.63±0.09* 0.84±0.07# 
Factor VII 1±0.16 0.69±0.12* 0.70±0.11* 0.62±0.08* 0.88±0.09# 
Factor X 1±0.19 0.51±0.12* 0.61±0.10* 0.56±0.14* 0.91±0.06 
Factor XI 1±0.10 1.50±0.17* 1.39±0.23* 1.26±0.25 1.26±0.27 
Factor XII 1±0.11 0.75±0.12* 0.87±0.11 0.76±0.09* 0.89±0.12 
Antithrombin 1±0.11 0.71±0.10* 0.75±0.09* 0.59±0.08* 0.91±0.07# 
Protein S 1±0.10 1.25±0.12* 1.11±0.18 1.16±0.08 0.98±0.13 
GpX3: glutathione peroxidase 3. 
Relative expression levels were compared using the comparative threshold cycle method with β-actin as internal 
control. Data are presented as mean±standard error of the mean of n=12 mice per group and statistical differences 
between groups were evaluated using a one-way analysis of variances (ANOVA) with a Bonferroni post-hoc test. 
*p<0.05 compared to vehicle treatment, #p-value <0.05 compared to EE treatment. 
a: Combined EE/ICI182780 treatment was performed in a separate experiment 3 and data are compared to vehicle- and 
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In addition to mRNA levels, we also determined the plasma levels of a limited set of 
coagulation factors and observed an increase in FIX activity (+12%), and 
decreases in combined factor II/VII/X (-7%) and antithrombin (-10%) activity levels 
upon EE treatment, which were comparable to previous observations.3 Neither 
LNG or DSG alone, nor in combination with EE had an effect on these plasma 
parameters (data not shown). 
As DSG in combination with EE compared to EE treatment alone, showed a 
tendency to modulate GpX3 (p=0.20), factor XI (p=0.13), protein S (p=0.22) and 
antithrombin (p=0.06) transcript levels, we increased the DSG dose to the 
suprapharmacological range of 50 to 500 µg/mouse/day to further explore this 
potential (n=5/group). These high DSG doses did not cause liver toxicity, as 
evaluated by circulating liver enzyme levels, whereas the uterus phenotype was 
strongly affected, resulting in almost complete reversal of the EE-induced increase 
in uterus weight (122.7±4.6 mg for 1 µg EE vs. 34.5±1.9 mg for 1 µg EE/500 µg 
DSG, p<0.001). Only for the 500 µg DSG dose, a significant reversal of the EE-
induced effects on hepatic transcript levels of GpX3, FX and antithrombin was 
observed (relative expression levels 1 µg EE vs. 1 µg EE/500 µg DSG: 3.44±0.62 
vs. 1.79±0.52 for GpX3, 0.58±0.09 vs. 0.85±0.07 for FX and 0.69±0.13 vs. 
0.97±0.09 for antithrombin). 
In summary, the hepatic transcript levels of coagulation genes were only minimally 
affected by combined estrogen/progestin treatment, which is in contrast to the anti-
estrogenic effects observed on the uterus. One possible explanation for this 
discrepancy in responses could be that progesterone receptor transcript levels are 
only 2% of the ERα levels in the liver, which may not be sufficient to exert the anti-
estrogenic effects observed in the uterus.2  
The mouse data presented here suggest that the anti-estrogenic effects of 
progestins on the thrombotic risk in humans lay outside transcriptional modulation 
of coagulation factors produced in the liver. However, as the liver also produces 
several fibrinolytic factors, we cannot exclude that progestins modulate estrogenic 
effects on fibrinolysis. We speculate that the effects of progestins on thrombosis 
are at the level of the vasculature, as blood vessels express both estrogen and 
progesterone receptors. This may involve modulation of expression of coagulation 
genes like tissue factor, tissue factor pathway inhibitor, von Willebrand factor, 
endothelial protein C receptor or thrombomodulin.  
In conclusion, the present studies show that in the mouse the progestins 
levonorgestrel and desogestrel, while evidently and equally biologically active on 
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Background: Obesity and oral estrogens are independent risk factors for venous 
thrombosis, and their combined effect is stronger than the sum of the isolated 
factors.  
Objective: Investigate the interaction between obesity and estrogens at the level of 
coagulation, inflammation and the venous thrombotic tendency in a mouse model.  
Methods: Female C57Bl/6J mice were fed a standard fat diet (SFD) or a high fat 
diet (HFD) to induce nutritional obesity. After 14 weeks, while maintaining their diet, 
mice were orally treated 8 days with 1 µg ethinylestradiol or vehicle (n=25 per 
group), and subsequently subjected to an inferior caval vein (ICV) thrombosis 
model.  
Results: The ICV thrombosis model resulted in an increased thrombus weight in 
vehicle-treated HFD mice (3.0±0.7 mg) compared to vehicle-treated SFD mice 
(1.4±0.4 mg; p=0.064). Surprisingly, estrogens reduced the thrombus weight, which 
was significant for the HFD group (0.8±0.5 mg; p=0.013). As compared to SFD 
feeding, HFD feeding significantly increased plasma levels of coagulation factor 
VIII, combined factor II/VII/X (p<0.001), and plasminogen activator inhibitor-1 
(p=0.009), causing a prothrombotic shift of the coagulation profile. Estrogens had 
no significant effects on this profile with either diet, whereas serum amyloid A and 
hepatic inflammatory cytokines were minimally affected.  
Conclusions: The synergistic effect of obesity and estrogens on the venous 
thrombotic risk in women could not be translated into the mouse context. Short-
term ethinylestradiol administration in a mouse ICV thrombosis model counteracts 
the prothrombotic phenotype associated with nutritionally-induced obesity, despite 
a comparable activated plasma coagulation profile in estrogen-treated and 





Obesity and the use of oral estrogens, as in contraceptive use and hormone 
replacement therapy, are both associated with an enhanced activity of the 
coagulation system and an increased risk of venous thrombosis.1-6 Interestingly, 
large case-control studies have shown that the combined effect of obesity and 
contraceptive use is higher than the sum of the separate factors, at least for the use 
of oral contraceptives, but not for transdermal patches.4,7,8 This latter observation 
suggests that the first-pass effect of the liver, the main site for the production of 
coagulation factors, is important for the interaction of obesity and estrogens.  
Besides the joint effects of obesity and estrogens on the coagulation profile, they 
both affect fibrinolysis, the lipid profile and inflammatory state, although these 
effects are predominantly opposite. For example, whereas estrogens have 
beneficial effects on the lipid profile, improve fibrinolysis and have anti-
inflammatory actions, obesity is associated with lipid disorders, reduced fibrinolysis 
and it is considered to be a chronic, low-grade inflammatory state which may 
contribute to the venous thrombotic risk.2,9-12  
Animal studies, including ferric chloride injury of the mouse femoral artery, have 
demonstrated that obesity enhances the arterial thrombotic tendency.13-16 However, 
the effects of obesity or oral estrogens on the venous thrombogenicity are less well 
characterized. In the present study, we have evaluated the effects of nutritionally 
induced obesity and short-term oral estrogen administration, alone and in 
combination, on venous thrombosis using a murine inferior caval vein thrombosis 
model. To study their effects on hemostasis regulation, we analysed the plasma 
coagulation profile and the hepatic mRNA levels of coagulation factors and of 
inflammatory cytokines.  
 
Materials and methods 
Dose finding 
Female C57Bl/6J mice (Charles River, Maastricht, The Netherlands) were fed a 
standard chow diet (Tecnilab-BMI, Someren, The Netherlands) and at eight weeks 
of age, they were bilaterally ovariectomized under isoflurane anesthesia. After a 
two-week recovery period, mice were treated with increasing doses of 
ethinylestradiol (EE; Sigma Aldrich Chemie, Steinheim, Germany), administered 
daily at a fixed time-point as 100 µl arachid oil containing 0, 0.03, 0.1, 0.3, 1, or 3 
µg EE by oral gavage (n=6 per group).  In a separate experiment, ovariectomized 
mice were treated orally with 1 µg EE per day, in the presence or absence of 100 
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µg non-selective estrogen receptor antagonist (ICI 182780; Sigma Aldrich Chemie, 
Steinheim, Germany) which was subcutaneously injected. For both experiments, 
mice were treated for 10 days after which a blood sample on acid citrate was drawn 
and plasma was obtained by centrifugation and stored at -80°C.17 Subsequently, 
mice were sacrificed by cervical dislocation and the liver was isolated and snap 
frozen in liquid nitrogen for RNA analyses. The uterus was collected and weighed 
to monitor the biological activity of the EE. 
 
Nutritionally-induced obesity and estrogen treatment  
Five-week-old female C57Bl/6J mice (generated at the K.U. Leuven animal 
facilities) were fed a standard fat diet (SFD; KM-04-k12, Muracon, Carfil, Oud-
Turnhout, Belgium, containing 13% kcal as fat with a caloric value of 10.9 kJ per g) 
or a high fat diet (HFD; TD88137, Zeist, The Netherlands, containing 42% kcal as 
fat with a caloric value of 20.1 kJ per g) to induce nutritional obesity (n=50 mice per 
group). After 14 weeks, while maintaining their diet, they were treated by oral 
gavage for eight days with 1 µg EE per day or a vehicle (n=25 per group). 
Subsequently, mice were subjected to an inferior caval vein thrombosis model as 
described by Singh et al.18 In brief, under isoflurane anesthesia, a midline 
laparotomy incision was made and the inferior caval vein (ICV) was exposed. After 
applying a neurosurgical vascular clip to the dissected ICV, the ICV was ligated 
upon deposition of a Prolene thread.19 By removing the Prolene thread after 
ligation, slow flow was restituted, triggering platelet activation, stasis and thrombus 
formation. The abdomen was closed, and 24 hours later the ICV was harvested 
and the thrombus was isolated and weighed after overnight drying. In each group, 
the ICV from 2-3 animals subjected to the venous thrombosis model were formalin-
fixed, paraffin-embedded and stained with hematoxylin/eosin for histological 
analyses. Furthermore, the uterus and liver were isolated and weighed, as well as 
the epididymal (gonadal) and inguinal (subcutaneous) fat pads. Before the start of 
oral EE/vehicle treatment and before the thrombosis experiment, a blood sample 
on acid citrate was taken from the retro-orbital sinus after overnight fasting and 
plasma was stored at -80°C. All animals were housed in micro-isolation cages 
under a 12 hour day/night cycle, and had free access to drinking water and 





Alkaline phosphatases (ALP), aspartate transaminase (AST) and alanine 
aminotransferase (ALT), as well as the total, HDL and LDL cholesterol and 
triglyceride levels were determined using routine clinical assays. Antithrombin 
antigen was measured by one-dimensional electrophoresis using an anti-human 
antithrombin polyclonal antibody.15 Plasminogen activator inhibitor-1 (PAI-1) 
antigen levels were measured with a specific ELISA20 and fibrinogen antigen levels 
were assessed using an ELISA with an anti-human fibrinogen polyclonal antibody. 
Coagulation factor V, factor VIII and combined factor II/VII/X plasma activity levels 
were measured as described by Nagai et al.15 Antithrombin activity levels and 
thrombin-antithrombin (TAT) complexes were determined with commercial kits 
(Coamatic Antithrombin kit, Chromogenix, Mölndal, Sweden and Enzygnost TAT 
micro, Dade Behring, Marburg GmbH, Marburg, Germany, respectively). 
6-keto Prostaglandin F1α (6-keto PGF1α) was assessed with a commercially 
available kit (Cayman Chemical Company, Ann Arbor, MI, USA); serum amyloid A 
and interleukin-6 measurements were performed using commercial immunoassay 




In each group, six animals were sacrificed without being subjected to the venous 
thrombosis model. Livers were isolated and snap frozen in liquid nitrogen for 
quantitative RNA analyses. RNA isolation and real-time qPCR was performed on 
20 to 30 mg of liver tissue, according to the method previously described by Ter 
Horst et al. for lung tissue.21 Gene-specific primers were designed with the Primer 
Express software (Applied Biosystems) and are presented in table 1. Data were 
analyzed with the supporting ABI Prism software package using the comparative 
threshold cycle method with β-actin as an internal control. The standard fat diet 
group treated with the vehicle was set as the reference group and the ∆Ct values of 
the individual samples were related to the mean ∆Ct of the reference group.   
 
Statistical analyses 
Data are expressed as mean ± standard error of the mean (SEM). Statistical 
significance for differences between groups was analyzed by non-parametric t-
testing (Mann-Whitney). Analyses were performed using GraphPad Instat (San 
Diego, CA, USA) and p-values <0.05 were considered to be statistically significant.  
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Table 1: RT-PCR primer sequences 
Gene  Forward primer Reverse primer 
β-actin AGGTCATCACTATTGGCAACGA CCAAGAAGGAAGGCTGGAAAA 
Factor II GGACGCTGAGAAGGGTATCG CCCCACACAGCAGCTCTTG 
Factor V CATGGAAACCTTACCGACAGAAA CATGTGCCCCTTGGTATTGC 
Factor VII CGTCTGCTTCTGCCTAGA ATTTGCACAGATCAGCTGCTCAT 
Factor VIII CTTCACCTCCAGGGAAGGACTA TCCACTTGCAACCATTGTTTTG 
Factor X GTGGCCGGGAATGCAA AACCCTTCATTGTCTTCGTTAATGA 
Antithrombin TGGGCCTCATTGATCTCTTCA CCTGCCTCCAGCAACGAT 
Fibrinogen-γ TGCTGCCTGCTTTTACTGTTCTC TCTAGGATGCAACAGTTATCTCTGGTA 
PAI-1 CGCTGCACCCTTTGAGAAAG TGATGAGTTCAGCATCCAAGATG 
IL-6 ACAAGTCGGAGGCTTAATTACACAT AATCAGAATTGCCATTGCACAA 
TNF-α CCCCAAGGGATGAGAAGTTC TGTGAGGGTCTGGGCCATAG 
MMP-12 TGTGGAGTGCCCGATGTACA AGTGAGGTACCGCTTCATCCAT 
MCP-1 CAGCACCTTTGAATGTGAAGTTG TGCTTGAGGTGGTTGTGGAA 
PAI-1 : plasminogen activator inhibitor-1 ; IL-6 : interleukin-6 ; TNF-α : tumor necrosis factor- α ; MMP-12 : matrix 





A dose-finding study in ovariectomized mice was performed prior to the obesity / 
estrogen experiment in order to determine the minimal oral dose of ethinylestradiol 
(EE) required to induce changes in the coagulation profile. Oral EE dose-
dependently induced an increase in the uterine wet weight, and changes in 
antithrombin levels (figure 1a), combined factor II/VII/X, factor VIII activity and PAI-
1 levels, without affecting plasma ALT, AST or ALP levels (data not shown). The 
reduced plasma factor II/VII/X activity and antithrombin was paralleled by dose-
dependent decreases of hepatic mRNA levels (figure 1 panel b). A dose of 1 μg EE 
per mouse per day caused significant reductions in antithrombin antigen and 
activity levels (120±2% of normal pooled plasma (NPP) vs. 105±5% NPP 
antithrombin antigen levels for vehicle-treated and estrogen-treated animals 
respectively, p=0.013; 123±2% NPP vs. 102±5% NPP, p=0.006 for activity levels), 
and combined factor II/VII/X activity (105±4% NPP vs. 87±3% NPP, p=0.006), 
whereas PAI-1 plasma levels were significantly increased as compared to vehicle-
treated mice (1.48±0.10 ng/ml vs. 2.48±0.32 ng/ml, p=0.009). Significant changes 
in the hepatic transcript levels of estrogen-treated mice included a reduction of 
antithrombin (relative transcript level: 1±0.08 vs. 0.46±.15, p=0.025), factor V 
(1±0.04 vs. 0.69±0.04, p=0.037), factor VII (1±0.04 vs. 0.67±0.03, p=0.004) and 
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factor X (1±0.04 vs. 0.66±0.03, p=0.016). Additional treatment with the estrogen 
receptor antagonist ICI182780 resulted in significant counteraction of the estrogen 
induced effects, including the plasma antithrombin levels (figure 1c; 93.1±1.9% 
NPP for control treated animals, 84.2±2.4% NPP for estrogen treatment and 
94.6±1.9% NPP for both estrogen and ICI182780 administration) and combined 
factor II/VII/X activity (91.6±2.1% NPP vs. 82.7±2.2% NPP vs. 95.1±2.2% NPP, 
respectively). Also on hepatic mRNA levels, estrogen receptor antagonist 
administration caused normalization of the effects of the oral estrogens in 
antithrombin (figure 1d; 1±0.15 for vehicle-treated animals vs. 0.66±0.06 for 
estrogen treated mice vs. 0.91±0.07 for combined estrogen and estrogen receptor 
antagonist treatment), factor VII (1±0.06 vs. 0.61±0.04 vs. 0.98±0.10, respectively) 
and factor X (1±0.11 vs. 0.52±0.05 vs. 0.91±0.06). Therefore, a dose of 1 µg EE 
per mouse per day was selected for further studies, being the lowest oral dose that 
resulted in significant and estrogen-specific changes in plasma coagulation 






Nutritionally induced obesity 
After 15 weeks, mice on a HFD receiving the vehicle treatment showed a significant 
increase in body weight, liver weight and gonadal and subcutaneous fat pads (all 
p<0.001) as compared to vehicle-treated mice on SFD (table 2). Plasma lipids 
including total plasma cholesterol, HDL and LDL cholesterol and triglyceride levels, 
Figure1: Dose-dependent effects 
of oral ethinylestradiol (EE) on 
the plasma antithrombin antigen 
(panel a) and hepatic mRNA 
levels related to ß-actin (b). The 
effects of 1 µg EE per mouse per 
day on plasma and hepatic 
mRNA levels of antithrombin are 
normalized by additional 
treatment with 100 µg of the 
estrogen receptor antagonist ICI 
182780 (ICI; panel c and d).  
NPP: normal pooled plasma.  
Data are represented as 
mean±SEM. *p<0.05 and 
**p<0.01 versus vehicle 
treatment, ‡p<0.01 and 
‡‡p<0.001 versus estrogen 
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as well as plasma levels of the liver enzymes AST and ALT, were significantly 
higher in vehicle-treated HFD mice than in vehicle-treated SFD mice (table 3). 
Levels of 6-keto PGF1α showed a non significant decrease in nutritionally-induced 
obese vehicle-treated mice as compared to mice on a standard fat diet without 
estrogen treatment (100±36.1% vs. 42.7±23.1%, p=n.s.). 
 
Estrogen treatment 
Eight days of treatment with an oral dose of 1 µg EE did not cause significant 
changes in the body weight although the uterus weight in estrogen-treated mice 
was significantly increased as compared to vehicle-treated mice on the same diet 
(for both groups, p<0.001; table 2). The liver weight showed a significant increase 
due to estrogen administration in the SFD group only (p<0.001), whereas 
estrogens induced a reduction in gonadal as well as subcutaneous fat pads 
(p=0.010 for the subcutaneous fat pads in the HFD fed mice). Total plasma 
cholesterol and LDL cholesterol levels were significantly increased after estrogen 
treatment in mice on a SFD (both p<0.001), whereas no significant changes in 
plasma lipid levels were observed in the HFD group (table 3). AST levels 
decreased significantly in both diet groups upon orally administered estrogens 
(SFD p=0.010, HFD p=0.002), whereas ALT levels were significantly reduced in the 
HFD fed mice only (p=0.011). Estrogen administration in SFD as well as HFD fed 
mice did not had an effect on 6-keto PGF1α levels as compared to the vehicle 
treatment (from 100±36.1% to 133.1±51.5% for estrogen-treated SFD mice and 
from 42.7±23.1% to 52.9±23.3% for estrogen-treated HFD mice; p=n.s.) 
 
 
Table 2: Organ and adipose tissue weights of mice kept on a standard (SFD) or high fat 
(HFD) diet, treated with ethinylestradiol (EE+) or vehicle (EE-). 
 SFD HFD 
EE– (n=23) EE+ (n=19) EE– (n=23) EE+ (n=24) 
Body weight (g) 23.5±0.3 24.1±0.4 33.2±1.1‡ 31.1±0.6 
Liver weight (mg) 982±17 1209±24** 1348±60‡ 1385±38 
Uterus wet weight (mg) 69±5 114±3** 75±5 109±3** 
Gonadal fat (mg) 302±29 246±25 1822±174‡ 1430±122 
Subcutaneous fat (mg) 233±18 185±17 1109±76‡ 850±51* 
Data represented as mean±SEM of n animals. 
*p<0.05 and **p<0.001 versus vehicle treatment same diet, ‡p<0.001 versus SFD vehicle treatment. 
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Table 3: Plasma metabolic parameters and liver enzymes of mice kept on a standard (SFD) 
or high fat (HFD) diet, treated with ethinylestradiol (EE+) or vehicle (EE-). 
 SFD HFD 
EE– (n=17) EE+ (n=13) EE– (n=16) EE+ (n=17) 
Total cholesterol (mg/dl) 98±3 113±2*** 185±9‡‡ 177±7 
HDL cholesterol (mg/dl) 76±3 81±2 132±6‡‡ 124±5 
LDL cholesterol (mg/dl) 22±2 32±1*** 63±6‡‡ 68±4 
Triglycerides (mg/dl) 53±3 59±3 66±5‡ 58±5 
Alkaline phosphatases (U/l) 136±6 161±8 129±6 123±3 
Aspartate transaminase (U/l) 274±20 196±28** 378±36‡ 234±23** 
Alanine aminotransferase (U/l) 92±10 92±20 155±22‡‡‡ 93±11* 
Data represented as mean±SEM of n animals. 




Inferior caval vein thrombosis 
In total, 69 mice were subjected to the inferior caval vein thrombosis model, of 
which 5 mice died during the surgical procedure. Ligation of the inferior vena cava 
for 24 hours resulted in a thrombus weight of 1.4±0.4 mg for mice on SFD receiving 
vehicle treatment, and a borderline (in)significant increase in thrombus weight to 
3.0±0.7 mg for vehicle-treated mice on a high fat diet (p=0.064; figure 2). 
Surprisingly, estrogen treatment resulted in both diet groups in a reduction in 
thrombus weight, which was statistically significant for the HFD group (3.0±0.7 mg 
vs. 0.8±0.5 mg; p=0.013), resulting in a thrombus weight comparable to vehicle-
treated SFD mice.  
 
 
Figure 2: Thrombus weight for mice kept on a 
standard (SFD) or high fat (HFD) diet, treated with 
ethinylestradiol (EE+) or vehicle (EE-). 69 animals 
were subjected to the inferior caval vein 
thrombosis model (see Methods) of which 11 
veins were embedded for histological analyses 
and 5 animals died during surgery. Data 
represented as mean±SEM of n animals. 
*p<0.05 versus vehicle treatment same diet. 
 
Estrogens, obesity and venous thrombosis 
75 
Histological analyses of the ligated veins revealed that the thrombi in all groups, 
with the exception of the EE-treated SFD group in which the harvested veins did 
not contain a thrombus, showed lamination with the presence of erythrocytes, 
platelets and nucleated cells, which is typical for venous thrombi. The platelet 
content of the thrombi of vehicle-treated HFD fed mice was decreased as 
compared to those of the vehicle-treated SFD mice (29±5% for the HFD and 
41±10% for the SFD; p=n.s.). Thrombi of EE-treated HFD mice consisted of 23±2% 
platelets, which was comparable for the vehicle-treated HFD group.  
 
Coagulation profile 
Plasma factor VIII and combined factor II/VII/X activity levels were significantly 
higher in the vehicle-treated HFD fed mice than in vehicle-treated SFD fed mice 
(both p<0.001; table 4). Oral estrogen treatment resulted in both diet groups in a 
trend towards decreased plasma factor II/VII/X activity levels. This decreasing trend 
under estrogen treatment was also observed for factor V activity and for plasma 
antithrombin activity levels. Antithrombin antigen levels were significantly increased 
in the HFD group that received the vehicle treatment as compared to the vehicle-
treated SFD fed mice (p<0.001), whereas oral estrogens in the HFD group resulted 
in a significant reduction in antithrombin antigen levels (p=0.002). Thrombin-
antithrombin complexes were somewhat higher in HFD fed mice, without an effect 
of estrogen treatment. PAI-1 plasma levels showed a significant increase in 
nutritional obese mice compared to the vehicle-treated SFD group (p=0.009), 
whereas oral estrogens did not cause changes in PAI-1 levels in mice either on a 
SFD or HFD. Finally, the HFD resulted in an increasing trend in plasma fibrinogen 
levels, but administration of estrogens had no effect on the fibrinogen levels in both 
diet groups.  
In contrast to the plasma data, nutritionally-induced obesity resulted in significantly 
reduced relative mRNA levels of coagulation factors II, V, VII, VIII, X and 
antithrombin compared to vehicle-treated SFD fed mice (p<0.01 for factor II, V, VII, 
X and antithrombin, p=0.015 for factor VIII; table 5). Compared to the SFD group 
receiving the vehicle treatment, vehicle-treated HFD mice had significantly 
increased levels of hepatic PAI-1 transcripts (p=0.021), which paralleled the 
plasma data. Orally administered estrogens caused significant reductions in 
hepatic mRNA levels of factor II, V, VII, X, antithrombin and fibrinogen-γ in both diet 





Table 4: Plasma coagulation profile for mice kept on a standard (SFD) or high fat (HFD) diet, 
treated with ethinylestradiol (EE+) or vehicle (EE-). 
 SFD HFD 
EE– (n=17) EE+ (n=17) EE– (n=16) EE+ (n=17) 
Factor V Act (nM) 30±3 22±2 38±4 31±3 
Factor VIII Act (%NPP) 91±4 80±5 155±13‡‡ 160±11 
Factor II/VII/X Act (%NPP) 101±5 96±5 126±5‡‡ 115±7 
Antithrombin Act (%NPP) 126±6 114±4 137±7 132±4 
Antithrombin Ant (%NPP) 110±4 103±2 129±3‡‡ 114±3* 
TAT (ng/ml) 86±35 86±27 122±40 111±31 
Fibrinogen (mg/ml) 2.6±0.2 2.5±0.2 3.2±0.1 3.8±0.3 
PAI-1 (ng/ml) 1.8±0.4 2.0±0.3 4.0±0.7‡  3.7±0.5 
Act: activity level; Ant: antigen level; TAT: thrombin-antithrombin complexes; PAI-1: plasminogen activator inhibitor-1; 
%NPP: percentage of value normal mouse pool plasma.  
Data represented as mean±SEM of n animals. 




Table 5: Hepatic mRNA levels for mice kept on a standard (SFD) or high fat (HFD) diet, 
treated with ethinylestradiol (EE+) or vehicle (EE-).  
 SFD HFD 
EE– (n=6) EE+ (n=6) EE– (n=6) EE+ (n=6) 
Antithrombin 1±0.10 0.47±0.02** 0.60 ±0.03‡‡ 0.40±0.02** 
Factor II 1±0.07 0.56±0.04** 0.70±0.04‡‡ 0.46±0.03** 
Factor V 1±0.10 0.47±0.03** 0.57±0.04‡‡ 0.37±0.03** 
Factor VII 1±0.10 0.47±0.03** 0.52±0.05‡‡ 0.39±0.02* 
Factor VIII 1±0.16 0.73±0.07 0.57±0.06‡ 0.56±0.04 
Factor X 1±0.10 0.50±0.03** 0.51±0.04‡‡ 0.37±0.02* 
Fibrinogen-γ 1±0.11 0.53±0.04** 0.81±0.39 0.40±0.03* 
PAI-1 1±0.24 1.18±0.30 2.37±0.51‡ 1.64±0.84 
MMP-12 1±0.30 1.24±0.44 3.73±2.20‡ 5.09±2.01 
MCP-1 1±0.21 2.16±0.26 1.95±0.57 3.54±0.34 
PAI-1: plasminogen activator inhibitor-1; MMP-12: matrix metalloproteinase-12; MCP-1: monocyte chemoattractant 
protein-1. 
Data represented as mean±SEM; data normalized for β-actin with the vehicle-treated SFD group set as reference.  
*p<0.05 and **p<0.005 versus vehicle treatment same diet, ‡p<0.05 and ‡‡p<0.005 versus SFD vehicle treatment. 
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Inflammation  
To determine whether the decrease in thrombus weight in HFD fed mice following 
estrogen treatment was related to estrogen-mediated regulation of inflammatory 
pathways, systemic inflammation was monitored by measuring serum amyloid A 
(SAA) and interleukin-6 (IL-6) levels in the plasma. SAA levels of vehicle-treated 
mice on HFD were comparable to vehicle-treated SFD fed mice (13.7±3.9 µg/ml vs. 
12.7±3.7 µg/ml, respectively). Estrogen administration resulted in both diet groups 
in increased SAA levels, which reached statistical significance in the SFD group 
(12.7±3.7 µg/ml vs. 25.3±3.9 µg/ml; p=0.003), but not in the HFD group (13.7±3.9 
µg/ml vs. 21.8±5.7 µg/ml; p=0.430). Plasma IL-6 levels, with the exception of a few 
mice, were undetectable and thereby precluded statistical analysis. 
Hepatic mRNA levels of IL-6, tumor necrosis factor-α (TNF-α), matrix 
metalloproteinase-12 (MMP-12) and monocyte chemoattractant protein-1 (MCP-1) 
were measured to further evaluate liver inflammation. Expression of IL-6 and TNF-
α were not detectable before Ct 35 and therefore considered not to be present in 
significant amounts. The MMP-12 transcript level was significantly increased in 
vehicle-treated HFD fed mice as compared to vehicle-treated SFD fed mice 
(p=0.0411; table 5) and in both diet groups, estrogen treatment caused a further 
non-significant increase.  MCP-1 mRNA levels were slightly enhanced by estrogen 
treatment of mice both on a SFD and on a HFD.  
 
Discussion 
In the present study, we found that nutritionally-induced obesity results in increased 
plasma levels of factor II/VII/X, factor VIII and PAI-1 and causes a trend towards an 
increased thrombus weight in a caval vein thrombosis model. Surprisingly, under 
obese conditions, short-term oral estrogen administration results in a significant 
lower thrombogenicity, which is not paralleled by a reversal of the obesity-induced 
procoagulant state, nor does it coincide with changes in the inflammatory state. 
The present mouse study was designed to further investigate the epidemiological 
observation on the synergistic effect of obesity and oral estrogen use on the 
venous thrombotic risk. However, the finding that oral estrogens in women are 
prothrombotic cannot simply be translated into the mouse context, which may have 
several causes. First, matching an established thrombotic risk in epidemiological 
studies versus the detection of a thrombotic tendency in acute models of 
experimental thrombosis in mice, may not simulate the cumulative risk for 
thrombosis correctly, since this is a chronic risk. Second, human data show that 
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both obesity and oral estrogens result in increased plasma levels of factor II and 
factor VII.1,4,7,9,11 Together with an increased resistance against activated protein C 
under these conditions, this may explain the thrombophilic interaction between 
obesity and estrogens in women. However, although the effects of estrogens 
observed are dose-dependent and receptor specific, our present data show that 
mice respond differently to oral estrogen administration, i.e. rather tend to induce a 
reduction in plasma factor II/VII/X activity, suggesting a species difference,. Finally, 
the duration and dose of exposure to estrogens is important for its actions.7,8,22,23   
The EE dose used in the present study was based on a preliminary dose-finding 
study in ovariectomized mice; in the obesity / estrogen study, the selected dose 
showed a similar effect on the plasma coagulation profile in non-ovariectomized 
mice, but less pronounced. As the uterus weight under ovariectomized and non-
ovariectomized conditions increased to a similar level, the duration of treatment (10 
versus 8 days) might contribute to the more pronounced changes in the plasma 
coagulation profile in the dose-finding study. Although this suggests the need for 
long-term treatment to achieve results more in line with human exposure and risk 
development, preliminary data of 7 week treatment in SFD fed ovariectomized mice 
showed comparable results on the plasma coagulation profile as observed for 
short-term EE-treated controls (i.e. non-significant antithrombotic shift). These data 
suggest that a more prolonged exposure does not affect the thrombotic tendency 
differently than short-term exposure does. In addition, using a carotid artery 
photochemical injury model, Abu-Fanne and colleagues also showed that chronic 
treatment with estradiol in non-ovariectomized as well as ovariectomized mice 
suppressed thrombosis.24 Bleeding time was also evaluated and revealed that OVX 
mice treated with estradiol had a longer bleeding time compared to vehicle-treated 
mice. Thus also in this mouse study, estrogen administration has antithrombotic 
effects. Nevertheless, by using mouse models displaying a more spontaneous 
venous thrombotic phenotype, like the Factor V Leiden mouse model, 
thrombomodulin or antithrombin mutant mice, in combination with a prolonged 
exposure to estrogens, the cumulative chronic risk in humans may be better 
represented. Despite this shortcoming, comparison of the plasma coagulation 
profile in estrogen-treated lean and obese mice, suggests other factors than 
coagulation factor regulation to explain the impact of estrogens on the thrombotic 
tendency. 
The trend towards an increased thrombus weight under obese conditions can be 
explained by a prothrombotic shift of the coagulation profile. On the other hand, the 
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observed protective effect of short-term estrogen administration on the thrombotic 
tendency could not be explained by a reversal of the prothrombotic shift in the 
plasma coagulation profile associated with obesity (table 4). Abdollahi et al. already 
showed that the interaction between obesity and oral estrogens on the thrombotic 
risk remained after adjustment for several coagulation factor levels, suggesting an 
alternative pathway affecting the risk of venous thrombosis.1 Inflammation could be 
such an alternative pathway, as obesity and estrogen use affect the inflammatory 
state in an opposite direction, and inflammation and coagulation are closely related. 
However, inflammation and inflammation-related parameters did not provide 
evidence that could explain the unexpected antithrombotic effect of short-term 
estrogen administration under obese conditions. Several (in vitro) studies provide 
evidence for a role of estrogens in modulating endothelial cell function and/or gene 
expression and platelet function, both in a genomic and non-genomic manner.24-30 
We considered prostacyclin as a mediator of the suppressive effects of estrogens 
in the thrombosis model. However, plasma levels of 6-keto prostaglandin F1α were 
not significantly affected by estrogen administration. 
Besides the thrombus weight, estrogen administration also (partially) 
counterbalanced the increased gonadal and subcutaneous fat pads and increased 
levels of circulating liver enzymes. This latter observation is in line with a study 
performed by Moorthy et al., who showed that estrogen treatment in naturally 
menopausal rats also results in a decrease in AST and ALT levels.31 Strikingly, in 
our study the AST levels, and to a lesser extend ALT levels, parallel the thrombus 
weight under the different dietary and hormonal conditions. It therefore seems that 
the HFD induced liver damage is partially reversed by the estrogen treatment, an 
effect already apparent for AST in the SFD group. However, it is unclear whether 
the reduced thrombogenicity and liver damage are directly or indirectly coupled via 
metabolic estrogen-regulated pathways. 
In the present study, changes in relative transcript levels of coagulation genes in 
the liver not always paralleled the observed plasma protein levels. Estrogen 
administration resulted in both diet groups in significant decreases of hepatic 
mRNA levels of coagulation factors, but this did not coincide with the plasma levels. 
On the other hand, vehicle-treated HFD fed mice had lower hepatic transcript levels 
as compared to vehicle-treated mice on a SFD, whereas the plasma coagulation 
factor levels were significantly increased under nutritionally induced obesity. These 
latter differences could be explained by the fact that the HFD caused a significant 
increase in liver weight compared to the SFD group. For each treatment group the 
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RNA recovery from liver tissue was equal, suggesting that the absolute expression 
is higher when the liver is enlarged. However, the liver weight of the vehicle- and 
estrogen-treated HFD fed mice were comparable, indicating that the reduced 
mRNA levels under estrogen administration are absolute, and no direct relation 
between expression and plasma levels exists. These data suggest that both 
obesity and estrogens induce changes in the plasma coagulation levels via 
mechanisms including posttranslational modifications and/or a decreased 
clearance capacity for these coagulation factors.  
In summary, the synergistic effect of obesity and estrogen on the venous 
thrombotic risk in women could not be translated into the mouse context. However, 
nutritionally-induced obesity in mice resulted in an activated plasma coagulation 
profile and in a trend towards an enhanced venous thrombotic tendency. Short-
term oral estrogen administration on the other hand, only had a very mild impact on 
the coagulation profile and did not result in aggravation of the thrombotic tendency 
but suppressed experimentally induced venous thrombosis in obese mice.  
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Dear editors,  
 
In thrombin generation assays, the resulting area under the curve (endogenous 
thrombin potential; ETP) is considered to have a predictive value. A low ETP value 
is associated with a bleeding tendency, whereas an increased value represents a 
hypercoagulable state. Regarding this latter category, it has been shown that 
women using oral contraceptives, which are associated with an increased risk for 
venous thrombosis, have higher ETP values than non-users.1  
The estrogen in oral contraceptives, often 17α-ethinylestradiol, is considered to be 
the predominant thrombogenic component. We have previously shown that oral 
ethinylestradiol (EE) in mice has profound effects on the plasma levels of pro- and 
anticoagulant factors.2 Now, we report the overall effect of these estrogen-induced 
alterations on the hemostatic balance by assessing thrombin generation and 
determine the net effect on a spontaneous thrombotic phenotype, i.e. fibrin 
depositions in lung tissues of the prothrombotic factor V Leiden (FVQ/Q) and 
thrombomodulin proline mutant (TMpro/pro) mice.  
Hereto, ovariectomized FVQ/Q and TMpro/pro, and wild-type mice as a reference, 
were orally treated with 1 µg EE/day or a vehicle for either 10 days or 10 weeks 
(n=12 mice per group). After the last EE or vehicle administration, mice were 
exsanguinated and platelet-poor plasma was obtained.3 In order to determine the 
estrogen-induced effects on fibrin depositions, lungs of 10-week treated mice were 
isolated as previously described.4,5  
To evaluate the effects on the overall plasma coagulability after 10 days of 
treatment, we assessed thrombin generation by means of the Calibrated 
Automated Thrombogram method using 1 pM tissue factor to trigger 1:6 diluted 
mouse plasma.6 Oral EE treatment resulted in significantly increased ETP values in 
FVQ/Q (fig. 1A) and TMpro/pro mice (fig. 1B), which was comparable to the effects 
observed in wild-type animals (448±30 nM*min vs. 930±41 nM*min, p<0.001). The 
thrombin generation curves in figures 1A and 1B show that the inhibition of 
thrombin activity, i.e. the tail of the curve, is predominantly affected in EE-treated 
mice, which largely determines the differences in ETP values between the vehicle- 
and EE-treated groups. Since antithrombin is the main inhibitor of thrombin activity, 
we measured the antithrombin activity levels in plasma (Coamatic antithrombin kit, 
Chromogenix) and found that estrogen administration caused a significant 15% 
reduction in antithrombin activity levels, which negatively correlated with the ETP 
values (Pearson r=-0.51, p=0.002).  
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To determine the relation between thrombin generation and a spontaneous 
thrombotic phenotype, FVQ/Q and TMpro/pro mice were daily treated with vehicle or 1 
µg EE/day for 10 weeks. During these 10 weeks, none of the mice died or showed 
signs of abnormalities. In addition, careful inspection of the mice upon sacrifying 
revealed no signs of macrovascular thrombosis. Thrombin generation curves and 
ETP values after 10 weeks of treatment showed a comparable pattern to the 10-
day treatment, with ETP values of 446±40 nM*min vs. 746±98 nM*min (p<0.01) for 
FVQ/Q mice and 683±75 nM*min vs. 901±70 nM*min (p<0.05) for TMpro/pro animals, 
indicating a sustained increase in thrombin generation during the 10 weeks of oral 





Figure 1: Factor V Leiden (A) and thrombomodulin proline mutant (B) mice were orally treated with 1 µg ethinylestradiol 
(EE; dashed line)  or a vehicle (solid line) per day for 10 days after which thrombin generation was determined in 1:6 
diluted plasma triggered with 1 pM tissue factor. The resulting endogenous thrombin potential (ETP) values are 
presented in the inserts. Plasma thrombin-antithrombin (TAT) complexes (C) and fibrin concentrations in lung 
homogenates of FVQ/Q and TMpro/pro (D) were determined after 10 weeks of treatment. Data are presented as mean ± 
standard error of the mean of n=12 mice per group (A-C) or as individual measurements (D). ‡p<0.001 as compared to 
vehicle-treated animals.  
A B 
C D 
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As a biochemical marker for a thrombotic phenotype, fibrin depositions in lung 
homogenates were determined via Western blotting.5 Although fibrin depositions of 
FVQ/Q and TMpro/pro mice were in the lower range of detection (2-10 ng/mg tissue), 
they were higher than fibrin concentration present in wild-type mice, which did not 
exceed the detection threshold of 2 ng/mg. However, oral estrogen administration 
for 10 weeks did not result in significant increased fibrin depositions in either the 
FVQ/Q (4.0±0.5 ng/mg vs. 5.5±0.7 ng/mg) or TMpro/pro mice (5.3±0.6 ng/mg vs. 
4.8±0.4 ng/mg; figure 1C). In addition, plasma thrombin-antithrombin complex 
analyses (Enzygnost TAT micro, Dade Behring) did also not differ between vehicle- 
and EE-treated animals (figure 1D), which supports the absence of an effect on 
fibrin depositions despite a sustained increased potential to generate thrombin 
upon estrogen treatment.  
Previous studies have shown that the FVQ/Q status converts to a spontaneous 
perinatal lethal phenotype when combined with mice carrying gene deletions in 
anticoagulant genes that in itself are not lethal, like tissue factor pathway inhibitor 
and protein Z.7,8 In addition, microvascular thrombosis in lungs of TMpro/pro mice 
proved highly responsive to hypoxia,5 showing that these models are capable of 
displaying enhanced fibrin deposition upon risk factor exposure. On the other hand, 
with respect to oral ethinylestradiol administration, we have previously shown that 
short-term EE exposure was not able to aggravate the thrombogenicity in a stasis-
induced thrombosis model,9 which is in line with these current observations. 
From the data presented here, we conclude that despite the fact that long-term oral 
ethinylestradiol administration can induce a sustained increase in thrombin 
generation in factor V Leiden and thrombomodulin proline mutant mice, this does 
not translate into a spontaneous macrovascular or microvascular thrombotic 
phenotype, which argues against the use of these mice in studying the effects of 
estrogens on thrombosis.  
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Background: Obesity is associated with a hypercoagulable state and increased risk 
for thrombotic cardiovascular events. 
Objective: Establish the onset and reversibility of the hypercoagulable state during 
the development and regression of nutritionally-induced obesity in mice, and its 
relation to transcriptional changes and clearance rates of coagulation factors as 
well as its relation to changes in metabolic and inflammatory parameters.  
Methods: Male C57Black/6J mice were fed a low fat (10% kcal fat; LFD) or high fat 
diet (45% kcal; HFD) for 2, 4, 8 or 16 weeks, and in vivo clearance rates of human 
factor (F) VII, FVIII and FIX proteins were determined after 2 weeks of HFD-
feeding. To study the effects of weight loss, mice were fed the HFD for 16 weeks 
and switched to the LFD for 1, 2 or 4 weeks. For each time point plasma and 
hepatic mRNA analyses were performed after overnight fasting.  
Results: HFD feeding gradually increased the body and liver weight, which was 
accompanied by a significant increase in plasma glucose levels from 8 weeks 
onwards, while insulin levels were affected after 16 weeks. Plasma levels of 
fibrinogen, FII, FVII, FVIII, FIX, FXI and FXII were significantly higher in mice on a 
HFD for 2 weeks, which in general persisted throughout the 16 weeks of HFD-
feeding. Remarkably, the effects on plasma levels were in general not paralleled by 
changes in relative hepatic transcript levels and neither by decreased clearance 
rates. Switching from the HFD to the LFD reversed the HFD-induced procoagulant 
shift, but again this did not coincide with transcriptional modulation. 
Conclusions: Changes in dietary fat content rapidly alter the mouse plasma 
coagulation profile, thereby preceding metabolic changes. In addition, these rapid 
changes could not be explained by changes in relative expression levels of 




The prevalence of obesity in the Western world is rising and forms an increasing 
public health problem since obesity affects, amongst others, the development of 
cardiovascular diseases through its influence on risk factors like hyperlipidemia, 
hypertension, glucose intolerance and inflammation. The risk for thrombotic 
cardiovascular events is even further enhanced by the hypercoagulable state that 
is associated with obesity, as obese subjects have increased plasma levels of 
procoagulant factor (F) VII, VIII, XII and fibrinogen, while fibrinolysis is decreased 
as reflected by increased levels of plasminogen activator inhibitor-1 (PAI-1).1-3 On 
the other hand, levels of the anticoagulant factors protein C and protein S are 
higher, and tissue plasminogen activator (tPA) levels are lower under obese 
conditions, which might be considered to be a compensatory response to the 
hypercoagulable state.4,5  
Previous studies evaluating the effect of weight loss on hemostatic parameters 
showed that levels of tissue factor, FVII, PAI-1 and tPA decreased upon weight 
loss, resulting in a decrease in thrombin generation.6,7 In addition, it has been 
suggested that almost one-third of all thrombotic events could be prevented by 
weight loss.8 Taken together, these data indicate that the plasma coagulation 
profile and the subsequent thrombotic risk may follow both the unfavorable and 
favorable changes in body weight gain and weight loss, respectively.  
Using an experimental animal approach, we and others have previously shown that 
obesity in mice also results in a hypercoagulable state, which is characterized by 
increased plasma levels of procoagulant factors and decreased fibrinolysis.9,10 
These results were obtained in mice being on a high fat diet for 4 to 5 months, and 
during this time, many other metabolic changes may have occurred influencing the 
coagulation profile indirectly. Therefore, the aim of the present study was to identify 
whether changes in coagulation stand by itself or whether it is the result of other, 
earlier manifesting metabolic changes. Hereto, we used mice to establish the onset 
and reversibility of the hypercoagulable state during the development and 
regression of nutritionally-induced obesity, and determined its relation to changes 
in hepatic transcript levels and clearance rates of coagulation factors, as well as it 
relation to changes in metabolic and inflammatory parameters.  
 
Materials and methods 
Animals 
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Six week old male C57Black/6J mice (Charles River) were fed a diet with 10% kcal 
as fat (low fat diet; Research Diets) for 4 weeks as a run-in period, after which half 
of the group switched to an iso-caloric diet with 45% kcal as fat (high fat diet; 
Research Diets), while the other group remained on the low fat diet (LFD). After 2, 
4, 8 or 16 weeks mice (n=15 per group) were fasted overnight and subsequently 
anesthetized with a mixture of ketamine, xylazine and atropine. The abdomen was 
opened and a blood sample on sodium citrate (final concentration of 0.32%) was 
directly drawn from the inferior caval vein. Platelet-poor plasma was obtained and 
stored at -80°C until use. In addition, part of the left liver lobule and lungs were 
snap-frozen for mRNA analyses.  
In order to compare nutritionally-induced obesity with genetically-induced obesity, 6 
weeks old ob/ob mice, and their lean wild-type littermate controls (Charles River) 
were fed the low fat diet for 4 weeks and plasma and tissue samples were obtained 
for analyses after overnight fasting.  
Plasma clearance of the vitamin K-dependent coagulation factors VII and IX, and 
FVIII were determined in a separate experiment in which 2-week HFD-fed mice 
received a single intravenous injection (200 µl) of either the human prothrombinase 
complex (Cofact) or FVIII concentrate (Aafact, both kindly provided by Dr. K. 
Mertens, Sanquin). Clearance rates of the human plasma-derived factors from the 
mouse plasma were determined by successive blood sampling via the tail vein.  
To study the effects of weight loss on the obese phenotype, mice received the HFD 
for 16 weeks, and while half of the group remained on the HFD (n=45), the other 
half switched to the low fat diet. After 1, 2 or 4 weeks, mice were sacrificed after 
overnight fasting for plasma and tissue mRNA analyses.  
All experimental animal procedures were approved by the animal welfare 
committee of the Leiden University.  
 
Plasma analyses 
Plasma triglyceride and insulin levels were measured using commercially available 
kits from Roche Diagnostics and Crystal Chem Inc., and glucose levels were 
determined according to the hexokinase method (Instruchemie). Plasma levels of 
multiple cytokines were evaluated simultaneously by using pre-coated multisport 
plates in an ELISA-based electrochemiluminescence assay (Meso Scale 
Discovery). 
Coagulation factor levels were measured as previously described and pooled 
mouse plasma was used to generate standard curves.11 The in vivo clearance of 
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human coagulation factors VII, VIII and IX was analyzed with home-made ELISAs 
specific for human proteins that were proven not to cross-react with mouse plasma 
proteins. Standard curves were generated by adding Cofact or Aafact to pooled 
mouse plasma (final concentration 20%) to calculate human antigen levels, and the 
level measured directly after injection (1 minute) was set as a reference (100%).  
 
RNA isolation and real-time RT-PCR 
Individual liver samples (15-20 mg) of 10 animals per group were homogenized in 
RNAzol (Tel-Test), and RNA isolation and cDNA synthesis was executed as 
previously reported.11 Quantitative real-time PCR was performed using SybrGreen 
(Applied Biosystems) and gene-specific primers11 and the comparative threshold 
cycle method with ß-actin as internal control was used for quantification and 
normalization. To evaluate the effects of weight gain on transcript levels, LFD-fed 
mice were set as a reference, whereas the HFD-fed mice were set as a reference 
to determine the effects of weight loss. The ΔCt values of individual samples were 
related to the mean ΔCt of the reference group.  
 
Statistical analyses 
Data are expressed as mean ± standard error of the mean (SEM) or as the median 
and range for cytokine levels. Gene expression data are presented as the mean 
including the minimum and maximum expression levels. Data were analyzed with 
the GraphPad Instat software and statistical differences between the LFD and HFD 
groups were evaluated using a Student’s t-test, or a Mann-Whitney test in case of 
cytokine levels, to compare the LFD with HFD group. P-values <0.05 were 
considered to be statistically significant. 
 
Results 
Induction of obesity 
Two weeks of HFD-feeding resulted in a significantly increased fasted body weight 
as compared to the LFD-fed mice (25.0±0.6 g vs. 22.3±0.3g, p<0.001), which 
gradually increased further over time (table 1). From 8 week onwards, liver weights 
of HFD-fed mice were also significantly higher than those of LFD-fed mice.  
Plasma cytokine levels showed a transient rise in interleukin (IL) 1ß and 
keratinocyte chemoattractant (KC) levels after 2 weeks of HFD-feeding (3.2 (0.7-
20.7) pg/mL vs. 7.0 (1.1-88.9) pg/mL for IL-1β, p<0.05; 34.6 (19.1-246.8) pg/mL vs. 
55.9 (28.7-233.6) pg/mL for KC, p<0.05). The levels of IL-6, IL-10, IL-12, interferon-
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γ (IFN-γ) and tumor necrosis factor α (TNFα) were not affected (data not shown). 
Triglyceride levels were also transiently increased at the 2 week time point in mice 
fed the HFD (0.70±0.04 mmol/L vs. 0.86±0.06 mmol/L, p<0.05), and again after 16 
weeks of HFD feeding (table 1). Plasma glucose levels were higher due to the high 
fat diet from 8 week onwards (5.7±0.2 mmol/L vs. 7.7±0.4 mmol/L, p<0.001), 
whereas insulin levels were only increased after 16 weeks (table 1).  
The high fat feeding-related changes in metabolic parameters after 16 weeks 
largely resembled the observations in the LFD-fed ob/ob mice, which had a 
comparable weight and enlarged liver (table 1). In addition, the insulin and glucose 
levels were also higher as compared to their wild-type littermates. KC and IFN-γ 
levels were increased in ob/ob mice (KC 4.4 (16.5-229.1) pg/mL vs. 100.1 (17.6-
268.9) pg/mL, p<0.05; IFN- γ 7.3 (2.0-53.9) pg/mL vs. 45.9 (1.2-125.0) pg/mL, 
p<0.05), but they displayed surprisingly lower fasted plasma triglyceride levels 
(table 1).  
 
 
Table 1: Metabolic parameters of mice on a low fat diet (LFD) or high fat diet (HFD) for 16 
weeks as compared to genetically obese ob/ob mice with their littermate wild-type controls 
after 4 weeks of LFD feeding. 
 LFD (n=15) HFD (n=15) WT (n=15) ob/ob (n=15) 
Body weight (g) 27.4±0.5 41.6±0.9‡ 22.1±0.6 40.3±0.6‡ 
Liver weight (g) 0.79±0.01 1.08±0.06‡ 0.78±0.04 2.14±0.06‡ 
Triglycerides (mmol/L) 0.54±0.03 0.65±0.04* 0.62±0.05 0.39±0.02‡ 
Insulin (pg/mL) 97.4±1.0 105.0±2.8* 94.1±0.9 105.4±1.8‡ 
Glucose (mmol/L) 5.7±0.2 8.0±0.6‡ 5.8±0.6 11.6±0.9‡ 




Within 2 weeks, the high fat diet induced a clear procoagulant shift of the plasma 
coagulation profile, with significant increases in fibrinogen, FII, FVII, FVIII, FIX, FXI 
and FXII levels (fig. 1A). Continuation of the HFD resulted in sustained increased 
levels of fibrinogen, FII and FVII while the effects on FVIII, FIX, FXI and FXII levels 
became less pronounced and did not reach statistical significance after 16 weeks 
HFD-feeding. Factor X and antithrombin plasma levels were only significantly 
increased after 16 weeks of HFD-feeding (fig. 1B). Comparing the 16 week HFD-
fed animals with ob/ob mice showed a similar procoagulant shift, although these 
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effects were more pronounced in ob/ob mice (fig. 1C). Remarkably, factor VII 
levels, like the triglyceride levels, were lower in ob/ob mice than in the wild-type 




Figure 1: Effects on plasma coagulation parameters after 2 (panel A) and 16 (panel B) weeks of low fat diet (white) or 
high fat diet (black) feeding. Panel C shows the plasma coagulation profile of genetically obese ob/ob mice (striped) 
and their wild-type littermates (white) after 4 weeks on a low fat diet. Data are presented as mean±SEM. *p<0.05 and 
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Since the liver is the main site of production of plasma coagulation factors, we 
determined whether the changes in the plasma coagulation profile due to the high 
fat diet were related to changes in hepatic transcript levels, as we have previously 
shown that changes in plasma levels can coincide with transcriptional effects.11 
Surprisingly, at the 2-week time point where the liver weight between diet treatment 
groups are comparable but clear increases in plasma levels are observed, relative 
mRNA levels of coagulation genes were not affected with the exception of FXI 
which was increased and FVIII which was decreased (table 2). Despite the 
differences in liver weight after 16 weeks of high fat-feeding, we evaluated whether 
prolonged exposure to dietary fat was able to affect transcription. However, HFD-
feeding for 16 weeks was also not able to induce increases in relative mRNA levels 
of hepatically expressed coagulation factors (data not shown).  
As the changes in the plasma coagulation profile were not paralleled by changes in 
transcript levels, we determined whether HFD-feeding for 2 weeks affected plasma 
protein turnover, i.e. decreased the clearance rate. A bolus injection of either the 
human FVIII concentrate or prothrombin complex concentrate resulted in both the 
HFD and LFD group in single-phase clearance curves with comparable half-lives 
between LFD-fed and HFD-fed mice (FVIII 18.6±1.8 min vs. 15.3±1.7 min, FVII 
112.6±7.1 min vs. 99.4±5.9 min and FIX 79.0±9.5 vs. 76.5±5.7 min).  
  
 
Table 2 Hepatic mRNA levels of coagulation genes of mice on a low fat diet (LFD) or high fat 
diet (HFD) for 2 weeks.  
 LFD (n=10) HFD (n=10) 
Fibrinogen 1 (0.93-1.08) 0.87 (0.83-0.90) 
Factor II 1 (0.93-1.08) 1.05 (0.97-1.13) 
Factor VII 1 (0.95-1.05) 1.07 (1.01-1.13) 
Factor VIII 1 (0.94-1.06) 0.64 (0.54-0.77)* 
Factor IX 1 (0.95-1.05) 1.08 (1.03-1.13) 
Factor X 1 (0.96-1.04) 1.01 (0.96-1.07) 
Factor XI 1 (0.92-1.09) 1.51 (1.44-1.58)‡ 
Factor XII 1 (0.95-1.05) 1.06 (1.01-1.12) 
Antithrombin 1 (0.95-1.05) 1.05 (1.00-1.10) 
     Data are expressed as mean (minimum-maximum expression level). *p<0.05 and ‡p<0.001 as  






Regression of obesity 
Since the dietary fat intake resulted in a rapid procoagulant shift of the plasma 
coagulation profile, we determined whether regression of the nutritionally-induced 
obesity also resulted in an altered coagulation profile. Therefore, part of the mice 
receiving the HFD for 16 weeks switched to the low fat diet (n=45) while the 
remaining mice continued the HFD (n=45). Switching to the LFD resulted in an 
immediate decrease in body weight, which was already significant after 1 week 
(37.3±1.5 g vs. 42.9±1.1 g, p<0.01), while effects on the liver weight were apparent 
after 2 weeks (1.05±0.06 g vs. 1.22±0.08 g, p<0.05). Fasted plasma glucose levels 
were also rapidly affected (6.4±0.4 mmol/L vs. 8.7±0.7 mmol/L, p<0.01), whereas 
insulin levels only differed at 4 weeks after switching to the LFD (103.5±1.0 pg/mL 
for the mice switched to LFD vs. 109.3±2.4 pg/mL for the HFD mice, p<0.05) and 
triglyceride levels were not affected due to the change in dietary fat content. 
Furthermore, KC levels were significantly increased after the first week of switching 
to the LFD (58.2 (36.1-168.2) pg/mL for HFD vs. 90.8 (36.3-542.6) pg/mL, p<0.05). 
The plasma coagulation profile showed a remarkably rapid shift after switching to a 
low fat diet, with significantly reduced activity levels of FII, FVII, FIX, FX and FXI 
after only 1 week (figure 2a), and these changes persisted throughout the 
remaining for 4 weeks. In addition, factor VIII and antithrombin levels were altered 
after 2 weeks of switching diets (100±9.8% vs. 72.4±5.0%, p<0.01 and 100±2.3% 
vs. 86.6±4.4, p<0.05 respectively), whereas FXII levels were lower after 4 weeks 
(100±1.5% vs. 92.1±1.5, p<0.01). 
As one week after switching diets was able to alter the plasma coagulation profile, 
while liver weights were not significantly affected, hepatic mRNA analyses were 
performed to determine whether transcript levels of coagulation genes were 
modulated by the diet switch. The non-significant decrease in plasma fibrinogen 
levels coincided with a significant reduction in transcript levels, and also for FXI the 
decrease in plasma was paralleled by a decrease in relative mRNA levels. 
However, for all other coagulation factors measured in plasma, no effects on 
hepatic mRNA levels were observed (figure 2).  
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Figure 2: Plasma (A) and relative transcript levels (B) of mice on a high fat diet for 17 weeks (black) and mice that were 
switched after 16 weeks of HFD-feeding to the LFD for 1 week (white). Data are presented as mean±SEM for the 
plasma data and as mean with the error bar representing the calculated maximum expression level of n=10 mice per 
group for the expression levels. Relative expression levels were compared using the comparative threshold cycle 
method with ß-actin as internal control and the HFD-fed mice were set as a reference. *p<0.05, †p<0.01 and ‡p<0.001 




Obesity is becoming an increasing public health problem and it is associated, 
amongst others, with a hypercoagulable state. In order to gain more insight in this 
relation between obesity and hypercoagulability we used an in vivo approach to 
study the onset and potential reversibility of the hypercoagulable state during the 
development and regression of nutritionally-induced obesity. In addition, we 
determined the mechanisms leading to this hypercoagulable state by evaluating 
transcription and clearance of coagulation factors, as well as determining metabolic 
and inflammatory parameters since they may aggravate the hypercoagulable state 





We have shown that that nutritionally-induced obesity coincides with an early-onset 
procoagulant shift of the plasma coagulation profile, which was already apparent 
within 2 weeks after the start of the HFD. Furthermore, these changes largely 
persisted during the continuation of the HFD for 16 weeks, thereby preceding the 
effects in metabolic parameters like glucose and insulin levels since these were 
only affected in overt obese mice. Switching from a high fat to a low fat diet to 
induce weight loss resulted in a rapid reversal of the HFD-induced procoagulant 
shift of the plasma coagulation profile, as evaluated 1 week after switching diets. 
Surprisingly, these effects on the plasma coagulation profile after switching dietary 
fat intake appeared to be independent of changes in relative transcript levels and 
clearance rates of coagulation factors.  
A remarkable observation in this study is that the changes observed in plasma 
activity levels were not paralleled by changes in relative transcript levels of 
hepatically expressed coagulation genes. In addition, clearance studies, although 
performed with human proteins, could also not explain the increased plasma levels 
in HFD-fed mice. This difference between mRNA levels and clearance rates on the 
one hand, and plasma levels on the other, may have several reasons. Regarding 
the clearance studies, human coagulation factors may be differently cleared from 
mouse plasma than murine factors. Secondly, since high fat feeding can affect liver 
physiology, we were interested whether the RNA recovery in liver samples of LFD 
and HFD mice differed. Although the liver weights after 2 weeks of HFD feeding 
were comparable, the amount of RNA per mg liver weight was approximately 20% 
higher as compared to the RNA recovery from LFD-fed mice. One can speculate 
that this increased recovery might result in an overall increase in absolute 
transcript levels, while the relative mRNA levels are similar between diets, and 
therefore contribute to the increased plasma activity levels. Finally, although we 
have previously shown that transcript levels correlate well to plasma activity 
levels,9 post-transcriptional or post-translational mechanisms may affect the activity 
of the resulting protein. A comparable situation, in which protein activity is 
increased while transcription is down-regulated under nutritionally-induced obesity, 
has also been reported for phosphoenolpyruvate carboxykinase (PEPCK), an 
enzyme associated with hepatic glycogen storage.12 
The fact that there is a transient rise in IL-1β and KC levels when mice switch diet 
types, suggests that the system has to adapt to the new diet in order to maintain 
homeostasis. These data are in concordance with the metabolic stress response 
that occurs during short-term high fat feeding.13 Furthermore, a recent genome-
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wide mRNA expression study which focused on changes in hepatic gene 
expression during high fat feeding, also showed that exposure to dietary fat first 
results in inflammation which under long-term high fat feeding causes a switch to a 
steatotic transcriptional program.14 Besides their roles in coagulation, fibrinogen 
and factor VIII also play a role in inflammation as acute phase proteins and their 
transcription can be induced by nuclear factor (NF)-κB, which transcriptional 
activity is increased under inflammatory conditions.15,16 However, although both 
fibrinogen and FVIII levels in plasma are increased after 2 weeks of HFD-feeding, 
their transcript levels are decreased, making an increased transcriptional activity of 
NF-κB resulting in increased plasma coagulation factor levels less likely.  
By studying coagulation during the development and regression of nutritionally-
induced obesity, we were able to show that the dietary fat content plays and 
important role in affecting the plasma coagulation profile. We also evaluated 
genetically obese ob/ob mice, mainly as a control for determining the effects of 
HFD on metabolic parameters like insulin resistance. The ob/ob mice have been 
predominantly used to study metabolic disorders leading to type 2 diabetes, and 
although they have been used in studies focusing on tissue factor and PAI-1, in 
general little is known about their overall plasma coagulation profile.17,18 Here we 
show that ob/ob mice have more pronounced increases in plasma procoagulant 
factor levels as compared to mice on a HFD for 16 weeks, with the exception of 
FVII levels since they are decreased in ob/ob mice. As these mice display 
metabolic abnormalities, this may aggravate the hypercoagulable state, for 
example via an increased transcriptional activity of nuclear factor (NF)-κB which in 
turn can induce expression of coagulation genes as previously mentioned. 
Because of the underlying pathologies that can potentially affect coagulation, the 
ob/ob mouse seems to be less suitable to study obesity with respect to coagulation 
and a (short-term) nutritionally-induced obesity model seems warranted.  
In summary, this in vivo study shows that the plasma coagulation profile is able to 
rapidly respond to changes in dietary fat content, both in weight gain which is 
associated with a procoagulant shift, and in subsequent weight loss resulting in a 
reversal of the HFD-induced hypercoagulability. These changes in the plasma 
coagulation profile seem to be independent of changes in relative transcript levels 
of coagulation genes and changes in protein clearance rates. In addition, the 
effects on coagulation precede alterations in metabolic parameters like insulin and 
glucose levels. The fact that weight loss is associated with rapid beneficial effects 
Chapter 7 
102 
on coagulation, and late effects of metabolic parameters, may eventually translate 
in a risk reduction for thrombotic cardiovascular events.   
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Background: Thyroid dysfunction is associated with changes in coagulation. 
Objective: To gain more insight in the role of thyroid hormone in coagulation 
control.  
Methods: C57Black/6J mice received a low-iodine diet and drinking water 
supplemented with perchlorate to suppress endogenous triiodothyronine (T3) and 
tetraiodothyronine (T4) production. Under these conditions, the impact of 
exogenous T3 on plasma coagulation, and hepatic and endothelium-associated 
coagulation gene transcription was studied. 
Results: A single T3 injection (0.5µg/mouse) increased hepatic transcript levels of 
the T3-responsive genes deiodinase type 1 and Spot14 within 4 hours. This 
coincided with significantly reduced mRNA levels of fibrinogen-γ, antithrombin, 
protein C, protein Z and protein Z-related protease inhibitor (ZPI), and the reduction 
of the latter three persisted upon daily treatment with T3 for 14 days. Prolonged T3 
treatment also induced a significant down-regulation in factor (F) II, IX and X 
transcript levels, while FXI and FXII levels increased. Activity levels in plasma 
largely paralleled these mRNA changes. Thrombomodulin transcript levels in the 
lung were significantly up-regulated after a single T3 injection, which persisted upon 
prolonged T3 exposure. Two-week T3 administration also resulted in increased von 
Willebrand factor (VWF) and tissue factor pathway inhibitor (TFPI) mRNA levels, 
whereas tissue factor levels decreased.  
Conclusions: Our mouse data show that T3 has profound effects on coagulation, 
with fibrinogen-γ, antithrombin, protein C, protein Z, ZPI and thrombomodulin 
responding rapidly, making these likely direct thyroid hormone receptor targets. FII, 
FIX, FX, FXI, FXII, VWF, TF and TFPI are late responding genes and therefore 





Abnormalities of blood coagulation are common in patients with thyroid 
dysfunctions. In general, hyperthyroidism is associated with a hypercoagulable 
state and increased risk for venous thrombosis.1 In hypothyroidism, the severity of 
the disorder determines whether the coagulation profile is shifted towards an 
anticoagulant or procoagulant state as subclinical hypothyroidism is associated 
with hypercoagulation whereas patients with overt hypothyroidism have a bleeding 
tendency.2,3  
The mechanism of action of thyroid hormones and thyroid hormone receptors has 
been well established in a number of metabolic processes, including lipoprotein 
homeostasis, cell proliferation and mitochondrial respiration.4-6 Experimental 
evidence regarding the mechanisms by which thyroid hormones modulate blood 
coagulation is more limited, and consists mainly of in vitro data showing that T3 is 
able to modulate transcript levels of fibrinogen, factor (F) II, FX and antithrombin.7-9 
In vivo studies with thyroid hormone receptor knock-out mice identified fibrinogen-γ 
to be modulated by T3, whereas T3 administration in thyroidectomized rats was 
able to increase fibrinogen-α, FII and FX mRNA levels.5,9 
Here, we used an in vivo approach to study the modulatory role of thyroid hormone 
on plasma coagulation and transcript levels of coagulation genes, by treating mice 
with the active thyroid hormone, i.e. triiodothyronine (T3), under conditions of a 
suppressed endogenous thyroid hormone production. Our mouse data 
demonstrate that under these conditions, T3 is able to modulate coagulation by 
controlling transcription of coagulation genes, and that these effects can be both 
immediate and late.  
 
Material and Methods 
Animal experiments 
Eight week old C57Bl/6J mice were purchased from Charles River (Maastricht, the 
Netherlands) and fed a low iodine diet (ICN Biomedicals, Inc.) while drinking water 
was supplemented with 1% (wt/vol) potassium perchlorate (Sigma Aldrich) to 
suppress endogenous thyroid hormone production. 3,3′,5-Triiodo-L-thyronine 
sodium salt (T3; Sigma Aldrich) stocks of 1 mg/ml were prepared in 4 mM sodium 
hydroxide and stored at 4°C until use. Before injections, the T3 stock was diluted (0-
10 µg T3 /200 µl) in phosphate buffered saline (PBS) supplemented with 0.02% 
bovine serum albumin with a final concentration of 0.2 mM sodium hydroxide. To 
determine the effects of a prolonged T3 exposure on transcription as well as plasma 
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levels of coagulation factors, mice received a daily intraperitoneal injection of 200 
µl T3 for 14 days. To determine which factors are rapidly modulated by T3, a single 
dose of either 0.5 µg T3/mouse or vehicle (PBS supplemented with 0.02% bovine 
serum albumin with a final concentration of 0.2 mM sodium hydroxide) was 
administered. After the last administration, mice were anesthetized by an 
intraperitoneal injection with a mixture of ketamine (100 mg/kg), xylazine (12.5 
mg/kg) and atropine (125 μg/kg) after which the abdomen was opened by a midline 
incision and a blood sample on sodium citrate (final concentration 0.32%) was 
drawn from the inferior caval vein. Platelet-poor plasma was obtained and stored at 
-80°C until use. The liver was isolated and weighed, and part of the left liver lobule 
and the lungs were snap-frozen for mRNA analyses. All experimental procedures 
were approved by the animal welfare committee of the Leiden University. 
 
Plasma analyses 
Plasma triiodothyronine (T3) and tetraiodothyronine (T4) levels were measured with 
in-house radioimmunoassays as previously described.10 Plasma alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline 
phosphatase (ALP) levels were determined using routine clinical chemistry assays. 
Plasma FII and FX activity were analyzed by means of chromogenic substrate 
conversion, factor VII activity was evaluated using the commercially available 
Biophen FVII kit (Hyphen Biomed) and activity levels of factor VIII, IX, XI, XII were 
measured in APTT based assays.11 Plasma fibrinogen and protein C antigen levels 
were assessed with a commercial murine ELISA kit from Affinity Biologicals and an 
in-house ELISA using antibodies from Haematologic Technologies Inc, 
respectively. Antithrombin activity was measured by means of the Coamatic 
Antithrombin kit (Chromogenix). For all plasma assays of individual coagulation 
factors, pooled normal mouse plasma was used to generate standard curves and 
the vehicle-treated group was subsequently set as a reference (100%). 
Global coagulability of the plasma was determined by measuring the activated 
partial thromboplastin time (APTT) using the STA Neoplastine Plus reagent on the 
STart 4 analyzer (Diagnostica Stago). The prothrombin time was determined with 
the Simple Simon PT system (Zafena) and thrombin generation was assessed by 
means of the Calibrated Automated Thrombogram, using 5 pM tissue factor 
(Thrombinoscope) to trigger 1:6 diluted mouse plasma. Thrombin generation was 
measured on the Fluoroskan Ascent reader (Thermo Scientific) and the curves and 
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area under the curve (endogenous thrombin potential; ETP) were calculated using 
the Thrombinoscope software.  
 
RNA isolation and real-time RT-PCR 
Individual liver (20-30 mg) and lung samples (40-50 mg), as a substitute for the 
endothelium, were homogenized in RNAzol (Tel-Test) and RNA isolation and 
cDNA synthesis was performed as previously described.11 Quantitative real-time 
PCR using SybrGreen (Applied Biosystems) and gene-specific primers 
(supplemental table S1) was performed on the ABI Prism 7900 HT Fast Real-Time 
PCR System from Applied Biosystems. Data were analyzed using the 
accompanying Sequence Detection System software. The comparative threshold 
cycle method with β-actin as internal control was used for quantification and 
normalization. Vehicle-treated animals were set as a reference and the ΔCt values 
of the individual samples were related to the mean ΔCt of the reference group.  
 
Statistical analyses 
Data are analyzed with the GraphPad Instat software and statistical differences 
between groups of the dose-finding were evaluated using a one-way analysis of 
variance (ANOVA) with a Dunnett post-hoc test. For studies using only one dose of 
thyroid hormone, a Student’s t-test was used to compare the thyroid hormone- and 





A dose-finding study was performed in which the effects of exogenous T3 in a range 
from 0-10 µg/mouse/day (n=6 per group) was tested in order to determine specific 
T3-induced effects on a representative panel of coagulation factors, and to 
establish an optimal T3 dose to use for further evaluation.  
Increasing amounts of exogenous T3 in hypothyroid mice, i.e. having a suppressed 
endogenous thyroid hormone production, resulted in a dose-dependent increase in 
body weight up to a dose of 5 µg/day (weight gain during 14 days: 0.18±0.26 g vs. 
2.26±0.36 g, p<0.01), whereas the liver weight dose-dependently decreased 
(1.51±0.07 g vs. 1.09±0.01 g, p<0.01; table S2). As expected, plasma T3 levels 
increased dose-dependently from 0.31±0.01 nmol/L for vehicle-treated hypothyroid 
mice to a maximum of 51.2±5.8 nmol/L for mice treated with 10 µg T3/day (p<0.01). 
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T4 levels were low (range 8.8±0.6 – 14.0±1.0 nmol/L) and did not differ between 
treatment groups (table S2). Plasma T3 and T4 levels of regular C57Bl/6J mice were 
measured for reference values, being 1.22±0.04 nmol/L and 60.7±4.2 nmol/L 
respectively, indicating that the endogenous thyroid hormone production in our 
experimental set-up was successfully suppressed.  
Circulating liver enzymes were determined as a marker of possible liver damage 
due to T3 administration and showed that ALT and AST levels were not affected in 
T3-treated mice as compared to vehicle treatment. However, administration of 
increasing amounts of T3 (from 0.5 µg/day upwards) resulted in relatively modest 
increased ALP levels that differed significantly from vehicle-treated mice (61.3±1.0 
U/L vs. 140.0±15.1 U/L for 0 and 0.5 µg T3/mouse/day respectively, p<0.01; table 
S2).  
Plasma levels of a limited but representative panel of coagulation factors were 
measured and revealed for fibrinogen antigen and factor II, X and antithrombin 
activity levels dose-dependent decreases (maximal effects -60%, -50%, -30% and -
30% respectively for the 10 µg T3/day dose), whereas FXII activity was increased 
(+30%), and as compared to the vehicle treatment these effects were significantly 
different from a dose of 0.5 µg upwards (table S2). FIX was not significantly 
affected and FVIII levels showed no unambiguous dose-dependent increase or 
decrease as compared to vehicle-treated mice. 
As doses of 5 and 10 µg T3/day had no additional effects on plasma coagulation 
factor levels, these doses were excluded from subsequent mRNA analyses. In the 
range from 0–1 µg T3/mouse/day, hepatic transcript levels of deiodinase type 1 
(D1), a well-established T3 response gene,
12 was dose-dependently up-regulated 
as expected (table S3). Dose-dependent decreases in plasma fibrinogen and FII 
levels coincided with reduced transcript levels, which were significantly different in 
mice treated with 0.5 µg T3/day as compared to vehicle-treated animals (-50% for 
fibrinogen and -35% for FII), whereas the transcript levels of FXII and antithrombin 
were not significantly affected (table S3). Transcript levels of the endothelium-
associated coagulation factors were determined in the lung as a substitute for the 
endothelium since this organ is highly vascularized. Increasing T3 doses resulted in 
a dose-dependent decrease of tissue factor mRNA levels (-30%) and a rise in 
thrombomodulin levels (+55%). Transcript levels of von Willebrand factor (VWF) 
and the endothelial protein C receptor (EPCR) were not affected (table S3).  
Based on these data, a daily dose of 0.5 µg T3/mouse/day was chosen for further 
studies, as this caused higher plasma T3 levels as compared to regular C57Bl/6J 
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mice and was the lowest dose able to induce nearly maximal changes in both 
plasma and transcript levels of coagulation factors.  
 
Prolonged T3 treatment 
To evaluate the effects of T3 on coagulation in more detail, 12 mice with a 
suppressed thyroid hormone production per group were treated with either the 
vehicle (0 µg T3/mouse/day) or a dose of 0.5 µg T3/mouse/day for 2 weeks. This 
treatment regime again resulted in an increase in body weight (weight gain: 
0.24±0.15 g vs. 2.12±0.20 g, p<0.001) and a reduction in liver weight (0.84±0.02 g 
vs. 0.74±0.02 g, p<0.001). As expected, T3 levels were significantly higher in T3-
treated mice (5.64±0.21 nmol/L vs. 0.33±0.01 nmol/L, p<0.001), whereas T4 levels 
were low and did not differ between treatment groups (7.2±0.2 nmol/L vs. 8.7±1.0 
nmol/L).  
Figure 1A shows that, in line with the dose-finding study, plasma FII and FX activity 
levels decreased upon T3 treatment, while FXII levels increased and FVIII and FIX 
levels were not significantly affected. In addition, FVII levels did also not differ 
between vehicle- and T3-treated animals, whereas FXI activity levels increased due 
to T3 administration. Plasma antithrombin and protein C levels were both 
significantly lower in T3-treated mice (100±1.6% vs. 92.6±1.2%, p<0.001 for 
antithrombin; 100±4.0% vs. 85.9±3.1%, p=0.009 for protein C). 
Consistent with the lower FII and FX levels upon T3 treatment, the prothrombin time 
was longer in T3-treated animals and the increased FXI and FXII levels resulted in 
a shorter APTT (fig. 2). To assess the overall plasma coagulability, thrombin 
generation was measured, showing a lower endogenous thrombin potential in mice 
treated with 0.5 µg T3/day as compared to vehicle-treated mice, which was mainly 
due to a lower peak height and an earlier onset of the inhibition of thrombin activity 
(fig. 2C). 
With the exception of FIX levels, the T3-induced effects on plasma proteins were 
completely paralleled by changes in hepatic transcript levels (fig. 1A and 1B). The 
transcript levels of additional anticoagulant genes and the fibrinolytic factors 
plasminogen and α2-antiplasmin were determined and presented in figure 3A. 
Strikingly, T3 administration caused only significant decreases, no increases, in 
mRNA levels of anticoagulant factors which included protein C, protein S, protein 
Z, protein Z-related protease inhibitor (PZI) and plasminogen. Antithrombin, 
heparin cofactor II and α2-antiplasmin levels were not affected.  
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In line with the dose-finding study, tissue factor transcript levels in the lung were 
reduced and thrombomodulin levels were up-regulated upon two-week T3 exposure 
(fig. 4A). In addition, VWF levels now showed a significant increase, as well as the 
mRNA levels of tissue factor pathway inhibitor (TFPI), whereas EPCR levels 
remained unaffected by T3 treatment.  
These data show that prolonged T3 exposure is able to modulate the plasma 
coagulation profile by controlling hepatic transcript levels of coagulation genes. In 
addition, transcription of endothelium-associated coagulation genes, measured at 




Figure 1: Plasma (A) and 
hepatic transcript levels (B and 
C) of procoagulant coagulation 
factors in mice treated with 0 µg 
T3 (white bars) or 0.5 µg T3 
(black bars) for 14 days (panels 
A and B). Panel C shows the 
T3-induced changes in hepatic 
transcript levels 4 hours after a 
single T3 injection. Data are 
presented as mean±standard 
error of the mean (panel A) or 
mean with the error bar 
representing the calculated 
maximum expression level 
(panels B and C) of n=12 mice 
per group, with the vehicle-
treated group set as a 
reference. Relative expression 
levels (B and C) were 
compared using the 
comparative threshold cycle 
method with ß-actin as internal 
control. *p<0.05, †p<0.01 and 











Single T3 dose 
In order to determine whether T3 is able to directly affect transcription of 
coagulation genes, i.e. via a direct interaction between the ligand-bound thyroid 
hormone receptor and the promoter region of coagulation genes, we examined the 
mRNA levels 4 hours after a single T3 injection (0.5 µg/mouse). 
Already within these 4 hours, the mRNA levels of the canonical T3-responsive 
genes D1 and Spot14 were increased (1±0.18 vs. 136.4±29.3 for D1 and 1±0.36 
vs. 5.80±1.26 for Spot14). Under these conditions, hepatic transcript levels of 
fibrinogen-γ and antithrombin were significantly reduced (fig. 1C and 3B), whereas 
these effects were not apparent after prolonged T3 exposure. Although the 
immediate decrease of protein S mRNA levels was comparable to the reduction 
observed after a prolonged T3 treatment, this did not reach statistical significance. 
Protein C, protein Z and PZI transcript levels were significantly affected after both 
the prolonged T3 administration and a single dose of T3. In contrast to the two-week 
T3 treatment, a single T3 dose was not able to induce significant changes in FII, FX, 
FXI, FXII and plasminogen transcript levels (fig. 3B). Transcript levels of most 
endothelium-associated clotting factors in the lung remained unaffected, however, 
thrombomodulin transcript levels increased markedly after a single T3 injection (fig. 
4B). 
Figure 2: Plasma prothrombin time (PT; 
A), activated partial thromboplastin time 
(APTT; B) and averaged thrombin 
generation curves with the resulting 
endogenous thrombin potential values 
(ETP; C) for mice treated with 0 µg T3 
(white bars, dotted line) or 0.5 µg T3 
(black bars, solid line) for 14 days. Data 
are presented as mean±standard error of 
the mean of n=12 mice per group. 
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Figure 3: Hepatic transcript levels of anticoagulant and fibrinolytic factors in mice treated with 0 µg T3 (white bars) or 
0.5 µg T3 (black bars) for 14 days (A) or given a single dose (B).  Data are presented as mean with the error bar 
representing the calculated maximum expression level of n=12 mice per group and the vehicle-treated group set as a 
reference. Relative expression levels were compared using the comparative threshold cycle method with ß-actin as 




Figure 4: Transcript levels of endothelium-associated coagulation factors measured in mice treated with 0 µg T3 (white 
bars) or 0.5 µg T3 (black bars) for 14 days (A) or given a single dose (B). Data are presented as mean with the error 
bar representing the calculated maximum expression level of n=12 mice per group and the vehicle-treated group set as 
a reference. Relative expression levels were compared using the comparative threshold cycle method with ß-actin as 






Evidence is accumulating that overt hypothyroidism and hyperthyroidism are 
associated with changes in the hemostatic balance, which translates to either a 
bleeding tendency or an increased thrombosis risk.1-3 However, the underlying 
mechanism how thyroid hormone can modulate coagulation is largely unknown. In 
the present study, we demonstrate that intraperitoneal administration of the thyroid 
hormone triiodothyronine (T3) to mice with a suppressed endogenous thyroid 
hormone production is able to modulate transcription of both hepatic and 
endothelium-associated coagulation factors. Fibrinogen-γ, antithrombin, protein C, 
protein Z, protein Z-related protease inhibitor and thrombomodulin responded 
rapidly upon a single T3 injection. On the other hand, factors II, IX, X, XI, XII, von 
Willebrand factor, tissue factor and tissue factor pathway inhibitor were only 
modulated after a prolonged T3 exposure, i.e. 14 days. Although analyzed for a 
limited set of liver-derived coagulation factors, the changes in transcript levels were 
largely paralleled by changes in plasma levels. Based on these observations, we 
conclude that thyroid hormone can have widespread effects coagulation in mice. 
Our data are in line with observations by Flores-Morales et al., who showed that T3 
can have both immediate and late effects on mouse hepatic gene transcription, and 
that  these effects can be either up- or down-regulating.5 The coagulation factors 
that responded within 4 hours after injection are likely to be directly regulated by 
thyroid hormone, via interaction with the thyroid hormone receptor and specific 
response elements in the promoter region of coagulation genes. Surprisingly, most 
of these genes are regulated in a negative fashion, with the exception of 
thrombomodulin. Although it is known that transcriptional suppression is a common 
action of thyroid hormones,4-6 the mechanisms underlying this negative regulation 
are poorly understood and may involve binding of co-repressors like NCOR1 or 
post-transcriptional microRNA binding, while chromatin remodelling and DNA 
methylation may also play a role in transcriptional suppression.13,14 
For the genes that require a prolonged T3 exposure to evoke a clear transcriptional 
response, an indirect modulation is more likely which can involve intermediate 
transcription factors additional to the thyroid hormone receptor. Despite the fact 
that there are many intermediates possible, we hypothesized that the hepatic 
nuclear factor 4α (HNF4α) would be a good candidate since it is known that thyroid 
hormone can up-regulate HNF4 expression,15 and the well-established HNF4α 
targets coagulation factor XI and XII16 are clearly up-regulated upon prolonged T3 
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exposure. However, the candidature of HNF4α was not supported by the data as 
we observed a 20% decrease in hepatic mRNA levels in livers of T3 mice.  
Our observations in lung samples as a substitute for the vasculature clearly 
indicate that also the (micro)vasculature with its endothelium-associated 
coagulation factors is responsive to T3, as the levels of most factors analyzed were 
affected after prolonged T3 administration. Interestingly, thrombomodulin appeared 
to be an immediate responder and could be induced by a T3 dose as low as 0.05 
µg/mouse/day, indicating that thrombomodulin transcription is highly sensitive to 
variation in T3. Although we were not able to determine whether the changes in 
thrombomodulin transcript levels translated into altered protein levels, it has been 
reported that patients with hyperthyroidism have increased levels of circulating 
soluble thrombomodulin.17  
In humans, hyperthyroidism is associated with an increased risk for thrombosis, 
while we showed that thyroid hormone administration in mice results in an increase 
in prothrombin time and a decrease in the endogenous thrombin potential, which 
point towards a bleeding tendency instead of a thrombotic tendency. These results 
can at least be partially explained by the observed decreases in plasma FII and FX 
levels. On the other hand, the APTT was shorter due to the increased FXI and FXII 
levels, suggesting a thrombosis-prone condition, which is more in line with what 
would be expected based on human observations. Altogether, these findings 
indicate that the use of mice in studying thyroid disorders in human-like 
coagulopathies, i.e. bleeding or thrombosis, faces limitations.  
In conclusion, our mouse study demonstrates that T3 administration to mice with 
suppressed endogenous thyroid hormone production has widespread effects on 
transcription of hepatic and endothelium-associated coagulation genes, as 
measured at the level of the lung. Furthermore, we identified both immediate and 
late responding coagulation genes, suggesting that T3 can either directly or 
indirectly control transcription. In addition, the transcriptional changes resulted in 
altered plasma levels as analyzed for a panel of coagulation factors. We believe 
that this mouse study contributes to a better understanding of the relation between 
thyroid dysfunctions and coagulation disorders in human.  
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Background: Factor V (FV) has a dual role in coagulation by expressing both a 
procoagulant and an anticoagulant function. In factor V Leiden (FVL) hemizygosity, 
i.e. the co-inheritance of FVL and a quantitative FV deficiency, defects of both FV 
functions are combined. Surprisingly, this combination confers a thrombotic risk, 
suggesting a complex role for FV in (anti)coagulation.  
Methods and results: To gain further insight in FV function, FVL (FVQ/Q) and FV+/- 
mice were crossed to generate FVL hemizygous mice. An underrepresentation of 
FVQ/- mice as compared to FVQ/+ mice was observed at the time of weaning. Timed 
matings showed that FVQ/- animals progressed normally to term, but half of the 
FVQ/- mice died in the immediate postnatal period coinciding with features of 
thrombosis. On a tissue factor pathway inhibitor heterozygosity background, the 
FVQ/- genotype was fully fatal confirming that FVL hemizygosity is associated with a 
thrombotic and not a bleeding phenotype. Analyses of the plasma coagulation 
profiles of FVQ/+, FVQ/Q and viable FVQ/- mice showed a reduced overall 
procoagulability in FVQ/- as compared to FVQ/+ and FVQ/Q mice with decreased 
thrombin generation and longer prothrombin times. Activated protein C resistance 
and FV-mediated FVIIIa inactivation was decreased in FV
Q/- mice as compared to 
FVQ/+ animals, but comparable to that of FVQ/Q mice.  
Conclusion: This mouse study demonstrates the physiological importance of the 
anticoagulant function of normal FV, of which a critical fraction is retained in factor 





Coagulation factor V (FV) is a central regulator of the coagulation cascade. It 
serves as a non-enzymatic cofactor for activated FX (FXa) in the prothrombinase 
complex, enabling rapid thrombin formation. Thrombin bound to endothelial 
thrombomodulin can activate protein C, which subsequently inactivates FVa and 
FVIIIa, thereby providing a natural feedback loop that down-regulates thrombin 
formation. To inactivate FVa, activated protein C (APC) together with its cofactor 
protein S, cleaves FVa at arginine 506, 306 and 679.
1,2 Although the Arg506 is the 
kinetically favored cleavage site, approximately 40% activity of FVa remains and an 
additional cleavage at Arg306 is necessary for complete inactivation.1  
Factor VIII is highly homologous to FV, not only in domain structure, but also in 
function as it acts as the non-enzymatic cofactor for FIXa in the tenase complex. 
Activated FVIII is also inactivated by APC, which cleaves FVIIIa at arginine 336 and 
562. Although the cleavage at Arg336 is the fastest, this results in only partial 
inactivation, whereas the slower Arg562 cleavage completely inactivates FVIIIa.
2 To 
perform this function, APC needs protein S and factor V as cofactors,3-5 indicating 
an additional anticoagulant function for FV. 
The factor V Leiden mutation (FVL) leads to an arginine to glutamine substitution at 
position 506 of factor V and therefore the FVL protein confers a partial resistance to 
the inactivation by activated protein C. Additional to this reduced susceptibility to 
inactivation, it also possesses little cofactor activity in the inactivation of activated 
FVIII, as FV first has to be cleaved at Arg506 to express this cofactor function.6,7 
These two functional defects result in an increased risk for venous thrombosis, 
which is 7-fold increased in FVL heterozygotes and 80-fold increased in 
homozygotes.8  
Factor V Leiden hemizygosity, also known as pseudo-homozygosity for APC 
resistance, is the co-inheritance of the FVL mutation and a quantitative FV 
deficiency on different alleles,9 and thus combines the factor V Leiden-related 
increased venous thrombotic risk and the deficiency-related bleeding tendency. 
With the prevalence of parahemophilia (FV deficiency with levels <1%) being 1:106 
and the prevalence of factor V Leiden being 1:20 in the Caucasian population, it is 
estimated that 1:1000 FVL carriers is actually hemizygous and with approximately 
26 million FVL carriers in Europe alone, this would make up for a substantial 
number of hemizygotes.10 However, most knowledge on this condition comes from 
case reports and small patient studies. Thus far, it has been shown that FVL 
hemizygosity results in an increased venous thrombotic risk comparable to, or even 
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higher than, the risk in FVL homozygotes.11-13 This unexpected finding suggests a 
more complex role and contribution for FV in coagulation. To gain further insight 
into the complex role of factor V in (anti)coagulation, we used an in vivo approach 
in which we crossed mice carrying the factor V Leiden knock-in allele with factor V 
heterozygous mice to generate FVL hemizygous animals.   
 
Materials and Methods 
Mice 
Generation of mice carrying the R504Q knock-in mutation, which is orthologous to 
the human FVL mutation, was previously described as was the generation of FV+/- 
mice.14,15 Tissue factor pathway inhibitor (TFPI) deficient mice were a kind gift of 
Dr. George Broze.16  All mice used in this study were backcrossed to C57BL/6J 
mice for at least 20 generations before intercrossing. Genotyping for FV, FVL and 
TFPI was performed by PCR analysis of tail DNA using primers as previously 
reported.14-16 Timed matings were performed to analyze in utero progeny from 
gestational day 18.5.17 Mice were housed and cared for at the University of 
Michigan, under compliance with the University of Michigan Committee on the Use 
and Care of Animals.  
 
Histology 
Newborn pups were zinc formalin fixed and sagittally sectioned. Whole-mount 
paraffin sections were routinely stained with hematoxylin and eosin. Fibrin(ogen) 
staining was performed as previously described.16  
 
Plasma analyses 
Mice were anesthetized and blood samples on sodium citrate (final concentration 
0.32%) were drawn directly from the inferior caval vein. Blood was centrifuged 
twice to obtain platelet free plasma which was immediately frozen at -80°C until 
analysis.  
Plasma activity levels of factors II, VIII, IX, X, XI and XII were determined as 
described elsewhere.18 The activity of FV was assessed in a 2-step procedure, in 
which FV is activated with thrombin and subsequently the FVa activity is quantified 
by determining the rate of FXa-catalyzed prothrombin action. Plasma FVII, 
antithrombin and TFPI activity levels were analyzed by means of commercially 
available kits from respectively Hyphen Biomed, Chromogenix and American 
Diagnostica. Fibrinogen antigen levels were measured with a commercial murine 
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ELISA kit (Affinity Biologicals), and protein C levels were determined with an in-
house ELISA using antibodies from Haematologic Inc. Pooled mouse plasma from 
wild-type mice was used to generate standard curves from which the plasma 
activity and antigen levels of individual mouse samples could be calculated.  
To evaluate overall coagulability of mouse plasmas, the activated partial 
thromboplastin time (aPTT-SP reagent, Instrumentation Laboratories) and the 
prothrombin time (STA neoplastin plus reagent, Roche) were measured on the 
STart 4 analyzer (Diagnostica Stago). Thrombin generation was assessed by 
means of the Calibrated Automated Thrombogram, using 1 pM tissue factor (PPP-
reagent Low, Thrombinoscope) to trigger 1:6 diluted mouse plasma. Thrombin 
generation was measured on the Fluoroskan Ascent reader (Thermo Scientific) 
and the curves and area under the curve (endogenous thrombin potential; ETP) 
were calculated using the Thrombinoscope software. APC resistance was 
determined by quantifying the effect of added APC on the ETP.19 The cofactor 
activity of FV on FVIIIa inactivation was evaluated with the Immunochrom APC 
Response assay (Progen Biotechnik), according to the protocol described by 
Govers-Riemslag et al.20 with the last incubation step being reduced to 2 minutes.  
 
Statistical analyses 
Plasma data is presented as mean ± standard error of the mean (SEM) and were 
analyzed with the Graphpad Instat software package. Survival data was evaluated 
using a Chi-square test and statistical differences between genotypes were 
evaluated using a one-way analysis of variance (ANOVA) with a Bonferroni post-
hoc test to compare FVL hetero- and homozygous mice with FVL hemizygous 
mice. A p-value <0.05 was considered to be statistically significant. 
 
Results 
Effect of FVL hemizygosity on survival 
To generate FVL hemizygous (FVQ/-) mice, FV+/- mice were crossed with FVQ/Q 
mice. Although equal numbers of FVQ/+ and FVQ/- progeny were expected, only 23 
of 91 mice carried the FVQ/- genotype at the time of weaning (p<0.001; table 1). To 
address the effect of FVL dosage on viability, FVQ/Q and FVQ/- mice were mated 
and again less FVQ/- mice were present at the time of weaning (53 FVQ/- vs. 131 
FVQ/Q, p<0.001), indicating that decreasing the dose of FVL in the absence of wild-
type FV has adverse effects on viability. FVQ/+ and FVQ/- mice were crossed to 
provide a direct comparison of FVQ/+, FVQ/Q and FVQ/- in an identical genetic 
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context, which resulted in a significant reduction of FVQ/- progeny as compared to 
both FVQ/+ and FVQ/Q (p<0.001 and p<0.01 respectively; table 1). 
Timed matings were performed to analyze progeny from gestational day 18.5, just 
prior to birth. Genotypes for 171 mice from a FVQ/+ x FV+/- cross showed that the 
observed distribution did not differ from the expected distribution (table 1), 
indicating that the FVQ/- mice progress normally to term but succumb between birth 
and weaning. A second series of timed matings between FV+/- and FVQ/Q mice were 
performed, resulting in 52 mice of which 29 carried the FVQ/+ and 23 the FVQ/- 
genotype. However, 20 mice died within 24 hours after birth, of which 15 were FVQ/- 
(p=0.02). These data show that the distribution of genotypes at birth is as 
expected, but that a substantial fraction of the FVL hemizygotes dies in the 
immediate postnatal period.  
 
 
Table 1: Genotype distribution of weaning pups and embryos obtained from experiments 
designed to assess the lethality of the FVQ/- genotype compared to FVQ/+ and FVQ/Q. 
Number of 
offspring/genotype 
FV+/+ FV+/- FVQ/+ FVQ/Q FVQ/- Total number of 
pups analyzed 
Parental genotypes       
FV+/- FVQ/Q - - 68 - 23** 91 
FVQ/Q FVQ/- - - - 131 53** 184 
FVQ/- FVQ/+ - 18 23 14 5* 60 
Embryonic mating       
FVQ/+ FV+/- 36 49 50 - 36 171 
* p<0.01, **p<0.001 (Chi square analysis) 
 
 
To establish the cause of death, newborn pups that died shortly after birth were 
collected, of which some showed macroscopic features of coagulopathy (figure 
1A). Additional histological analyses of FVQ/- pups revealed signs of macrovascular 
thrombosis and in 2 out of 6 FVQ/- pups large thrombi within vessels were found 
which demonstrated the typical layering of fibrin as a hallmark of thrombosis, 
discriminating these from postmortem blood clots (figure 1). Furthermore, livers of 
2 FVQ/- animals featured infarcted areas with necrosis and the presence of 
multicellular infiltrates. Analysis of serial sections did not show thrombi located 
outside blood vessels or the presence of bleeding. No histological abnormalities 
were found in the FVQ/+ pups (n=5).                         































Figure 1: Macroscopic and microscopic examination of dead factor V Leiden hemizygous mice.  
Macroscopic features of coagulopathy were observed in FV
Q/-
 mice that succumbed within 24 hours after birth (A). 
Microscopic analyses of these FV
Q/-
 animals (hematoxylin/eosin and fibrin(ogen) staining) showed infarcted areas in 
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In order to confirm that the FVQ/- genotype predisposes to a thrombotic and not 
bleeding tendency, we combined these mice with mice lacking one allele of TFPI. 
Whereas either FVL homozygosity or TFPI heterozygosity does not result in early 
lethality, we previously demonstrated that a TFPI+/- background transforms 
homozygosity for factor V Leiden into nearly complete lethality in the immediate 
perinatal period due to widespread thrombosis.21 Of the 203 progeny analyzed 
from a FVQ/-,TFPI+/+ x FVQ/+,TFPI+/- cross, 27 mice were FVQ/Q TFPI+/+ which 
corresponds with the expected 12.5% distribution. However, only 16 FVQ/- TFPI+/+ 
mice were present at the time of weaning, confirming the decreased viability of the 
hemizygous mice on a wild-type background. On a TFPI+/- background, only 3 
FVQ/Q mice and 1 FVQ/- mouse out of 203 were present. Thus, on a prothrombotic 
TFPI+/- background, the FVQ/- genotype was nearly fully fatal supporting the 
presence of a thrombotic and not a bleeding phenotype.  
 
Plasma coagulation 
The mating studies suggested that the reduced anticoagulant rather than the 
reduced procoagulant function of FV(L) contributed to the early lethality of the FVL 
hemizygous mice as compared to the FVL heterozygous mice. Therefore we 
studied the effect of hemizygosity on coagulation by comparing plasmas from 
viable FVQ/- mice and FVQ/+ littermates. In addition, plasmas from FVQ/Q mice from a 
parallel cross were included in the comparison.  
As expected, FV activity levels were decreased in FVQ/- mice as compared to both 
FVQ/+ and FVQ/Q animals (table 2). In addition, FVIII levels were also lower whereas 
FII and FVII levels were higher in FVQ/- mice than in FVQ/+ and FVQ/Q mice. To 
assess the impact of the differences in individual coagulation factors on the overall 
coagulability, thrombin generation assays were performed showing a significantly 
higher endogenous thrombin potential (ETP) in FVQ/+ mice (272±5 nM*min) as 
compared to FVQ/- mice (213±13 nM*min, p<0.01), with an intermediate ETP value 
for FVQ/Q mice (232±10 nM*min, p=n.s.). Furthermore, the prothrombin time was 
longer in FVQ/- (11.9±0.1 sec) than in FVQ/+ and FVQ/Q animals (both 11.3±0.1 sec, 
p<0.05). The activated partial thromboplastin time was also increased in FVQ/- 
mice, although this did not reach statistical significance (FVQ/+ 29.3±0.6 sec, FVQ/Q 
31.0±0.9 sec and FVQ/- 31.3±0.9 sec).  
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Table 2: Plasma levels of procoagulant factors from factor V Leiden heterozygous (FVQ/+), 
homozygous (FVQ/Q) and viable hemizygous mice (FVQ/-). 
 FVQ/+ FVQ/Q FVQ/- p-value  
Fibrinogen  121.8±5.0 112.5±6.0 106.7±8.5 n.s. 
Factor II 126.2±3.9 121.4±2.5** 134.6±2.9 0.012 
Factor V 101.8±4.7** 97.2±6.1** 56.5±3.8 <0.001 
Factor VII 103.4±2.7* 103.6±3.0 115.9±5.1 0.034 
Factor VIII 110.0±3.4* 101.9±6.8 88.5±6.3 0.020 
Factor IX 96.3±1.8 98.7±3.7 100.6±3.9 n.s. 
Factor X 99.6±3.1 101.6±2.9 109.9±4.1 n.s. 
Factor XI 104.9±5.3 107.4±9.7 106.1±7.7 n.s. 
Factor XII 105.3±2.0 98.8±2.3* 108.8±1.8 0.014 
Data are expressed as mean percentage of pooled mouse plasma ± standard error of the mean of n=15 (FVQ/+ and 
FVQ/Q) or n=10 (FVQ/-) mice. *p<0.05 and **p<0.01 as compared to FVQ/- mice by performing an analysis of variance 




To evaluate the effects of FVL hemizygosity on anticoagulation, plasma levels of 
antithrombin, protein C and TFPI were measured. However, no differences 
between genotypes were present (data not shown). In addition, an ETP-based APC 
sensitivity ratio was determined. The APC resistance of FVQ/- mice was comparable 
to FVQ/Q (2.85±0.12 vs. 3.12± 0.31) but significantly higher than FVQ/+ mice 
(1.78±0.11, p<0.01; figure 2). As the ETP-based APC sensitivity ratio does not 
distinguish between the 2 functional defects of factor V Leiden, i.e. the decreased 
susceptibility to be inactivated by APC and the reduced cofactor activity in FVIIIa 
inactivation, we performed an APTT-based APC sensitivity test in which pooled 
mouse plasma from either wild-type or FVL homozygous mice were titrated in FV 
deficient plasma.(22) Figure 2b shows that in wild-type plasma, factor V has an 
obvious cofactor function, whereas this is less present in FVL plasma. Therefore, 
the specific FV-mediated FVIIIa inactivation was measured, showing a significant 
decreased capability of FVIIIa inactivation in FV
Q/- mice (1.25±0.03)  than in FVQ/+ 
mice (1.59±0.07, p<0.01), with FVQ/Q having an intermediate phenotype 








Figure 2: Overview of anticoagulant properties of factor V Leiden heterozygous (FVQ/+), homozygous (FVQ/Q) and viable 
hemizygous mice (FVQ/-). 
The activated protein C (APC) sensitivity ratio for individual mouse plasmas was based on the endogenous thrombin 
potential (panel A). The APC sensitivity ratio was also assessed in an APTT-based assay, in which pooled wild-type 
mouse plasma (black) or factor V Leiden mouse plasma (open) was titrated with human factor V deficient plasma, 
showing that murine FV acts as a cofactor in FVIIIa inactivation (B). FV-mediated FVIIIa inactivation per genotype is 
shown in panel C. Data are expressed as mean ± standard error of the mean of n=15 (FVQ/+ and FVQ/Q) or n=10 (FVQ/-) 
mice. **p<0.01 as compared to FVQ/- mice by performing an analysis of variance (ANOVA) with an additional 





In the present study we combined FVQ/Q and FV+/- mice to generate unique factor V 
Leiden hemizygous mice that allowed us to gain further insight into the complex 
role of factor V and factor V Leiden in (anti)coagulation. The data presented here 
demonstrate that the FVQ/- genotype induces an unexpected partial lethality in the 
immediate postnatal period that is related to macrovascular thrombosis; findings 
that were also confirmed on a TFPI+/- background. Compared to FVQ/+ mice, viable 
FVQ/- mice had an expected overall reduced procoagulant plasma profile, with less 
thrombin generation and longer prothrombin times. Anticoagulability was also 
decreased with a more pronounced APC resistance and a diminished capability to 
inactivate activated FVIII in a FV-dependent manner. As FVQ/- mice die with 
features of thrombosis and not bleeding, we conclude that the impaired FV 
anticoagulant function in FVL hemizygosity underlies the fatal phenotype. In 
addition, comparison of plasma coagulation profiles of FVQ/- and FVQ/Q animals 
showed only subtle differences. However, as FVQ/Q mice do not display early 
lethality, this implies that factor V Leiden has maintained a vital and critical fraction 
of its anticoagulant activity. Overall, this mouse study demonstrates the 
physiological importance of the anticoagulant function of the factor V allele. 
A B C 
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Our data regarding the reduced anticoagulability in surviving FVL hemizygous mice 
reproduce two important observations for their human counterpart, i.e. decreased 
FV-mediated FVIIIa inactivation and pseudo-homozygosity for APC resistance.
11 
However, the recently reported lower TFPI levels associated with FV deficiency 
and FVL hemizygosity that is thought to significantly contribute to increased 
coagulability12 could not be reproduced in mice as we did not detect a lower 
plasma TFPI levels upon lack of one FV allele (9.4±0.3 U/mL vs. 10.0±0.2 U/mL for 
FVQ/+ and FVQ/- mice, respectively). Both in mice and human, TFPI has 2 isoforms: 
TFPIα and TFPIß, which are different in protein structure. The predominant isoform 
in mouse plasma is TFPIß, whereas in human TFPIα is the main plasma isoform,23 
which may explain the absence of an association between FV and TFPI levels in 
mice. Besides the absence of a FV-TFPI association, we found an evident 
postnatal lethality associated with the FVL hemizygous state in mice. For humans, 
it is estimated that 1:1000 FVL carriers is actually hemizygous, and with 
approximately 26 million FVL carriers in Europe alone, this would make up for a 
considerable number of hemizygotes.10 Whether reduced postnatal survival in 
humans contributes to the relatively limited reports on factor V Leiden hemizygotes 
is subject to speculation. 
Viable FVQ/- animals had lower fibrinogen and FVIII plasma levels as compared to 
FVQ/+ mice. Although we have no good explanation for these findings, they were 
confirmed in offspring from multiple matings with different parental genotypes. Low 
levels of FVIII and fibrinogen provide a reduced procoagulant state and may have 
enabled survival of those expressing the low levels through selection. On the other 
hand, the lower fibrinogen and FVIII levels may also be the result of consumptive 
coagulopathy and thus a secondary effect.24 In this respect, it is interesting that 
FVQ/Q mice, which have increased tissue fibrin deposition as a marker of 
microvascular thrombosis, show intermediate levels of both fibrinogen and factor 
VIII. Whether FVQ/- mice have more microvascular thrombosis and therefore lower 
plasma levels of both factors as compared to FVQ/Q mice has not been determined. 
Since FV and FVIII are structurally related and share steps in posttranslational 
processing,25 we considered that the lower FVIII levels result from the decreased 
FV levels as a significant correlation between these factors was found (Pearson 
r=0.52, p<0.001). However, in FV+/- mice, we did not observe lower FVIII levels, 
thus making a direct relation between FV and FVIII in these mice less likely. 
Although the survival of FVQ/Q and viable FVQ/- mice differs markedly, we were 
unable to detect major differences in plasma coagulation profiles. This implies a 
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residual anticoagulant function for the factor V Leiden allele that reaches a 
functionally adequate level in the homozygous but not hemizygous state. Indeed, 
the level of FVIIIa inactivation appeared to be somewhat higher in FV
Q/Q mice as 
compared to FVQ/-, which has also been observed in humans.11 However, FV might 
also have an additional function besides it pro- and anticoagulant role in 
coagulation. For example, a role for FV in fibrinolysis has been revealed,26-28 and a 
more impaired fibrinolysis in FVL hemizygosity as compared to FVL homozygotes 
may contribute to the observed thrombotic phenotype. 
In conclusion, our data show partial lethality of factor V Leiden hemizygous mice in 
the immediate postnatal period due to macrovascular thrombosis. These 
observations indicate that the lack of the anticoagulant function rather than the lack 
of the procoagulant function of factor V is of vital importance. In addition, our data 
imply a residual anticoagulant function of the factor V Leiden allele which can 
rescue the lethal phenotype associated with factor V Leiden hemizygosity.  
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In this thesis, we aimed to identify the biological mechanisms by which acquired 
risk factors like female hormones, thyroid hormone and obesity result in a 
hypercoagulable state and increased risk for venous thrombosis, as these 
mechanisms are currently poorly understood. Since these risk factors are all, to a 
certain extent, able to interfere with liver metabolism we hypothesized that they 
modulate hepatic transcription of coagulation genes, either directly via nuclear 
hormone receptors and hormone response elements in target genes (female 
hormones and thyroid hormone), or indirectly as a result of altered liver 
homeostasis (obesity). To study these hypotheses, we used an in vivo approach, 
which provides a complete physiological system including intact mechanisms 
through which risk factors potentially impact transcriptional modulation of 
coagulation genes. In addition, this approach allows us to study the relation 
between transcriptional changes on the one hand and plasma protein levels and a 
thrombotic tendency on the other.  
We show that estrogens and thyroid hormone are both able to modulate 
transcription of hepatically expressed coagulation genes, and that these effects can 
be immediate, i.e. within only a few hours after administration. These observations 
make it likely that these hormones modulate transcription via a direct interaction 
with their receptor and subsequent binding to hormone response elements in the 
promoter region of coagulation genes. In contrast, progestins were not able to 
modulate transcription, neither in the presence nor absence of estrogens. Dietary 
fat intake rather than body fat mass was found to be a strong modulator of the 
plasma coagulation profile albeit transcription levels of only a limited number of 
coagulation genes were affected.  
In genetic mouse models of thrombosis that lack a vascular injury component, oral 
estrogen-induced transcriptional modulation of coagulation genes was not able to 
trigger a micro- or macrovascular thrombotic phenotype. This is in strong contrast 
to conditions where a disturbance of the coagulation balance is evoked by genetic 
means, as illustrated by the partial perinatal death of factor V Leiden hemizygous 
mice.  
Taken together, our studies clearly demonstrate that modulation of hepatic 
coagulation gene transcription is a key mechanism by which acquired risk factors 





Transcriptional modulation of coagulation genes 
Over the past years, mouse studies have demonstrated that estrogens, progestins, 
thyroid hormone and dietary fat intake are able to modify gene transcription of 
multiple pathways in multiple tissues. A large body of evidence has come from 
mouse studies employing microarrays as a key technology to identify pathways and 
networks of genes affected.1-10 However, transcript levels of coagulation genes 
never appeared to be altered in microarray studies dedicated to the liver.3,7,8 This 
seems to be rather counterintuitive, as female hormones, thyroid hormone and 
obesity are all associated with changes in the plasma coagulation profile and most 
of these plasma factors are synthesized in the liver.  
In chapters 3, 4 and 8 we have demonstrated, by using quantitative PCR methods, 
that the transcript levels of coagulation genes are clearly modulated by the risk 
factors studied. The apparent discrepancy with previous studies might be explained 
by the different detection techniques used, i.e. quantitative PCR versus 
microarrays. Microarrays generate large amounts of data and give a relatively high 
background signal. Therefore, it is necessary to set a threshold value to determine 
truly induced effects, and these thresholds are often set so only changes over 1.5-
fold are included in the analyses.2,5,7,10 With our qPCR data, we have shown that 
the risk factor-induced effects on transcript levels of coagulation genes are 
relatively small, generally remaining within the 50% range, and therefore not 
exceed the threshold values set in microarray studies. Hence, microarray analysis 
should not be the method of choice for studying modulating effects on transcript 
levels of genes that, like coagulation genes, are regulated within a relatively narrow 
window.  
In addition to microarrays, in silico and ChIP-on-chip analyses are valuable tools to 
predict how risk factors may impact the transcription of coagulation genes. 
Previous in silico and ChIP-on-chip studies have predicted and identified several 
estrogen receptor targets belonging to coagulation.4,11,12 These observations were 
used as a starting point for the hypothesis that oral ethinylestradiol can directly 
modulate transcription via ligand-bound estrogen receptor interaction with estrogen 
response elements in coagulation genes. We have shown that transcript levels of 
nearly all coagulation genes could be modulated within 2.5 to 5 hours after oral 
ethinylestradiol administration, indicating immediate effects. Comparing our data 
with the in silico and ChIP-on-chip data showed that almost all genes we found 
were previously predicted to have either an estrogen response element, or are able 
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to bind to the estrogen receptor α in vivo.4,11 In addition, we also found several 
factors that have not been identified previously, including factor V and factor IX.  
Taken together, these data show that predicted estrogen response elements in 
silico will not necessarily bind estrogen receptors in vivo. On the other hand, 
estrogen receptor binding to coagulation genes will not automatically lead to 
transcriptional modulation. By determining transcript levels within 5 hours after 
estrogen administration, we were able to identify coagulation genes that can be 
rapidly modulated. Although we are aware of the fact that with this approach fast 
indirect effects on transcription cannot be excluded, it is highly likely that these 
effects are caused by direct interactions. However, the unequivocal evidence 
whether estrogen receptor binding to coagulation genes truly results in 
transcriptional modulation can only come from experiments in which ChIP is 
combined with a technique like RNA sequencing.  
 
For oral estrogen administration, prolonged exposure hardly yielded additional 
coagulation gene targets, and thus all coagulation targets appear to be under direct 
control, which fitted our hypothesis. In contrast, for thyroid hormone prolonged 
exposure affected transcription of a large number of coagulation genes, but for 
most an immediate response (4 hours) was absent, suggesting that a large panel 
of coagulation genes is indirectly regulated by thyroid hormone. This indirect 
regulation may still involve a relatively short chain of events where thyroid 
hormone, via its receptor, interferes with the constitutive expression of coagulation 
genes. However, it may also involve a long chain of events in which thyroid 
hormone for example affects liver metabolism which subsequently via a multistep 
process leads to changes in coagulation gene transcript levels by affecting 
transcriptional rate or RNA stability. By nature it will be hard to unwind the 
intermediate steps involved in this process resulting in altered transcript levels. 
Nevertheless, we considered the first option of interference with constitutive 
expression the most likely and therefore evaluated two potential intermediate 
transcription factors: hepatic nuclear factor 4α (HNF4α) and the growth hormone 
receptor, in an attempt to unravel the key players in this multistep process.  
HNF4α is an important transcription factor for the basal expression of a number of 
pro- and anticoagulant factors,13,14 and thyroid hormone has been reported to 
increase HNF4α expression in mouse hepatocytes.15 Following prolonged thyroid 
hormone exposure, a remarkable increase in transcript levels of coagulation factors 
XI and XII was observed (chapter 6), representing two typical HNF4α targets.13 
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Therefore, we determined HNF4α transcript and protein levels in livers of mice 
treated with thyroid hormone and found that in a setting where FXI and FXII were 
increased by 30-40%, HNF4α levels were reduced by 20%, thereby making HNF4α 
an unlikely intermediate in modulating the thyroid hormone-mediated effects on the 
transcription of coagulation genes.  
Another potential intermediate transcription we considered is the growth hormone 
receptor, as a recent report by Wong and colleagues showed that gender-specific 
growth hormone secretion contributes to the gender differences in hepatic 
anticoagulation gene transcription and thrombosis susceptibility.16 As thyroid 
hormone is a well-known modulator of growth hormone secretion17 and growth 
hormone receptor levels are key in the transcriptional effects of growth hormone, 
we analyzed growth hormone receptor transcript levels in the livers of mice treated 
with thyroid hormone. However, we were unable to detect differences in transcript 
levels between vehicle- and thyroid hormone-treated mice, which makes the 
growth hormone pathway also an unlikely intermediate in modulating the late 
effects of thyroid hormone.   
As shown, it will be difficult to delineate the multiple steps involved in the late 
modulating effects of thyroid hormone exposure on coagulation gene transcript 
levels. However, a genome wide approach that accurately records all late 
transcriptional changes that occur in parallel with changes in coagulation gene 
transcription may shine a light on the key players involved.  
 
Plasma coagulation profile 
We have shown that estrogen and thyroid hormone administration in mice can 
modulate transcription, both in a direct and indirect fashion, and in addition these 
transcriptional effects are often translated into altered protein (activity) levels in 
plasma (chapters 3, 5 and 8). Although this risk factor exposure in mice results in 
changes in the plasma coagulation profile as it does in humans, the net effect on 
individual plasma levels, i.e. whether plasma levels increase or decrease upon 
exposure, may differ between mice and humans. For example, antithrombin levels 
decrease in both mice and humans, whereas the decrease in levels of 
procoagulant factors in mice is in contrast to human observations.18,19  
Thrombin generation assays represent the overall hemostatic balance in plasma 
and are therefore considered to have a predictive value regarding a bleeding or 
thrombotic phenotype.20 The risk factors studied in this thesis are all associated 
with a hypercoagulable state that in humans corresponds to an increased 
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endogenous thrombin potential (ETP).21,22 Surprisingly, oral ethinylestradiol 
administration in mice, while causing decreases in procoagulant factor levels, 
resulted in an increased ETP although this did not translate into an increased 
thrombotic tendency (chapters 5 and 6). On the other hand, nutritionally-induced 
obesity resulted in higher procoagulant levels in plasma and an increased 
thrombotic tendency while this not coincided with higher ETP values (chapters 5 
and 7). These data indicate that the ETP in mice does not have a predictive value 
regarding the overall coagulability, like it has in humans.  
In order to find an explanation for the species-specific differences in coagulation 
factor levels, we first considered the way mice were exposed to the risk factor as a 
possible determinant. To study the effects of (oral) estrogens on coagulation, mice 
were treated with the semi-synthetic compound ethinylestradiol, and this compound 
might be differently metabolized in mice and humans. Nevertheless, we have 
shown that in mice the effects of oral ethinylestradiol on coagulation are dose-
dependent, which indicates a specific estrogen-induced response (chapter 3). In 
contrast, endogenously increased estrogen levels as observed during pregnancy, 
have shown to be associated with increased plasma levels of FII, FV and FX.23 
However, since pregnancy has more metabolic effects than only an increase in 
estrogen levels, it is difficult to conclude that these changes on coagulation are 
truly and only due to increased endogenous estrogen levels, especially since we 
have shown that injections with the naturally occurring 17ß-estradiol did not yield 
different results as compared to the oral ethinylestradiol-induced effects on 
coagulation.  
In chapter 7 we determined the relation between coagulation and nutritionally-
induced weight gain and subsequent weight loss, and also evaluated the 
genetically obese ob/ob mice as a potential model to study obesity in relation to 
coagulation. Ob/ob mice had more pronounced increases in plasma levels of 
procoagulant factors as compared to nutritionally-induced obese mice. In addition, 
they also display metabolic abnormalities like insulin resistance, which may 
aggravate the hypercoagulable state. As we show that the dietary fat intake rather 
than being obese rapidly affects coagulation, which thereby precedes metabolic 
changes, genetically obese mice may be less suitable for studying coagulation-
related effects.  
Taken together, exogenous exposure to risk factors does not seem to explain the 
species-specific responses on the coagulation profile, and therefore the 
explanation may be found in the different organization of the hemostatic balance 
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between mice and human. It is known that there is a higher activity of natural 
anticoagulants in mouse plasma,24 which in the case of oral ethinylestradiol 
administration may at least partially explain the increase in ETP value, since 
estrogens also cause a significant decrease in antithrombin levels (chapters 3 and 
6). This difference in the center of gravity between pro- and anticoagulant factors in 
the hemostatic balance questions whether mice are a suitable model organism to 
study quantitative effects of acquired risk factors on the overall coagulability and 
the thrombotic phenotype, although they have proven to be a valuable tool for 
mechanistic studies.  
 
Thrombosis models 
With respect to the effects of acquired risk factors on thrombosis as a read-out, the 
species-specific differences in the hemostatic balance have also shown to be 
challenging. In order to find the “holy grail” of a genetic model for spontaneous 
macrovascular thrombosis in adult mice we reviewed the available models in 
chapter 2. As factor V Leiden and thrombomodulin proline mutant mice display 
fibrin depositions as a marker for thrombosis and have the potential to develop 
macrovascular thrombosis,25,26 these models were used in studies described in 
chapter 6. However, prolonged ethinylestradiol administration did not result in 
spontaneous macrovascular thrombosis in factor V Leiden or thrombomodulin 
mutant mice, and for factor V Leiden mice it has been shown that pregnancy and 
obesity, two conditions associated with a hypercoagulable state, were also not able 
to induce thrombosis. 23,27  
In contrast, an additional genetic defect is able to cause a severe macrovascular 
thrombotic phenotype which might even result in partial lethality, as we have shown 
in factor V Leiden hemizygous mice which have a combination of factor V Leiden 
and factor V deficiency (chapter 9). An even more severe phenotype, with near-
complete lethality has also been shown for factor V Leiden homozygous mice that 
are also deficient in tissue factor pathway inhibitor or protein Z.28,29 The dual 
phenotype of factor V Leiden hemizygous mice implies that they are more prone to 
develop thrombosis and although further evaluation is necessary, this observation 
suggests that these mice can be valuable in the development of a new genetic 
thrombosis model.  
Due to the current lack of a good genetic model to study spontaneous thrombosis, 
experimental thrombosis models may provide a better setting to study acquired risk 
factors for thrombosis. By applying these experimental models, a thrombus or 
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reduced blood flow can be induced in virtually any mouse, including wild-type mice 
that have not been exposed to a certain risk factor (chapter 5). However, the 
underlying mechanisms are often not completely known and each model focuses 
on different aspects of thrombus formation.30,31 Therefore, a combination of models 
will be necessary to evaluate all aspects of thrombus formation in order to get a 
complete insight of how risk factors affect the thrombotic phenotype.  
 
Future perspectives 
Although we have come a long way to identify the biological mechanisms 
underlying the risk factor-associated an increase in the venous thrombotic risk, 
there is still a lot to explore. As more risk factors for venous thrombosis are being 
identified, and the prevalence of common acquired risk factors increases, it 
becomes more important to gain insight in biological mechanisms, as this may lead 
to disease prevention and better risk assessments. Fortunately, new high-
throughput technologies and the use of novel approaches in animal models may 
quickly expand our current knowledge and gain new fundamental insights in the 
pathophysiology of venous thrombosis.  
As previously discussed, microarray studies have contributed to our knowledge of 
hormonal regulation of gene transcription, but as the effects have to be relatively 
large to be detected, this method is less suitable to study minor modulating effects 
on transcription, as are observed for coagulation genes. With the development of 
next-generation sequencing methods, this limitation can be overcome. For 
example, RNA-sequencing can determine transcript levels with a comparable 
precision as has been shown for qPCR data, including accurate transcript levels in 
the low ranges. In addition, because of the high-throughput sequencing it will not 
only become less time-consuming than the current methods, but will also allow an 
unbiased approach and may therefore reveal new networks important for the 
regulation of coagulation gene transcription.32-34  
The use of genetic mouse models in hemostasis has been of great value for 
expanding our knowledge on the role of specific coagulation factors in the 
pathophysiology of venous thrombosis. However, several coagulation factors also 
play an important role in development, and therefore the complete knock-out of 
these factors results in non-viable mice (chapter 2). By using conditional knock-out 
techniques in which a gene can be knocked-out in a specific tissue at a specific 
time during life, this problem can be overcome.35,36 However, making conditional 
knock-outs can be very laborious and time-consuming. The recent discovery and 
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development of synthetic short interference RNA (siRNA) makes it possible to 
temporarily knock-down a gene or set of genes, and it has been shown that 
particularly hepatically expressed genes can be relatively easy targeted.37-39 
Therefore, the use of siRNAs may finally give us the opportunity to determine the 
contribution of a specific coagulation factor, or set of factors, on the thrombotic risk.  
Thrombotic disorders, including both arterial and venous thrombosis, are the 
second most common causes of mortality and morbidity in developed countries. 
The evidence that arterial and venous thrombosis are more alike than previously 
thought is increasing, and they share a common pathophysiologic background as 
well as several risk factors including age, dyslipidemia and obesity.40 More 
importantly, it is now known that experiencing a venous thrombotic event does not 
only predispose to recurrent venous thrombosis, but also predisposes to arterial 
thrombosis.41,42 This observation may lead to a reconsideration of the treatment for 
venous thrombosis, as it has been shown that anticoagulant therapy can also 
reduce the risk of arterial thrombosis and statins may have beneficial effects on 
both the arterial and venous thrombosis risk. In addition, it underlines the 
importance of elucidating the biological mechanisms by which acquired factors 
increase the risk for venous thrombosis as this may eventually not only result in 
reducing the venous thrombotic risk, but can also reduce the prevalence of 
vascular diseases in general.  
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Over the years, a number of acquired risk factors for venous thrombosis, either 
resulting in stasis or a hypercoagulable state, have been identified in large 
epidemiological studies. However, the exact mechanisms that lead to this 
hypercoagulable state and increased thrombosis risk are poorly understood. 
Therefore, this thesis focuses on identifying the biological mechanisms underlying 
acquired risk factors leading to venous thrombosis.  
 
Chapter 1 provides a general background on risk factors for venous thrombosis 
and shows that the risk factors studied in this thesis all have in common that they 
lead to a hypercoagulable state and can interfere with liver metabolism. Since the 
liver is also the main organ involved in the synthesis of plasma coagulation factors, 
we hypothesize that the risk factors of interest, i.e. female hormones, thyroid 
hormone and obesity, can modulate transcription of coagulation genes. Several 
mechanisms by which transcription can be modulated are discussed, ranging from 
a direct modulation via nuclear receptors that bind to response elements in 
coagulation genes, to indirect modulation where transcription is affected as a 
bystander effect of changes in liver homeostasis. In addition, different experimental 
approaches to study transcriptional modulation are explained, as well as the 
rationale to use mice as a model organism for the studies described in this thesis.  
 
Mice do not develop thrombosis spontaneously. To overcome this limitation, 
transgenic mice have been generated that carry defective or mutant alleles of 
genes that are involved in anticoagulation and therefore have the potential to 
develop a thrombotic phenotype. These models have been reviewed in chapter 2, 
in which it is shown that complete deficiencies of an anticoagulant factor often 
result in embryonic lethality due to hemodynamic dysfunction, while heterozygosity 
in general coincides with normal survival. However, models like the factor V Leiden 
and thrombomodulin proline mutant mouse display a spontaneous thrombotic 
phenotype characterized by tissue fibrin depositions as a sign of low-grade 
thrombosis, and are therefore considered to be valuable tools in thrombosis 
research.  
 
Experiments described in chapter 3 were performed in order to gain more insight in 
the underlying mechanism of estrogen-induced changes in coagulation. Oral 
ethinylestradiol treatment of mice is able to cause dose-dependent effects on the 
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plasma coagulation profile, which coincides with dose-dependent changes in 
hepatic transcript levels of coagulation genes. In addition, these ethinylestradiol-
induced effects were counteracted by additional estrogen receptor (ER) antagonist 
administration and studies performed in ERα and ERß knock-out mice 
demonstrated a crucial role for the ERα subtype in mediating the coagulation-
related alterations. Moreover, the changes in hepatic transcript levels could be 
rapidly induced, within 2.5 to 5 hours after oral ethinylestradiol administration, 
thereby suggesting a direct interaction between the estrogen-bound estrogen 
receptor and coagulation genes in the liver.  
 
There is a known difference in venous thrombosis risk associated with second and 
third generation oral contraceptives and it is believed that this is due to the anti-
estrogenic properties of the progestin compound, i.e. levonorgestrel or desogestrel. 
In chapter 4, these anti-estrogenic effects of progestins on hepatic mRNA levels of 
coagulation genes were determined, together with the biological changes in uterus 
morphology. Despite a comparable and clear anti-estrogenic effect of both 
levonorgestrel and desogestrel on the uterus, neither progestin was able to 
modulate the oral ethinylestradiol-induced alterations in transcript levels of 
coagulation genes expressed in the liver.  
 
Chapter 5 focused on the interaction between obesity and oral estrogen use on the 
thrombotic tendency by applying a stasis-induced thrombosis model in mice that 
were fed a high fat diet to induce obesity and / or were treated with oral 
ethinylestradiol. High fat feeding resulted in a procoagulant shift of the coagulation 
profile and a borderline significant increase in thrombus weight as compared to 
mice on a standard fat diet. Although oral ethinylestradiol administration did not 
affect the plasma coagulation profile, both transcript levels of coagulation factors as 
well as the thrombus weight were decreased, of which the latter was significant in 
obese mice. These data indicate that ethinylestradiol can counteract the 
prothrombotic phenotype of nutritionally-induced obesity in mice.  
 
After determining the oral ethinylestradiol-induced effects on individual coagulation 
factor levels in plasma, chapter 6 evaluates the overall effects of these changes on 
the hemostatic balance by measuring thrombin generation and determining the net 
effect on a spontaneous thrombotic phenotype in prothrombotic factor V Leiden 
and thrombomodulin proline mutant mice. Oral estrogen administration caused a 
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sustained increase in thrombin generation, however, this did not translate into a 
spontaneous macrovascular or microvascular thrombotic phenotype as evaluated 
by fibrin depositions in the lung. Therefore, these data imply the lack of a relation 
between an increased potential to generate thrombin and an enhanced thrombotic 
phenotype in these mice.  
 
Chapter 7 describes the onset and reversibility of the hypercoagulable state during 
the development and regression of nutritionally-induced obesity in mice, and its 
relation to changes in transcriptional and clearance rates of coagulation factors as 
well as its relation to changes in metabolic and inflammatory parameters. The 
plasma coagulation profile is able to rapidly respond to changes in dietary fat 
intake, both in weight gain which is associated with a procoagulant shift, and in 
subsequent weight loss resulting in a reversal of the high fat diet-induced 
hypercoagulability. These changes in the plasma coagulation profile did not 
coincide with changes in hepatic transcript levels or clearance rates of coagulation 
factors. In addition, effects on coagulation preceded the alterations in metabolic 
parameters, both in nutritionally-induced weight gain and weight loss. Levels of 
inflammatory cytokines were only transiently increased early after starting the high 
fat diet or switching back to the low fat diet. This study shows that changes in 
dietary fat intake can rapidly alter the plasma coagulation profile and this could not 
be explained by changes in relative transcript levels or clearance rates of 
coagulation factors.  
  
In chapter 8, the role of thyroid hormone in modulating coagulation was studied by 
evaluating the impact of exogenous triiodothyronine (T3) administration on 
transcript and plasma levels of coagulation factors in mice with a suppressed 
endogenous thyroid hormone production. Prolonged exposure to T3 affected 
transcript levels of several hepatically expressed and endothelium-associated 
coagulation genes, and for the genes expressed in the liver these effects were 
largely paralleled by changes in plasma activity levels. In addition, most 
anticoagulant genes, but not procoagulant genes, could be rapidly modulated, 
suggesting that thyroid hormone can have both immediate and late effects on 
coagulation gene transcription.  
 
Factor V has a dual role in coagulation since it can act as both a procoagulant and 
anticoagulant factor. Chapter 9 describes the generation of the factor V Leiden 
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hemizygous mouse, which combines the factor V Leiden-related increased venous 
thrombotic risk with the deficiency-related bleeding tendency. In mice, this 
combination of opposites results in partial lethality in the early postnatal period 
which coincides with features of macrovascular thrombosis, suggesting that it is the 
lack of the wild-type anticoagulant function that causes lethality. In addition, as 
factor V Leiden homozygosity is not lethal, these hemizygous data also implies that 
the factor V Leiden allele has retained a critical anticoagulant function which is 
sufficient to rescue the partial lethal phenotype of factor V Leiden hemizygous 
mice.  
 
Chapter 10 discusses the studies described in this thesis and puts them into 
perspective with respect to the currently available literature. Although we believe 
that our studies contribute to a better understanding how certain risk factors can 
affect the venous thrombotic risk, we are convinced that there is more to explore. 
Therefore, the final part of the general discussion includes some future 
perspectives and describes how new techniques can be of great value in 




Epidemiologische studies hebben in de afgelopen jaren verscheidene verworven 
risicofactoren voor veneuze trombose geïndentificeerd die de bloedstroom kunnen 
beïnvloeden en / of tot veranderingen in het plasma stollingsprofiel kunnen leiden, 
wat resulteert in een protrombotische verschuiving van de hemostase balans. 
Echter, de exacte biologische mechanismen waardoor deze factoren tot een 
protrombotische verschuiving en een verhoogd tromboserisico leiden zijn niet 
bekend. Daarom richt dit proefschrift zich op het indentificeren van de biologische 
mechanismen die ten grondslag liggen aan het verhoogde tromboserisico 
veroorzaakt door verworven factoren.  
 
Hoofdstuk 1 geeft achtergrondinformatie over risicofactoren voor trombose en 
veneuze trombose in het algemeen, en laat zien dat behalve een protrombotische 
verschuiving van het stollingsprofiel, de bestudeerde risicofactoren ook allemaal 
kunnen interfereren met het lever metabolisme. Omdat de lever van groot belang is 
voor de aanmaak van stollingsfactoren die zich in het plasma bevinden, hebben we 
de hypothese gepostuleerd dat de risicofactoren van interesse, dat wil zeggen het 
gebruik van oestrogenen en progestagenen, schilklierhormoon en overgewicht, in 
staat zijn om transcriptie van stollingsfactoren te moduleren. Enkele mogelijke 
mechanismen waarop transcriptie kan worden gemoduleerd worden beschreven, 
welke kunnen varieëren van een directe modulatie via nucleaire receptoren die 
binden aan specifieke respons elementen in stollingsgenen, tot een indirecte 
modulatie waarbij transcriptie is aangedaan als gevolg van een verandering in 
lever homeostase. Daarnaast worden verschillende experimentele modellen 
uitgelegd die gebruikt kunnen worden om transcriptionele modulatie te bestuderen, 
alsmede de reden om muizen als model organisme te gebruiken voor de studies 
beschreven in dit proefschrift.  
 
Een belangrijke tekortkoming van het gebruik van muizen in tromboseonderzoek, is 
dat ze niet spontaan trombose ontwikkelen. Er zijn echter transgene muizen 
gegenereerd die defecte of gemuteerde allelen hebben van genen die betrokken 
zijn in antistolling en daardoor wel een trombotisch fenotype kunnen ontwikkelen. 
Hoofdstuk 2 geeft een overzicht van deze modellen en laat zien dat een volledige 
deficiëntie van een specifieke antistollingsfactor vaak resulteert in embryonale 
lethaliteit terwijl heterozygotie vaak samengaat met een normale overleving. 
Modellen als de factor V Leiden en trombomoduline proline mutant muizen 
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vertonen een spontaan trombotisch fenotype, wat gekenmerkt wordt door fibrine 
deposities in weefsels. Dit maakt deze modellen interessant voor het gebruik in 
trombose-gerelateerd onderzoek.   
 
Experimenten beschreven in hoofdstuk 3 zijn ondernomen om meer inzicht te 
krijgen in het mechanisme dat ten grondslag ligt aan oestrogeen-geïnduceerde 
veranderingen in stolling. Orale ethinyloestradiol toediening in muizen is in staat 
om dosis-afhankelijke effecten op het plasma stollingsprofiel te veroorzaken welke 
samengaan met dosis-afhankelijke veranderingen in transcript niveaus in de lever. 
Daarnaast kunnen deze ethinyloestradiol-geïinduceerde effecten teniet worden 
gedaan door een oestrogenreceptor antagonist toe te voegen en studies 
uitgevoerd in oestrogeenreceptor-α en -ß knock-out muizen laten zien dat het α 
subtype van cruciaal belang is voor de stollingsgerelateerde veranderingen. Verder 
laten we zien dat de effecten op transcript niveaus van stollingsgenen snel kunnen 
worden geïinduceerd, binnen 2 ½ tot 5 uur na ethinyloestradiol toediening, wat 
suggereert dat de oestrogeen-gebonden oestrogeenreceptor een directe interactie 
heeft met de stollingsgenen in de lever en daardoor transcriptie beïnvloedt. 
 
Het is bekend dat er een verschil in tromboserisico is tussen anticonceptiepillen 
van de tweede en derde generatie en men veronderstelt dat dit komt door de anti-
oestrogene werking van de progestageen-component waarvan levonorgestrel en 
desogestrel vertegenwoordigers zijn van de verschillende generaties. In hoofdstuk 
4 hebben we de anti-oestrogene effecten van deze 2 progestagenen getest met 
betrekking tot zowel mRNA niveaus van stollingsgenen in de lever als de uterus 
morfologie. Ondanks het feit dat zowel levonorgestrel als desogestrel duidelijke 
anti-oestrogene effecten op de uterus hebben, was geen van beiden in staat de 
ethinyloestradiol-geïnduceerde veranderingen in transcript niveaus van 
stollingsgenen in de lever moduleren.  
 
De focus van hoofdstuk 5 ligt op de interactie tussen overgewicht en oraal 
oestrogeen gebruik met betrekking tot de trombose gevoeligheid. Dit laatste is 
bepaald door middel van een stase-geïnduceerd trombose model in muizen met 
voedingsgeïnduceerd overgewicht, al dan niet in combinatie met orale 
ethinyloestradiol toediening. Overgewicht leidde tot een protrombotische 
verschuiving van het plasma stollingsprofiel en een verhoogd trombus gewicht ten 
opzichte van muizen met een normaal lichaamsgewicht. Ondanks dat de 
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ethinyloestradiol behandeling in deze opzet geen effect had op het plasma 
stollingsprofiel, leidde dit wel tot verlagingen in transcript niveaus. Bovendien 
zorgde de oestrogeen behandeling voor een verlaging in het trombus gewicht, wat 
significant was in muizen met overgewicht. Dit toont aan dat ethinyloestradiol het 
protrombotische fenotype van voedingsgeïnduceerd overgewicht teniet kan doen in 
muizen.  
 
Nadat we de ethinyloestradiol-geïnduceerde effecten op plasma waarden van 
individuele stollingsfactoren hebben aangetoond, evalueren we in hoofdstuk 6 het 
netto effect van deze veranderingen op de hemostase balans door de 
trombinegeneratie in plasma te meten. Daarnaast stellen we de effecten op een 
spontaan trombotisch fenotype vast in factor V Leiden en trombomoduline proline 
mutant muizen door te kijken naar fibrine deposities in longen. Orale 
ethinyloestradiol toediening zorgde voor een aanhoudende verhoging in 
trombinegeneratie, maar dit werd niet vertaald in een spontaan macrovasculair of 
microvasculair trombotisch fenotype. Deze data impliceert dat er geen relatie 
tussen een verhoogde potentie tot trombinegeneratie en een trombotisch fenotype 
in deze muizen.  
 
Hoofdstuk 7 beschrijft het ontstaan en de reversibiliteit van de protrombotische 
status gedurende de ontwikkeling en regressie van voedingsgeïnduceerd 
overgewicht in muizen. Daarnaast worden ook de relaties tot veranderingen in 
transcriptie en klaring van stollingsfactoren, en de relaties tot veranderingen in 
metabole en ontstekingsgerelateerde parameters bekeken. Het plasma 
stollingsprofiel kan snel reageren op veranderingen in vet inname, zowel in 
gewichtstoename wat geassocieerd is met een protrombotische verschuiving, als 
bij het daar op volgende gewichtsverlies wat resulteert in reversibiliteit van de hoog 
vet-geïnduceerde protrombotische verschuiving. Deze veranderingen in het plasma 
stollingsprofiel gaan echter niet samen met veranderingen in mRNA niveaus of 
klaring van stollingsfactoren. Daarnaast gaan de effecten op stolling vooraf aan 
veranderingen in metabole parameters, zowel bij gewichtstoename als bij 
gewichtsverlies. Plasma waarden van cytokines zijn slechts tijdelijk verhoogd direct 
na de start van het hoog vet dieet en na het wisselen van een hoog naar een laag 
vet dieet om gewichtsverlies te bewerkstelligen. Deze studie laat daarmee zien dat 
een verandering in vet inname kan leiden tot snelle effecten op het plasma 
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stollingsprofiel en dat dit niet kan worden verklaard door veranderingen in 
transcriptie of klaring van stollingsfactoren.  
In hoofdstuk 8 hebben we gekeken naar de modulerende rol van 
schildklierhormoon op stolling, door naar de effecten van exogeen toegediende 
triiodothyronine (T3) op transcript en plasma waarden van stollingsfactoren te 
kijken in muizen met een onderdrukte endogene schildklierhormoon productie. T3 
blootstelling voor langere termijn beïnvloedt transcript niveaus van verschillende 
stollingsgenen die ofwel in de lever ofwel in endotheelcellen worden aangemaakt. 
Voor de genen die in de lever tot expressie komen zijn deze veranderingen in het 
algemeen ook terug te zien in veranderingen in plasma waarden. Daarnaast 
konden de transcript niveaus van de meeste antistollingsgenen, maar niet de 
prostollingsgenen, snel worden gemoduleerd wat suggereert dat schilklierhormoon 
zowel snelle als late effecten op expressie van stollingsgenen kan hebben.  
 
Factor V heeft een tweezijdige rol in stolling aangezien het zowel als prostollings- 
als antistollingsfactor kan dienen. Hoofdstuk 9 beschrijft de ontwikkeliing van de 
zogenaamde factor V Leiden hemizygoot muis, waarin het factor V Leiden 
gerelateerde tromboserisico en de factor V deficiëntie gerelateerde 
bloedingsneiging wordt gecombineerd. In muizen resulteert dit in een gedeeltelijke 
lethaliteit in de vroege postnatale periode wat samengaat met tekenen van 
macrovasculaire trombose, wat suggereert dat het verlies van de antistollende 
functie van factor V de lethaliteit veroorzaakt. Omdat factor V Leiden homozygotie 
niet lethaal is, impliceren deze data bovendien dat het factor V Leiden allel een 
kritisch deel van de antistollende functie heeft behouden en dat dit voldoende is om 
het gedeeltelijk lethale fenotype van de factor V Leiden hemizygoot muizen te 
redden.  
 
Hoofdstuk 10 bediscussieert de studies die beschreven zijn in dit proefschrift en 
plaatst deze in een breder perspectief met betrekking tot de huidige literatuur. 
Ondanks dat we van mening zijn dat onze studies bijdragen aan een beter begrip 
van de mechanismen die ten grondslag liggen aan hoe bepaalde verworven 
factoren het tromboserisico kunnen beïnvloeden, zijn we er ook van overtuigd dat 
meer onderzoek noodzakelijk is. Daarom richt het laatste deel van de algemene 
discussie zich op de toekomst en beschrijft hoe enkele nieuwe technieken van 
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